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Chapter 1 gives a brief introduction to brain tumors, approaches to deliver drug across 
the blood brain barrier (BBB), boron neutron capture therapy (BNCT) for brain tumors, 
application of carboranyl derivatives in attempt to treat brain tumors using BNCT.    
Chapter 2 involves synthesis, characterization and toxicity studies (In vitro and In vivo) 
of high boron containing pegylated cobaltabisdicarbollide porphyrin for treatment of 
brain tumors using BNCT. To improve the selectivity towards brain tumors we attempted 
conjugate several peptides to this non-toxic pegylated cobaltabiscabollide porphyrin. In 
vivo studies were conducted in collaboration with Dr. David G. Baker at LSU veterinary 
Medicine. 
Chapter 3 describes the synthesis, characterization and In vitro studies of carboranyl-
porphyrin polyamine conjugates and compared their biological behavior with pegylated 
carboranyl-porphyrin conjugate, which was also synthesized. The biological results show 
that the polyamine conjugates had a better cellular uptake and BBB permeability 
compared to pegylated carboranyl-porphyrin. These results also suggest that polyamine 
conjugates can be promising BNCT agents. 
Chapter 4   describes the synthesis, characterization and In vitro studies of carboranyl-
porphyrin glucose and polyethylene glycol peptide conjugates. Using the pegylated 
carboranyl-porphyrin conjugate from chapter 3 we could conjugate the peptides, which 
are interest of study. In vitro studies on some of the peptide conjugates are currently 
undergoing.   
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CHAPTER 1: INTRODUCTION 
1.1: Classification of Brain Tumors 
 
Over 50,000 people are diagnosed with either primary or metastatic brain tumors 
every year in the United States.1 It is estimated that about 13,000 deaths per year in the 
U.S. are caused as a result of brain tumors.1,2 Brain tumors can be classified according to 
their origin.3 Primary brain tumors originate from the brain or spinal cord; on the other 
hand metastatic brain tumors or secondary brain tumors arise from cancer cells in other 
parts of the body and spread to the brain. It is postulated that in the primary brain tumors 
the progenitor cells or neural stem cells undergo abnormal cell proliferation, resulting in 
malignance at different stages of cell growth, as shown in the Figure 1.1.3 The world 
health organization (WHO) has classified the grades of brain tumor as I, II, III or IV 
depending on their biological behavior,3 as  shown in Figure 1.1. For instance, 
medulloblastoma which is the grade IV brain tumor is thought to arise from neuronal 
precursors, and histologically found to have closely packed small round blue cells. This 
type of classification might help in effective treatment planning. Various studies 
conducted to identify the underlying cause of gliomas showed that alteration of genetics 
in neural stem cells are responsible for the normal and recurring gliomas.4 Therefore 
glioma stem cells are usually the focus of study instead of conventional human glioma 
cells.5 Brain tumors are infiltrative and their re-occurrence following conventional 
surgery, radiotherapy or photon therapies can also result in various side effects with a 
mean survival time of 15 months.6 So more new treatment modalities and chemical 
agents need to be studied in order to develop an effective treatment of brain tumors, 




Figure 1.1: The neuroglial lineage tree and WHO classification for diffuse glioma and 
medulloblastoma.3 
 
1.2:  Blood Brain Barrier (BBB) 
 
The treatment of brain tumors non-invasively is found to be a difficult task due to 
the presence of the BBB. The BBB, as the name indicates is the barrier between the blood 
vessel and brain. This dynamic barrier protects the brain from invading toxic substances 
and controls the internal environment of the brain, brain interstitial fluid (ISF) and 
cerebrospinal fluid (CSF), within extremely fine limits.7 The problem of having the BBB 
is that most of the promising drugs flowing in the blood stream to treat brain diseases, 
such as Alzheimer's, brain tumors and strokes, are being impeded. The BBB is made up 
of endothelial cells forming the capillaries of the brain with tight junctions (TJs), 
surrounded by astrocytes, pericytes, extracellular base membrane, and microglia, which 
form the internal part of the barrier.7 This is surrounded by neurons, as shown in Figure 
1.27 to form a complex brain microvasculature unit.8 The endothelial cells have a large 
volume of mitochondria with a lack of aperture and a few vesicles that allow fluids 
through the barrier.9-11 The endothelial cells that form the capillary are connected by TJs 
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and adherens junctions (AJs) that form a physical barrier. The TJs are formed by 
perplexing composite of transmembrane proteins containing junction adhesion molecule, 
occluding and claudins with cytoplasmic proteins such as zonula occludens-1 (ZO-1), 
zonula occludens-2 (ZO-2), cingulin, and afadin (AF-6) (Figure 1.3).12  The strength of 
the TJ is further enhanced by astrocytes and pericytes which interact with the endothelial  
 
Figure 1.2: Diagram illustrating Blood Brain Barrier 7 
 
cells.7,13Additional firmness between endothelial cells is obtained due to the presence of AJ 
which is present below the TJ in the basal laminal region formed by complex cytoplasmic 
protein ZO-114 (Figure 1.3). Apart from physical barriers there are transport barriers 
(containing amino acid receptor, transferring receptor, insulin receptor, lipoprotein 
receptor, p-glycoprotein receptor, multidrug resistance proteins (MRP’s) receptor), 15,16 
immunological barriers,17-20 and metabolic barriers16,21 that effectively seal off the brain 




              Figure 1.3: Physical barrier formed between adjacent endothelial cells12  
 
1.3: Drug delivery systems for transportation across the BBB 
 
 Treating brain tumors by a combination of radiotherapy and chemotherapy has 
limited success; as brain tumors recur frequently, which results in short survival time of 
the patient. This can be attributed to the poor prognosis of brain tumor and current 
available strategies required to treat tumors. Recently, several approaches have been used 
to improve the drug delivery across the BBB, which are sub divided into invasive and 
non-invasive approaches.23,24        
1.3.1: Invasive approach 
Invasive approaches involve the use of physical techniques such as implantation, 
where chips made of polymers or gels containing therapeutic drugs can be implanted 
after surgical resection of a tumor into the remaining cavity. These chips can be designed 
as biodegradable or non-degradable.24 Using this technique controlled release of the drug 
Copyright @ 2012 American Federation for Medical Research. Unauthorized reproduction of this article is prohibited.
is the targeting of protein trafficking whereby altering the location
of a protein is used as the means of modulating its activity. The
unique advantage to therapeutic subcellular misdirection (or re-
direction) of a protein is that its physiological impact can be
reversibly modified, despite pathology-induced changes in gene
transcription.53 Discussed below are 2 examples from our lab-
oratory, involving the drug efflux transporter P-glycoprotein
and the TJ transmembrane protein occludin, that demonstrate
the potential of therapeutic modulation of pathology-induced
changes in BBB protein trafficking to optimize CNS drug de-
livery in the presence of stressors (e.g., peripheral inflammatory
pain, hypoxia).
ALTERED P-GLYCOPROTEIN TRAFFICKING
PROMOTES INCREASED DRUG EFFLUX
AT THE BBB
P-glycoprotein (ABCB1/MDR1, EC 3.6.3.44) is the preemi-
nent molecular challenge to CNS drug delivery at the BBB.54Y56
Strategically enriched at the luminal membrane of cerebral mi-
crovascular endothelial cells,57Y59 P-glycoprotein uses energy
from ATP hydrolysis to expel an impressive variety of struc-
turally divergent drugs back into the microcapillary lumen against
steep concentration gradients. P-glycoprotein substrates range in
mass from È300 to 4000 Da and include analgesics, antican-
cer and immunosuppressive agents, psychotropics, antibiotics,
antiallergenics, antiepileptics, A-blockers, steroid hormones,
and HIV-1 protease inhibitors.54,55,60Y64 Although intense re-
search effort has focused on the development of P-glycoprotein
inhibitors, clinical trials incorporating direct inhibition of P-
glycoprotein have largely proved unsuccessful in improving
therapeutic efficacy.65Y70 High doses of inhibitor appear to be
required, unfortunately giving rise to systemic toxicity. Moreover,
complete inhibition of P-glycoprotein could be life-threatening
because of the lack of protection against potentially dangerous
blood-borne substances. Currently, research effort is focused on
identifying therapeutic targets within multiple signaling path-
ways that promote disease-related changes in P-glycoprotein
activity.45Y47,54,55,62,71Y73
In our laboratory, we discovered that the onset of periph-
eral inflammatory pain (experimentally induced by injection of
L-carrageenan in the rat hind paw) is followed within 3 hours
by an increase in P-glycoproteinYassociated efflux of morphine
at the BBB. The important consequence of this was a cor-
responding decrease in morphine efficacy in vivo due to a re-
duction in morphine uptake into the brain.74 These data
demonstrated that inflammatory pain itself hinders the ability of
clinically relevant pain drugs such as morphine to gain entrance
into the brain. Inflammation caused by tissue injury contributes
to the severity of postoperative pain,75 and therefore our finding
of increased morphine efflux by P-glycoprotein at the BBB
may explain in part the reported difficulties with achieving
FIGURE 1. Basic molecular organization of BBB TJs. Adapted from Hawkins and Davis.3
McCaffrey and Davis Journal of Investigative Medicine & Volume 60, Number 8, December 2012
2 * 2012 The American Federation for Medical Research
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can be achieved.25-46 Another way of delivering the drug is by BBB disruption using 
osmotic shock,47-49 ultrasound,50-52 and by activation of bradykinin B2 receptors53,54 
which make the TJ leaky. Intracerebroventricular delivery is another mode of delivering 
drugs into the brain.55-57 This is similar to intravenous (iv) injection except that the drug 
is delivered to the brain bypassing the BBB. Finally there is convection-enhanced 
delivery (CED) in which a hollow tube is inserted stereotactically into the parenchyma.58 
Then, using an infusion pump, drug is transferred carefully for a time period up to several 
days depending on the requirement.58 Once a therapeutic amount of drug is achieved the 
catheter is removed (Figure 1.4). Although these physical approaches can deliver high 
concentration of drug into the parenchyma there are some limitations, including the high 
cost, patient invasiveness, requires anesthesia, and proper knowledge on these techniques.   
 







1.3.2: Non-invasive approaches  
 
 The non-invasive methodologies include a pharmacological and a physiological 
approach.23 In the pharmacological approach the drug is formulated as to favor crossing 
the BBB by optimizing its solubility and stability.23 It has been observed that some low 
molecular weight compounds of high lipophilic character, such as nicotine, morphine, 
alcohol and benzodiazepine, can cross the BBB according to the Lipinski rules.60 
Modification of promising drugs, which cannot cross the BBB, should be carried out to 
increase their uptake into the brain. Some lipid carriers and polymeric micelles can also 
be used to make the drug stable and favoring BBB permeability.61-63  
The physiological approach takes advantage of the essential nutrients required for 
brain function, such as proteins, glucose, long-chain polyunsaturated fatty acids, 
hormones, and insulin.22,23 These nutrients pass through the BBB due to the presence of 
specific receptors on the capillary, which can also act as transport barriers as discussed in 
Section 1.2. A drug can be conjugated to ligands, which can then tag to these specific 
receptors followed by transportation of the drug across the BBB. Physiological 
approaches to deliver drugs across the BBB include adsorptive-mediated delivery, 
transporter-mediated delivery, receptor-mediated delivery, cell-mediated delivery and by 
inhibition of efflux pumps (Figure 1.5).7,64-66  
In receptor-mediated and adsorptive-mediated delivery, endocytosis of the drug 
occurs at the luminal followed by movement through the cytoplasm and finally 
exocytosis of the drug.7,23 The only distinction is that in adsorptive-mediated delivery the 
drug is conjugated to a protein or peptide, which is positively charged (cationic). This 
positively charged drug interacts electrostatically with the surface of the luminal plasma 
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membrane containing anionic charge. Then, the transportation of the drug occurs 
similarly to the receptor-mediated transcytosis. For example, using specific monoclonal 
antibodies that bind to the transferrin or insulin receptors present on the surface of the 
endothelial cells, the drug can be delivered into the brain. Pardridge et al. 67-71 used these 
strategies to deliver drugs across the BBB. Nanoparticle and liposome coated with 
transferrin-receptor antibodies have also been studied, where the transferrin receptor 
antibody acts as a Trojan horse.72,73  
 
Figure 1.5: Diagram showing Transport systems across the BBB7 
 
The low-density lipoprotein receptor pathway is another approach for drug 
delivery across the BBB, in which a range of proteins interact with the multiligand 
lipoprotein receptor.66 The diphtheria toxin receptor (DTR) present on the surface of 
endothelial cells can also be used to transport drugs across the brain capillary. Gillard et 
al.74 used a non-toxic mutant of diphtheria toxin for drug delivery to the brain. Large 
molecules can be delivered through these two above discussed physiological approaches. 
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Transport-mediated delivery is a different physiological approach for the delivery of 
small molecules across the BBB.  
Peptides and small molecules such as glucose, amino acids, nucleosides and folate 
transport across the barrier, which are essential nutrients for the brain, using specific 
transporters expressed on the luminal and basolateral side of the endothelial cells.66 
Modifying the drugs by attaching these essential nutrients to the drug, which is non-brain 
penetrant, is a strategy for increasing permeability across the BBB.  
In the cell-mediated drug transport system the drug is loaded into specific cells, 
which pass through the BBB and then delivered through the process of endocytosis.75 In 
this case the cells act as the Trojan horse and high concentration of drug can be delivered 
by incorporation into nano or micro carriers. Miller et al. 75 in the Kabanov laboratory 
used Pluronic block copolymers to inhibit the efflux pumps, such as p-gp, which 
prevent drugs from entering into the brain. They used copolymer Pluronic P85 to 
selectively accumulate rhodamine 123 in the cells. Among the above approaches for drug 
delivery across the BBB, scientists believe that the physiological approach is the most 
promising.7,22,23 Therefore, current research is centered on drug optimization. 
1.4: Boron Neutron Capture Therapy (BNCT) 
Boron neutron capture therapy is a binary therapy that involves delivery of stable-
nonradioactive 10B-containing compounds selectively to tumor, followed by irradiation of 
slow and low energy thermal or epithermal neutrons. This is followed by the spontaneous 
production of high linear energy transfer (high-LET) alpha and lithium-7 particles, and 




Figure 1.6: Nuclear fission reaction when neutron bombards a 10B nucleus.76-78 
 
BNCT, which is still in clinical trials can be an effective treatment since the high-
LET particles have only limited path length (5-9 µM) in tissues. Since the alpha and 
lithium particles are capable of destroying both dividing and non-dividing cells this 
treatment is more propitious in comparison with the conventional methods. This makes 
the BNCT potentially highly selective because it could destroy 10B-containing malignant 
cells in the presence of normal boron-free cells (see Figure 1.7).  
BNCT can also be used to treat hepatic metastases (liver cancer),80 lung tumor,81 
oral cancers,82,83 and prostate cancer.84,85 In 1951, the first clinical studies on BNCT for 
glioblastoma multiforme were carried at the Brookhaven National Laboratory and the 
Massachusetts Institute of Technology in collaboration with the Massachusetts General 
Hospital.85 Recent clinical studies Phase I/II were conducted on recurring head and neck 
cancer86-90 using BNCT, which showed improvement in patient’s condition.  
For an effective treatment of high-grade gliomas, head and neck cancer, primary 
melanoma and metastatic melanoma using BNCT requires an effective neutron source 
and effective 10B drug delivery. A fission reactor-based neutron source was developed in 
1960s to treat tumors, but the disadvantage is that the beams of thermal neutrons 
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the hydrophilicity of the nido-carborane cages and the hydrophobicity of the porphyrin 
macrocycle will be essential to achieve specificity to tumors. 
1.4 Boron Neutron Capture Therapy 
BNCT84 has been experimentally tested primarily as an alternative treatment for 
malignant brain tumors called glioblastomas. BNCT is a form of radio therapy that 
utilizes a neutron beam that interacts with boron injected into a patient. BNCT depends 
on the interaction of slow neutrons with boron-10 to produce highly cytotoxic particles 
(4He+2 and 7Li+3) and the release of 2.4 meV of kinetic energy, according to Scheme 1-7.  
 
10
5B + 10n 115B
4
2He + 73Li + 2.79 MeV (6%)
4
2He + 73Li + J0.48 MeV + 2.31 MeV (94%)  
 
Scheme 1-7: Nuclear reaction initiated by collision of a neutron with boron-10 
 
Patients are first given an intravenous injection of a boron-10 tagged chemical that 
preferentially binds to tumor cells. The neutrons are created either in a nuclear reactor or 
by colliding high-energy protons into a Lithium target. The neutrons pass through a 
moderator, which shapes the neutron energy spectrum suitable for BNCT treatment. 
Before entering the patie t the neutron beam is shap d by a beam collimator. While 
passing through the tissue of the patient, the neutrons are slowed by collisions and 
become low energy thermal neutrons. The thermal neutrons undergo reaction with the 
boron-10 nuclei, forming an unstable boron-11 nucleus which then undergoes 
spontaneous decay to lithium-7 and an alpha particle (Figure 1-6).  
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produced could not penetrate the tissue deeper than 4 cm.91-93 In 1990s advancements 
have been made to the fission reactor to produce epithermal neutrons that can penetrate 
through tissues up to 10 cm, so as to treat deep seated tumors, such as high grade (III and 
IV) tumors .94, 95 Additional improvements of the neutron source include optimization of 
the length of exposure, penetration range and energy of neutrons for quality treatment.  
Accelerator-based nuclear reactors are currently being developed so that neutron capture 
therapy will be feasible in general hospitals.96-98  
 






Figure 1.8: Diagram of epithermal neutron irradiation Massachusetts Institute of  
Technology Reactor (MITR)90 
 
  
The two approved boron drugs used in clinical trials for treatment of high-grade 
gliomas are disodium-mercapto-closo-dodecaborate (BSH) and 4-
dihydroxyborylphenylalanine (BPA) (Figure 1.9). Although these drugs are safe, they 
have some disadvantages, including 
1) Low tumor selectivity. 
2) Low retention time in tumors. 
3) Low boron conten of BPA.  





Figure 1.9: Disodium-mercapto-closo-dodecaborate (BSH) and 4-   
dihydroxyborylphenylalanine (BPA) are clinically-approved for use in BNCT 
 
Therefore, research is underway to find improved boron delivery drugs that show 
higher tumor selectivity and retention times in tumors.99,100 An effective boron delivery 
drug, should have the following characteristics: 
1) High Retention time in tumors 
2) Low systemic toxicity 
3) Selective high uptake in tumors compared to normal tissues or high tumor/normal 
tissue ratio 
4) High tumor/blood concentration ratio 
5) Deliver therapeutic boron concentration of about 30 µg/g to tumor 
6) Rapid clearance from blood stream and healthy tissues 
The development of improved boron delivery drugs will be discussed in the following 
sections. 
1.5: Carboranes and their Derivatives for BNCT  
 
As described in the previous section, high boron concentration (20-30µg/g) is 
essential for an effective BNCT treatment. In the 1950s high boron containing boron 
hydrates were developed and the Noble Prize was awarded to William Lipscomb for his 











Hawthorne and A. R. Pitochelli, among other chemists, started to synthesize and explore 
the polyhedral boron hydrates.103-108 Since then, the polyhedral carborane chemistry 
evolved and in the last three decades the carboranes shown in Figure 1.10 have been the  
 
Figure 1.10: Commercially available carboranes 
 
subject of interest for medical purposes, particularly for BNCT.109-111 As discussed in the 
section 1.3 several carborane-bio-molecules include amino acids, carbohydrates, 
peptides, nucleosides, pyrimidines, nitroimidazole, carboxamide, antibodies, liposomes, 
pthalocyanines and porphyrin derivatives were synthesized and tested, so as to facilitate 
the boron containing carboranes across the BBB invasively and non-invasively.77 Since 
the discovery of BPA (1.2) as a drug for BNCT several derivatives of BPA containing 
higher boron content, such as boron-containing natural amino acids, non-natural amino 
acids and cyclic amino acids have been synthesized (Figure 1.11).112-116 These derivatives 
can cross the BBB and reach the tumor through the amino acid transportation system. 
Among these, the cyclic amino acids have shown to be promising agents for BNCT, in 













closo o-carborane (1.5), closo m-carborane (1.7) and nido-carborane (1.10) were also 
synthesized. Among these compound 1.17 containing cobalta-carborane has shown 
promising results on melanoma cells.116   
 
Figure 1.11: Boronated amino acids112-116 
     
Carbohydrate-conjugated molecules generally have high water-solubility and can 
cross the BBB via the nutrient transport system through carbohydrate receptors. Low 
cytotoxicity is generally observed with these carbohydrate conjugates.117 Therefore, 
extensive research has been carried out on carbohydrate carborane conjugates (Figure 
1.12).89,117-121 Carbohydrate derivatives of BSH have been investigated for application in 
BNCT.89 Carboranyl-5-thio-D-gluco-pyranose conjugate 1.21 showed very high boron 
uptake per human hepatocellular carcinoma cell (SK-Hep1), about 100 times more than 
the desired boron per (SK-Hep1) cell for effective BNCT.117  
Boronated peptides have been studied for application in BNCT as the interest of 
study for BNCT as boronated peptides can cross the BBB via the peptide receptors on the 
surface of the cell (Figure 1.13). Usually, peptides show low toxicity because of their 
































synthesized recently for application in BNCT.122 Increased cellular uptake of cyclic RGD 
peptide conjugates  (1.26-1.28) has been observed in recent studies using U87MG and 
SCCVII cells.123 In vivo studies on RGD-carborane conjugates revealed that the RGD 
dimer 1.27 had high tumor uptake and long retention time in tumor compared with 
BSH.123             
 
Figure 1.12: Boronated carbohydrate conjugates89,117-121 
 
Boron derivatives of nucleosides, thymines and pyrimidines have been studied for 
BCNT.124-133 Since nucleosides can be converted to monophosphates by cytosolic kinases 
(Figure 1.14), nucleoside carborane conjugate can show selective uptake in tumor cells. 
The nucleoside carborane conjugates can also interact with DNA, which is an important 
target. Thymine derivative 1.38 has shown promising in vitro properties, including low 
cytotoxicity and selective tumor cell uptake.130 Synthesis and in vitro studies of high 







































































Carborane conjugates of nitroimidazole were studied (1.41,1.42), since nitroimidazoles 
have shown high tumor uptake and high retention in vascularized tumor regions.134,135     
 
Figure 1.13: Carborane peptide conjugates122,123 
 
Carborane-conjugated 2-quinolinecarboxamide was also used as BNCT agent 
(Figure 1.16).136 Translocator protein (TSPO) is overexpressed on the surface of the 
mitochondria in a tumor cell. Therefore using a ligand such as quinolinecarboxamide can 
induce mitochondria targeting. Boron-containing 2-quinolinecarboxamide derivatives 







































































































Figure 1.14: Boronated nucleosides125 and pyrimidines126-133 
 
 good uptake toward DHD cells. Among these compounds 1.45 and 1.46 showed the 
most uptake into DHD cells. Since mitochondria are the powerhouse of the cell, 
destruction of tumor cell could be achieved in BNCT by targeting mitochondria. 
Epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 
(VEGFR) and their mutant forms EGFRvIII are over-expressed in brain, head and neck 
cancers. Barth and coworkers used a monoclonal antibody (MAb) designated anti-EGFR 
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EGFRvIII.137-139 In vito and in vivo studies on carborane-EGF bioconjugate dendrimer 
showed high uptake in EGFR-containing tumor cells compared to tumor cells without 
any EGFR. Similar studies have been conducted on fifth generation PAMAM dendrimer 
carborane bioconjugate.140       
 
Figure 1.15: Boronated nitroimidazole134,135 
 
Low-density lipoprotein (LDL) receptors are also over-expressed in tumor cell. 
Since large amount of boron can be incorporated in the natural lipoprotein and in 
liposomes, extensive research has been focused on development of boron derivatives 
(Figure 1.17).141 Natural lipoprotein or LDL vesicles consist of cholesterol and glyceryl 
esters (lipid) surrounded by phospholipid and Apo lipoproteins. Therefore liposomes 
(synthetic LDL) can be constructed by incorporating carboranes in cholesterol, glyceryl 
esters and glycerols. Carborane conjugates of cholestrol, lipids and glycerols were 
synthesized and used to carry hydrophobic or lipophilic carboranes into the tumor 
cells.141   
Boronated phthalocyanines 1.60 and 1.61 were synthesized and cell studies were 
carried out (Figure 1.18).142,143 These two drugs were obtained as a mixture of 
regioisomers. The tumor was treated either by activation of 600-700 nm light using 

















showed that this compound efficiently accumulated in B16F1 melanotic melanoma cells 
and that upon red light irradiation, extensive cell mortality was observed.142 In vivo 
studies on C57BL/6 mice bearing a subcutaneously transplanted pigmented melanoma 
using 10B-ZnB4Pc resulted in delay of tumor growth after using neutron irradiation. These 
results exemplify the possibility of using one drug as both a photosensitising and a 
radiosensitising agent for the treatment of tumours by the combined application of PDT 
and BNCT. Pthalocyanine 1.61 was evaluated by the photooxidation of (S)-(−)-
citronellol to give high oxygen consumption.  
 

























































































1.6: Porphyrins and Carborane-porphyrins 
 
1.6.1: Chemistry and biology of porphyrin 
 
Porphyrin is a vital chemical used in Nature by several organisms. Chlorophyll a 
green pigment is a natural porphyrin deivative, which drives the photosynthesis process 
in plants. Heme, a component of hemoglobin, is another natural porphyrin, responsible 
for the transportation of oxygen to the tissues and Myoglobin is another protein that 
contains heme, and is responsible for storage of oxygen in animal tissue. Since the early 
19th century scientists have been studying porphyrins in the fields of chemistry, 
biochemistry, medicine and energy sources. A basic porphyrin macrocycle consists of 
four pyrrole rings joined by meso-carbons. It is an aromatic compound with 22-π 
electrons, and six different 18-π electron pathways.144 Porphyrins absorb in the visible 
 
Figure 1.18: Carborane phthalocyanine derivatives142,143 
 
region, with an intense Soret band observed around 400 nm and weaker Q-bands between 
450 and 700 nm. Porphyrins are generally stable under both acidic and basic conditions 




































(eg. Zn, Pd, Cu, Ni, Fe, Mn). The meso and β-pyrrolic position have been extensively 
used to conjugate several biomolecules for medical applications.145-151 In particular 
porphyrin derivatives are playing a crucial role in treating several cancers using PDT.  
1.6.2: Photodynamic Therapy (PDT) 
 
PDT is a cancer and infectious disease treatment modality. This treatment 
involves three key components: a photosensitizer, light, and tissue oxygen (Figure 
1.19).152 First, the photosensitizer (porphyrin) should be selectively accumulated inside 
the targeted tumor tissue, and then the area is irradiated by suitable light using optic 
fibers for easy access into the body. Once irradiated, the porphyrin molecules get excited
 
Figure 1.19: Mechanisms of action of PDT152 
 
to a singlet electronic state S1. Then intersystem crossing (singlet excited state (S1) to 
triplet excited state (T1)) or fluorescence (singlet excited state (S1) to singlet ground state 
	  
 23 
(S0)) can take place. If intersystem crossing occurs then the triplet excited state (T1) is 
converted to singlet ground state (S0) with possible outcomes being phosphorescence or 
the production of reactive oxygen species (ROS) or singlet oxygen which are toxic to the 
cells, ultimately resulting in death of tumor cells.   
There are two FDA-approved porphyrin drugs (Photofrin and Visudyne) used to 
treat lung, melanoma, digestive and genitourinary tract cancers.153-155 Promising 
porphyrins used as cancer drugs show high tumor selectivity and high retention times in 
tumors. Physical and chemical properties of porphyrins such as molecular weight, 
solubility, net charge, coordinated metal, aggregation, and the acidic tumor environment, 
influence their biological properties. Porphyrins, when hydrophilic, can be present in 
aqueous solutions in the monomeric form. However when lipophilic, porphyrins often are 
in the dimeric form or form large aggregates.156,157 Change in the ionic strength and pH 
can also result in the formation of different aggregate species. The net charge on the 
porphyrin can influence accumulation in certain cell organelles. In general, negatively 
charged porphyrins can accumulate inside lysosomes through electrostatic interaction 
with cationic lysosomes.158 On the other hand, positively charged porphyrins can 
accumulate in anionic mitochondria, also by electrostatic interaction.159 Studies 
confirmed that the pH around tumor cells is lower than that of normal cells.160 This can 
promote uptake of carboxylic acid porphyrins selectively into tumor cells after 




Figure 1.20: Basic structure of a porphyrin macrocycle 
 
1.6.3: Boronated-porphyrins and their derivatives for BNCT 
 
 Haushalter, Rudolph and co-workers in 1978 first reported the synthesis of 
boronated porphyrins containing closo- or nido-carborane cages for application as 
catalysts.161 Since the 1980’s the development of boronated porphyrins for application in 
BNCT increased with the discovery to deliver high concentration of boron to the 
tumors.162-173 Most of the porphyrin synthesized were obtained as a result of the 
functionalization of commercially available deuteroporphyrin IX, hematoporphyrin IX, 
and chlorin e6. Either o-carboranes or B12H122- clusters were attached to the above 
porphyrins resulting in compounds VCDP (1.62),174  BOPP (1.63),175 (1.64),176 (1.65),177 
(1.66),178-180 and (1.67).181 These porphyrin conjugates are good boron carriers for BNCT 










Figure 1.21: Natural carborane-porphyrin derivatives174-181 
 
 boron, 2) high retention time in tumors and high tumor selectivity, 3) general low dark 
toxicity and 4) using porphyrin for PDT which releases reactive oxygen species (ROS). 
In the beginning of 1990’s boronated porphyrins BOPP (1.63)175 was synthesized from 
preformed porphyrin and porphyrin CuTCPH182 was synthesized from condensation of 
pyrrole and carbonyl-substituted benzaldehyde. These two porphyrins were tested 
biologically (in vitro and in vivo) for their ability to deliver boron into tumors.183-193 
Although BOPP was investigated in clinical trials I, due to its toxicity levels in vivo it 
couldn’t reach Phase II trials. The toxicity of this boronated porphyrin might be attributed 
to the hydrolysis of the carbonyl ester resulting in the carboxylic carborane. 10B-



































































room temperature in the presence of pyridine.193 These porphyrins were also tested on 
mice bearing EMT-6 for BNCT efficacy, where there was no significant difference in 
their BNCT efficacy observed between 10B-CuTCPBr and 10B-CuTCPH.193-196              
1.7: Conclusions. 
 
 BNCT is a promising therapy that has the potential to treat different grades of 
brain tumors. Research in BNCT has led to tremendous advances in the development of 
neutron sources and boronated drugs. The major challenges have been delivering these 
promising drugs across the BBB using either invasive or non-invasive approaches, and 
the development of nuclear accelerators. Strategies have been investigated for delivery of 
therapeutic amount of boron invasively and non-invasively, with low toxicity. Boronated 
porphyrins have shown increased tumor selectivity and retention times compared with 
BSH and BPA, the only clinically approved BNCT drugs. Furthermore, boron-containing 
porphyrins retain the fluorescence and photosensitizing properties characteristic of this 
type of macrocycle, allowing the use of photodynamic therapy (PDT) as adjuvant 
treatment for BNCT, and facilitating the detection of tissue-localized boron and treatment 
planning. In the following Chapters I will be discussing the synthesis and biological 
studies of new types of carboranyl-porphyrin conjugates.     
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CHAPTER 2: SYNTHESIS, IN VITRO AND IN VIVO TOXICITY OF 




2.1.1: Porphyrin synthesis 
 
Hans Fisher, the Noble Prize winner for chemistry in 1930, successfully carried 
out the synthesis of etioporphyrin I, II, III isomers of octaethylporphyrin.1,2 Since then 
various porphyrin derivatives were synthesized using the MacDonald’s, Rothemund’s, 
Alder-Longo’s and Lindsey’s methods.3 MacDonald’s [2+2] method was used to 
synthesize C2-symmetrical porphyrins.4 This is a multi-step synthesis that often results in 
low yield product compared with the milder Lindsey’s method, due to the scrambling of 
the dipyrromethane under harsh acidic conditions. The synthesis of unsymmetric 
porphyrins (pyrrolic substituted) can be achieved through open chain pyrrolic 
intermediates such as (a,c-Biladienes)5-11 as observed with the synthesis of 
octaethylporphyrin (see Scheme 2.1).12  
A simple one-pot synthesis of symmetrical and unsymmetrical meso-substituted 
porphyrins can be achieved using the Rothemund method, Alder-Longo method or the 
Lindsey method. Using Rothemund’s method 5,10,15,20-tetraphenylporphyrin (TPP) was 
synthesized under high temperature and high pressure, in low yields (10%) (Scheme 
2.2).13,14 The yields of TPP were improved to 21% by Alder and Longo using propanoic 
acid at 1410C.15-17 Various substituted benzaldehydes were used in this method to obtain 
polar porphyrins.18 Recently using modified Adler-longo’s method 5,10,15,20-Tetra(4-




Scheme 2.1: Synthesis of symmetric octaethylporphyrin (2.3)12 
 
developed milder conditions (BF3.OEt2 or TFA/p-chloranil or DDQ) to obtain meso-
substituted porphyrins in higher yields. Lewis acid is used to form a porphyrinogen in the 
first step (a cyclic tetra pyrrole) and the oxidant converts porphyrinogen to the more 
stable porphyrin (Scheme 2.4).21 Using this method several unsymmetrical meso-
substituted porphyrins have been synthesized.22 More polar benzaldehydes, which are not 
soluble in solvents like DCM/CHCl3 cannot be used in this method. The Alder-Longo 
method is the one most suitable for polar benzaldehydes. Although higher yield of TPP 
was obtained using Lindsey’s method; the synthesis of TPP using Alder-Longo’s method 
is still the preferred as the porphyrins precipitates from cold propionic acid and can be 
filtered, therefore column chromatography is not needed. There is formation of polymer 
black tar during the synthesis of porphyrins due to pyrrole polymerization. Varying the 
time of reaction, solvent, acid and oxidant, the best yields of meso-substituted 
(symmetrical/unsymmetrical) porphyrins can be optimized using Lindsey or Alder-Longo 

















Scheme 2.2: Synthesis of TPP (2.6) using Rothemund’s method13 
 
 
Scheme 2.3: Synthesis of symmetric porphyrin (2.8) using modified Alder-Longo 
method19 
 
2.1.2: Symmetric carboranyl-porphyrins 
 
The synthesis of symmetrical carboranyl-porphyrins of high boron content was 
carried to deliver high concentration of boron to targeted cells, as discussed in Chapter 1. 
Two such examples are shown in Schemes 2.5 and 2.6 for the synthesis of porphyrins 
2.1223 and 2.15.24 Synthesis of 2.12 is carried out by first reacting pyrrole 2.4 with 






i) Pyridine/MeOH, 1500C, 24h
(2.4) (2.5) (2.6)
ii) Propionic acid, O2, 1410C, 2h
iii) BF3.OEt2, DCM, rt, 45 min
                     and
              DDQ, rt, 2h

















Scheme 2.4: Synthesis of porphyrin (2.10) using Lindsey’s method.22 
 
 
Scheme 2.5: Synthesis of carboranyl-porphyrin 2.1223 
 
Lindsey conditions, followed by conversion of the hydrophobic closo-carborane 
porphyrin to the hydrophilic nido carborane porphyrin, using 3:1 pyridine and piperidine, 
resulting in 27% overall yield of 2.12.23 In vitro studies showed that this porphyrin had 
good cellular uptake in T98G cells and preferentially localized in lysosomes. The 











i) 2.5M BF3.OEt2, DCM
   R.T, 45 min.
ii) p-chloranil, 1h reflux
              (or)
    DDQ, R.T, 2 h























vitro upake was good using T98G cells and 2.15 localized preferentially in lysosomes. 
This porphyrin din’t show any toxicity when tested on BALB/c mice with a maximum 
tolerable dosage (MTD) of 160 mg/kg.  
 
Scheme 2.6: Synthesis of carboranyl-porphyrin 2.1524 
 
2.1.3. Cobalta-carborane containing porphyrins 
 
 As discussed in Chapter 1, for an effective treatment of brain tumors by BNCT 
therapeutic boron concentrations of about 30 µg/g in tumor should be achieved. In order 
to increase the amount of boron by weight, high boron-containing stable 
cobaltabisdicarbollide anion [Co(C2B9H11)2]- has been conjugated to porphyrins and other 
biomolecules (liposomes, peptides, amino acids, nucleosides, and monoclonal antibodies) 
containing hydroxyl and amine groups.25 Among these, porphyrins containing  four or six 
cobalta-carboranes were found to be of particular interest. One such example is shown in 
Scheme 2.7.26 Porphyrin 2.17 has high boron concentration, and showed good uptake in 












i) BF3.OEt2, CH2Cl2, R.T, 1h/DDQ ( CH2Cl2, reflux, 1h
ii) CuCl2, toluene, reflux, 4h
iii) DDQ, toluene, reflux, 10 min
iv) conc. H2SO4, 5 min
v) Bu4NF, THF, reflux






Scheme 2.7: Synthesis of compound 2.1726 
 




































































conjugated to a tri cobalta-carborane to obtain porphyrin 2.18.27 Porphyrin 2.18 showed 
an enchanced cellular uptake in HEp2 cells (about 12 fold) when compared to the 
precursor tri cobalta-carborane porphyrin.27 Our strategy is to increase the boron 
containing peptides, by conjugating a hexa cobalta-carborane porphyrin rather than tri 
cobalta-carborane porphyrin that could result in promising BNCT drugs that can deliver 
therapeutic concentrations of boron to the tumor site, selectively. Opioid peptides and cell 
penetrating peptides (CPPs) (discussed in detail in Chapter 4) were the chosen molecules 
to be conjugated to porphyrin 2.28 that might have the ability to cross BBB and 
selectively target brain tumors. 




 In order to synthesize an hexa cobalta-carborane containing porphyrin with a free 
carboxylic group and conjugate several biomolecules, the unsymmetrical A3B-type 
porphyrins 2.21, 2.23, and 2.25 were synthesized using Lindsey’s mixed aldehyde 
condensation method with BF3.OEt2 as the catalyst and DDQ as the oxidizing agent. The 
best yields (9-12%) were obtained using 4 eq. of pyrrole, 3 eq. of 3,5-
dimethoxybenzaldehyde and 1.5 eq. of p-substituted benzaldehyde, after attempting 
reactions with different equivalents of pyrrole and benzaldehydes, as shown in Table 2.1. 
The pure products were characterized using 1H-NMR (for porphyrin 2.21 6 proton peak 
around 8.96 due to β-H, 2 proton peak around 8.78 due to another β-H, two proton peak 
around 8.45 due to o-PhH, 2 proton peak around 8.35 due to m-PhH, six proton peak 
around 7.40 due to o-PhH, 3 proton peak around 6.91 due to p-PhH, 18 proton peak 
around 3.97 due to methoxy proton, 2 proton peak around -2.81 due to NH protons of 
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porphyrin and a characteristic two proton CH2Ph peak around 5 ppm for compound 2.21, 
three proton peak around 2 ppm in case of compound 2.23 due to the acetate group, three 
proton peak around 4 ppm for compound 2.25 due to the methyl ester), 1H-NMR, 13C-
NMR, MALDI-TOF (5.20: m/z 901.355, 5.22: m/z 852.332, 5.24: m/z 852.759). The 
structures of compounds 2.21, 2.23 and 2.25 were also confirmed by X-ray analysis as 
shown in Figures 2.2, 2.3 and 2.4.  



















4 3.0 1.0 7.3% 1.0 8.0% 1.0 7.9% 
4 3.0 1.5 10.1% 1.5 12.0% 1.5 10.5% 
4 3.2 1.5 9.2% 1.5 9.0% 1.5 9.0% 
4 3.4 1.5 8.0% 1.5 8.5% 1.5 8.7% 
  4 3.5 1.5 7.0% 1.5 7.5% 1.5 8.0% 
   
 
 
Scheme 2.8: Synthesis of compound 2.21 
 
Deprotection of the methoxy and methyl ester groups on compound 2.25 was 
achieved in 90% yield using BBr3 and CH2Cl2 as solvent at room temperature for 24 h.26 
















1. BF3.OEt2/CH2Cl2, 2h, rt
2. DDQ/CH2Cl2, 45 min, rt





base and HOBT and TBTU as coupling reagents after stirring at room temperature for 48 
h to produce the desired product 2.26 in 80% yield (Scheme 2.11).28-32 Compound 2.26 
was characterized using 1H-NMR where a characteristic 9 proton singlet peak is observed 
around 1.44, due to presence to tert-butyl ester. This glycine linker is used to improve the 
yields during the conjugation to biomolecules. Then the conjugation of cobaltacarborane 
 
Scheme 2.9: Synthesis of compound 2.22 
 
  
Scheme 2.10: Synthesis of compound 2.25 
 
 
was achieved through nucleophilic ring opening of dioxane on zwiterionic 
cobaltabisdicarbollide  [3,3′-Co(1,2-C2B9H10)(1′,2′-C2B9H11)] resulting in the t-butyl-
















1. BF3.OEt2/CH2Cl2, 2h, rt
2. DDQ/CH2Cl2, 45 min, rt

















1. BF3.OEt2/CH2Cl2, 2h, rt
2. DDQ/CH2Cl2, 45 min, rt




(2.4) (2.19) (2.24) (2.25)
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deprotect the t-butyl ester resulting in compound 2.27 in 95% yield. Zwiterionic 
cobaltabisdicarbollide [3,3′-Co(8-C4H8O2–1,2-C2B9H10)(1′,2′-C2B9H11)] was prepared 
from reaction of commercially available Cs[Co(C2B9H11)2] with 1,4-dioxane in the 
presence of BF3.OEt2.33 The compound is characterized using 1H-NMR (characteristic 
carborane BH broad peak observed between 1.6–3.0), 13C-NMR and HRMS-ESI. Then 
the precious precursor 2.28 for conjugation of several cell penetrating and opioid peptides 
was achieved after conjugation of compound 2.27 with commercially available tert-butyl-
12-amino-4,7,10-trioxadodecanoate, using HOBt and HATU as coupling reagents in 20% 
yield, followed by deprotection of the  tert-butyl group using TFA, resulting in compound 
2.28 in quantitative yield (Scheme 2.12).  
 




Figure 2.3: X-ray structure of compound 2.23 
 




Scheme 2.11: Synthesis of compound 2.27 
 
An alternative synthetic route shown in Schemes 2.13 and 2.14 was followed to 
synthesize precursor 2.28, since the synthesis of 2.28 from 2.27 yielded 20% product, in 
part due to loss of compound during the purification. It is to be noted that synthesis of 

















































    K2CO3, acetone (85%)













Therefore synthesis of 2.28 was achieved alternatively by first synthesizing the 
compound 2.30 in 11% yield, using Lindsey’s method of mixed aldehyde conensation. 
Then the methyl ester was deprotected quantitatively using NaOH/MeOH resulting in the  
carboxylic acid porphyrin, which was then coupled to glycine tert-butyl ester amine, 
using HOBt/TBTU coupling reagents, resulting in compound 2.31 in 80% yield. The tert-
butyl ester of 2.31 was deprotected using TFA quantitatively, followed by conjugation of 
commercially available tert-butyl-12-amino-4,7,10-trioxadodecanoate. HOBt and TBTU 
coupling reagents were used which resulted in 20% yield of 2.32. Deprotection of the 
benzyl ethers on porphyrin 2.32 was achieved in 82% yield by using H2 with 10% Pd/C 
as a catalyst. This resulted in compound 2.33 containing six free hydroxyl groups which 
were used to conjugate cobalta-carborane by nucleophilic ring opening of  [3,3′-Co(8-
C4H8O2–1,2-C2B9H10)(1′,2′-C2B9H11)]. This step yielded 80% and after the deprotection 
of tetrt-butyl group, precursor 2.28 was obtained without much loss of the expensive 
[3,3′-Co(8-C4H8O2–1,2-C2B9H10)(1′,2′-C2B9H11)]. 
The final step was to conjugate several peptides to compound 2.28 using coupling 
conditions (solid phase and solution phase), but this reaction never yielded any targeted 
product even after using several coupling reagents and conditions as shown in the Table 
2.2. Coupling of pegylated peptide with compound 2.27 was also attempted under solid 
and solution phase (see Scheme 2.15) using several coupling reagents as shown in Table 







































































DMF, DIEA, HOBt, HATU (20%)



















1. BF3.OEt2/CH2Cl2, 2h, rt
2. DDQ/CH2Cl2, 45 min, rt

























































DIEA, HOBt, TBTU (20%)
10% Pd/C, THF
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1. TFA/DCM









































































































1. NH2(CH2CH2O)3CH2CH2COYPFR (solution or solid phase)


































































Table 2.2. Coupling reagents and conditions used in both solution and solid phase 
coupling reaction. 
Coupling Reagent Solution phase Solid phase 
HOBt/TBTU rt and 370C Rt 
HATU rt and 370C Rt 
HOBt/HBTU rt and 370C Rt 
PyBOP rt and 370C Rt 
PyAOP rt and 370C Rt 




2.2.2: In Vitro Studies  
 
2.2.2.1: Cytotoxicity. A dark toxicity study on compound 2.28 was conducted 
using the Cell Titer Blue assay on human carcinoma HEp2 cells. There was no significant 
toxicity observed with an IC50 value >400 µM. Upon exposure to 1.5 J/cm2 light dose, no 
toxicity was observed with IC50>100 µM. Since there was no significant toxicity 
observed with high boron containing compound, this can be a promising BNCT delivery 






Figure 2.5: Cytotoxicity of 2.28 toward HEp2 cells using the Cell Titer Blue assay, (a) in 
the dark and (b) after exposure to 1 J/cm2 light dose. 
 
 
2.2.2.2: Localization Studies. Compound 2.28 was studied on HEp2 cells for its 
internalization and preferential localization. The most preferential localization was found 
to be cell lysosomes (see Figure 2.6j), which showed a punctuate fluorescent pattern. This 
is generally observed for most of the carborane substituted porphyrins, which may be due 
to the endocytosis of small aggregates of porphyrin. Minor localization sites were found 
to be the Golgi apparatus and mitochondria (see Figure 2.6g). 

































Figure 2.6: Subcellular fluorescence of conjugate 2.28 in HEp2 cells at 10 µM for 6h. (a) 
Phase contrast, (b) overlay of the 2.28 fluorescence and phase contrast, (c) ER Tracker 
Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY Ceramide, 
(i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers with 2.28 
fluorescence. Scale bar: 10 µm. 
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2.2.3: In Vivo Toxicity Studies. In vitro studies revealed low toxicity for 
porphyrin 2.28. We then investigated the toxicity of this porphyrin in a mouse model. 
MTD studies on porphyrin 2.28 were conducted at the LSU Veterinary Medical School 
under the supervision of Dr. David G. Baker and Dr. Nobuko Wakamatsu. Mice in 
groups 2, 3, 4, 5 and 6 were administered test compound in 3% DMSO diluted in PBS, 
once via intraperitoneal injection, at increasing dosages; group 2 (20 mg/kg of a 2 mg/ml 
solution); group 3 (40 mg/kg of a 2 mg/ml solution); group 4 (80 mg/kg of a 2 mg/ml 
solution); group 5 (160 mg/kg of a 20 mg/ml solution); and group 6 (320 mg/kg of a 20 
mg/ml solution). Mice in group 1 served as vehicle controls and were administered 1.0 
ml/25 gms body weight of 3% DMSO, which corresponded to the volume of DMSO 
injected into mice in group 4. This represented the maximum volume of 3% DMSO 
injected into any group of mice.   
 Groups of mice were dosed sequentially and each group evaluated daily for signs of 
toxicity, including hunched posture, rough hair coat, and decreased responsiveness.  Mice 
were anesthetized with CO2 48 hours after compound administration, and blood collected 
by cardiocentesis for plasma clinical chemistry evaluation. Plasma chemistries performed 
included glucose, aspartic acid aminotransaminase (AST), alanine aminotransaminase 
(ALT), alkaline phosphatase (AP), bilirubin, total protein (TP), albumin, and globulin.  
Mice were exsanguinated and a necropsy performed. Tissues, including lung, kidney, 
thymus, heart, Harderian gland, spleen, stomach, small intestine, colon were fixed in 10% 




Table 2.3. Serum chemistry values for twelve BALB/c mice administered 2.28 with 3% 
DMSO in PBS (groups 2,3,4,5,6) and 3% DMSO in PBS (vehicle: group 1), by i.p. 
injection. 
  
Group               1             2   3    4            5           6 
 
Glucose          150.0             166.0            227.5             140.5             137.0                151.5 
(mg/dl) 
 
AST            1049.0           207.7           2248.5            147.5             146.5                589.5 
(U/L) 
 
ALT            159.5             244.0         337.0               28.5               26.5                 125.5   
(U/L) 
 
AP            116.5              112.0          130.0              125.5             108.0                152.0 
(U/L) 
 
Bilirubin           0.30               0.20          0.40        0.20       0.20        0.30 
(mg/dl) 
 
Total Prot.         5.4              5.0              5.5         5.9        5.9         5.4 
(g/dl) 
 
Albumin             3.1              2.8           3.2         3.3        3.4         3.0 
(g/dl) 
 
Globulin             2.3              2.2           2.3         2.6        2.5         2.5 
(g/dl) 
 
The values represent mean (SEM) serum chemistry levels. 
 
 No signs of toxicity were observed in any mice in this experiment. Plasma 
glucose levels generally increased, likely due to excitement and increased corticosteroid 
release. One mouse in group 1 (control) and both mice in group 3 (40 mg/kg) had highly 
elevated plasma AST levels most likely due to liver trauma during compound injection. 
Values for both mice in group 6 (320 mg/kg) were moderately elevated possibly 
suggestive of mild hepatocyte damage though this was not observed histologically.  A 
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more likely explanation for the moderate elevations in mice of group 6 was muscular 
overexertion. One mouse in each of groups 2 and 3 (20 and 40 mg/kg, respectively) had 
mildly elevated plasma ALT levels. One of these (from group 3) was one of the mice 
with elevated AST. These mild elevations were likely due to trauma to the liver during 
compound injection. Overall there did not appear to be a treatment effect on ALT. Plasma 
alkaline phosphatase levels were within normal limits suggestive of a lack of toxicity for 
several of the major organ systems including the renal, gastrohepatic, immune, and 
skeletal systems. Plasma bilirubin levels were within normal limits. Plasma total protein 
levels plateaued in mice of group 5 (160 mg/kg) and declined slightly in mice of group 6 
(320 mg/kg) most likely because of reductions in albumin levels. However, levels of total 
protein in all mice remained within normal limits.  
Plasma albumin levels declined slightly in mice of group 6 (320 mg/kg) but 
remained within normal limits.  No treatment effects were noted in plasma globulin 
levels. Values for all mice were within normal limits. In conclusion, elevated plasma 
AST and ALT were likely indicative of muscular overexertion and/or liver trauma during 
compound injection. No clinical chemical alterations could be directly attributed to 
compound toxicity. Further, lack of toxicologic effects was supported by the histologic 
findings.  
 Histopathologic examination revealed no lesions attributable to compound 
administration. Extramedullary hematopoiesis was observed in all mice, and may 
represent mild levels of stress, or may be normal for these animals. Moderate thickening 
of Bowman’s capsule (periglomerular fibrosis) was observed in one renal glomerulus of 
one mouse in group 3 and likely represented an incidental finding.   
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In summary, no clinical, biochemical, or histopathological effects were observed 
which could be attributed to administration of porphyrin 1. Likewise, no changes were 
noted that could be attributed to vehicle administration of 3% DMSO in PBS. Therefore, 
the maximum tolerated dose (MTD) is found to be 320 mg/kg. 
2.3: Conclusions 
 
 A high boron containing porphyrin 2.28 containing a PEG unit was synthesized 
by nucleophiclic ring opening of the dioxane ring on a cobaltabisdicarbollide, by 
nucleophilic phenoxy anion. This was done by two different ways where the alternative 
Scheme 2.13 and 2.14 gave compound 2.28 with minimal loss of [3,3′-Co(8-C4H8O2-1,2-
C2B9H10)(1′,2′-C2B9H11)] and easier purification. In vitro and In vivo toxicity studies 
were carried out on compound 2.28 to check its toxicity before proceeding with the 
conjugation of biomolecules. Compound 2.28 didn’t show any cytotoxicity (dark toxicity 
IC50>400 µM and phototoxicity IC50>100 µM) when tested on HEp2 cells and no 
systematic toxicity was observed with the MTD value of 320 mg/kg in BALB/c mice. 
Since this compound 2.28 is non-toxic, peptide coupling on compound 2.28 (solution and 
solid phase) was attempted using several coupling reagents but with no success. 
Pegylated peptide coupling on compound 2.27 (solution and solid phase) was also 
attempted, again without any success. Although, compound 2.27 gave the desired product 
2.28 when reacted with tert-butyl protected PEG in solution phase, the non reactivity of 
porphyrin 2.28 and 2.27 with peptides or pegylated peptide could be attributed due to the 
aggregation behavior of cobalta-carborane porphyrin26 or presence of bulky cobalta-
carboranyl moiety which could hinder the reactivity of peptides with compound 2.27 or 





2.4.1: General Information 
 
Commercially available reagents and solvents (HPLC grade) were purchased 
from Sigma-Aldrich and used without further purification. COSAN was purchased from 
Katchem, Inc. Silica gel 60 (70–230 mesh, Merk) used for column chromatography and 
silica gel TLC plates (0.2 mm thickness) were purchased from Sorbent Technologies. 
1H NMR and 13C NMR spectra were obtained using a Bruker AV-400 MHZ 
spectrometer; chemical shifts are expressed in ppm. Electronic absorption spectra were 
measured on a Perkin Elmer Lambda 35 UV-vis spectrophotometer. Mass analysis was 
conducted at the LSU Mass Spectrometry Facility on a Bruker Omniflex MALDI-TOF 
mass spectrometer and exact masses were obtained from HRMS-ESI under negative 
mode on an Applied Biosystems QSTAR XL. Melting points were measured on a 
Thomas hoover melting point apparatus. Analytical reverse phase HPLC was performed 
on a Waters system including a 2545 quaternary gradient module pump with a 2489 UV-
vis detector and a fraction collector III. Analytical column (4.6X250 mm-XBridgeTM 
BED300 C18 5 µm) and acetonitrile/water solvent system, varying gradient from 100% 
water (2 min) to 75% acetonitrile/water (5 min) to 100% acetonitrile (10 min). 
[3,3′-Co(8-C4H8O2-1,2-C2B9H10)(1′,2′-C2B9H11)] was prepared as previously described.32  
2.4.2: Synthesis  
 
5,10,15-tri(3,5-dimethoxyphenyl)-20-(4-benzyloxyphenyl) porphyrin (2.21)  
3,5-dimethoxybenzaldehyde (0.498 g, 3.0 mmol), 4-benzyloxybenzaldehyde 
(0.318 g, 1.5 mmol), and freshly distilled pyrrole (0.278 mL, 4 mmol) were mixed in a 1 
L flask. Dry CH2Cl2 (500 mL) was added and the solution stirred under argon for 20 min. 
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BF3.OEt2 (0.16 mL of 2.5 M in CH2Cl2) was added at once. The reaction mixture was 
stirred for 2 h under argon and in the dark. DDQ (0.492 g, 2.16 mmol) was added and the 
stirring continued for 45 min. Then the resulting mixture was neutralized using aqueous 
NaHCO3 and filtered through a silica gel pad using CH2Cl2 as the solvent. The resulting 
residue was further purified by silica gel column chromatography using CH2Cl2/hexanes 
(9.8:0.2). The main product was isolated and dried (0.09 g, 10%), mp > 3000C. 1H NMR 
(CDCl3, 400 MHz): δ, ppm 8.96 (d, J = 7.08 Hz, 6H, β-H), 8.78 (d, J = 4.64 Hz, 2H, β-
H), 8.45 (d, J = 8.04 Hz, 2H, o-PhH), 8.31 (d, J = 8.00 Hz, 2H, m-PhH), 7.40 (m, 10H, o-
PhH and m-PhH), 6.91 (m, 4H, p-PhH), 5.12 (s, 2H, OCH2), 3.97 (s, 18H, OCH3), -2.81 
(s, 2H, NH). 13C NMR (CDCl3, 100 MHz): δ, ppm 158.9, 147.2, 142.9, 135.1, 131.2, 
129.5, 127.8, 127.2, 120.3, 120.2, 118.6, 113.8, 100.9, 72.0, 55.8. MS (MALDI-TOF): 
m/z 901.358, calcd. for C52H44N4O8 901.355. UV-vis (acetone): λmax, nm (ε) 418 
(414400), 513 (16100), 553 (4400), 596 (2600). 
 5,10,15-tri(3,5-dimethoxyphenyl)-20-(4-acetoxyphenyl) porphyrin (2.23) 
 3,5-dimethoxybenzaldehyde (0.498 g, 3.0 mmol), 4-acetoxybenzaldehyde (0.246 
g, 1.5 mmol), and freshly distilled pyrrole (0.278 mL, 4.0 mmol) were mixed in a 1 L 
flask. Dry CH2Cl2 (500 mL) was added and the mixture stirred under argon for 20 min. 
BF3.OEt2 (0.16 mL of 2.5 M in CH2Cl2) was added at once. The reaction mixture was 
stirred for 2 h under argon and in the dark. DDQ (0.492 g, 2.16 mmol) was added and the 
stirring continued for 45 min. Then the resulting mixture was neutralized using aqueous 
NaHCO3 and filtered through a silica gel pad using CH2Cl2 as the solvent. The resulting 
residue was further purified by silica gel column chromatography using CH2Cl2/hexanes 
(9.8:0.2). The main product was isolated and dried (0.102g, 12%), mp > 3000C. 1H NMR 
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(CDCl3 , 400 MHz): δ , ppm 8.89 (d, J  = 8.80 Hz, 6H, β -H), 8.76 (d, J  = 5.46 Hz, 2H, β 
-H), 8.48 (d, J  = 8.54 Hz, 2H, o-PhH), 8.39 (d, J  = 7.68 Hz, 2H, m-PhH), 7.44 (s, 6H, o-
PhH), 6.95 (s, 3H, p-PhH),  3.96 (s, 18H, OCH3 ), 2.12 (s, 3H, CH3CO) -2.80 (s, 2H, 
NH). 13C NMR (CDCl3 , 100 MHz): δ , ppm 170.0, 158.7, 147.1, 143.7, 134.8, 131.2, 
129.0, 127.9, 120.1, 120.0, 118.6, 113.9, 100.2, 55.5, 20.1. MS (MALDI-TOF): m/z  
852.322, calcd. for C52H44N4O8 852.316. UV-vis (acetone): λmax , nm (ε ) 419 (426700), 
515 (15200), 549 (4200), 588 (2700).  
Synthesis 5,10,15-tri(3,5-dimethoxyphenyl)-20-(4-methylesterphenyl) porphyrin 
(2.25) 
 
3,5-dimethoxybenzaldehyde (0.498 g, 3.0 mmol), methyl-4-formyl benzoate 
(0.246 g, 1.5 mmol), and freshly distilled pyrrole (0.278 mL, 4.0 mmol) were mixed in a 
1 L flask. Dry CH2Cl2 (500 mL) was added and the mixture stirred under argon for 20 
min. BF3.OEt2 (0.16 mL of a 2.5 M solution in CH2Cl2) was added at once. The reaction 
mixture was stirred for 2 h under argon in the dark. DDQ (0.492 g, 2.16 mmol) was 
added and the stirring continued for 45 min. Then the resulting mixture was neutralized 
using aqueous NaHCO3 and filtered through a silica gel pad using CH2Cl2 as the solvent. 
The resulting residue was further purified by silica gel column chromatography using 
CH2Cl2/hexanes (9.8:0.2) for elution. The second and main fraction was collected and 
dried under vacuum 
(0.09 g, 11%), mp > 3000C. 1H NMR (CDCl3, 400 MHz): δ, ppm 8.95 (d, J = 8.08 Hz, 
6H, β-H), 8.79 (d, J = 5.04 Hz, 2H, β-H), 8.42 (d, J = 7.94 Hz, 2H, o-PhH), 8.21 (d, J = 
7.98 Hz, 2H, m-PhH), 7.42 (s, 6H, o-PhH), 6.98 (s, 3H, p-PhH), 4.12 (s, 3H, COOCH3), 
3.98 (s, 18H, OCH3), -2.81 (s, 2H, NH). 13C NMR (CDCl3, 100 MHz): δ, ppm 167.4, 
158.9, 147.0, 143.9, 134.5, 131.3, 129.6, 127.9, 120.1, 120.0, 118.6, 113.9, 100.2, 55.6, 
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52.5. MS (MALDI-TOF): m/z 852.779, calcd. for C52H44N4O8 852.316. UV-vis 
(acetone): λmax, nm (ε) 422 (466600), 519 (14500), 553 (1330), 596 (880).  
5,10,15-tri(3,5-dihydroxyphenyl)-20-[4-carboxyGly(Boc)]phenyl)porphyrin (2.26)  
To porphyrin 2.25  (0.095 g, 0.1 mmol) in dry CH2Cl2  (20 mL) at -200C was 
added dropwise a solution of BBr3  (0.52 mL, 5.3 mmol) in CH2Cl2 (1.5 mL) with 
vigorous stirring under argon over a period of 30 min. The reaction mixture was stirred at 
room temperature for 24 h and then poured into water and extracted with ethyl acetate 
(50 mL). The combined organic layers were washed successively with brine and aqueous 
NaHCO3. The organic layer was dried over Na2SO4 and evaporated to dryness to give the 
title porphyrin in 90% yield, mp > 3000C. 1H NMR (Acetone-d6, 400 MHz): δ , ppm 9.05 
(s, 6H, β -H), 8.86 (s, 2H, β -H), 8.73 (broad s, 6H, OH), 8.50 (d, J  = 7.88 Hz, 2H, o-
PhH), 8.39 (d, J  = 7.88 Hz, 2H, m-PhH), 7.25 (s, 6H, o-PhH), 6.84 (s, 3H, p-PhH), -2.79 
(s, 2H, NH). 13C NMR (d-acetone, 100 MHz): δ , ppm 166.9, 156.8, 146.8, 143.7, 134.5, 
130.1, 128.1, 120.4, 120.3, 118.5, 114.5, 102.3. MS (MALDITOF): m/z 755.432, calcd. 
for C45H30N4O8  755.209. UV-vis (Acetone): λmax , nm (ε ) 422 (360600), 519 (16700), 
553 (5900), 596 (5400), 654 (2800).  
To 5,10,15-tri(3,5-dihydroxyphenyl)-20-(4-carboxyphenyl)porphyrin (0.05 g, 
0.066 mmol) was added N ,N–diisopropylethylamine (0.0854 g, 0.66 mmol) and 1.5 mL 
DMF and the resulting mixture was stirred for 5 min. HOBt (0.009 g, 0.066 mmol) and 
TBTU (0.021 g, 0.066 mmol) were added and the stirring continued at room temperature 
for 15 min. Glycine tert -butyl ester hydrochloride (0.101 g, 0.1 mmol) was added and the 
final reaction mixture was stirred at room temperature under nitrogen for 48 h. Ethyl 
acetate was added and the organic solution was washed with brine. The resulting residue 
	  
 68 
was purified by silica gel column chromatography using ethyl acetate for elution. The 
title porphyrin was obtained in 80% yield, mp> 3000C. 1H NMR (Acetone-d6, 400 MHz): 
δ , ppm 9.05 (s, 6H, β -H), 8.86 (s, 2H, β -H), 8.37 (bs, 6H, OH),7.90 (d, J  = 8.44 Hz, 
2H, o-PhH), 7.69 (d, J  = 8.32 Hz, 2H, m-PhH), 7.26 (s, 6H, o-PhH), 6.85 (s, 3H, p-PhH), 
1.54 (s, 9H, C(CH3)3 ), -2.79 (s, 2H, NH). 13C NMR (Acetone-d6, 100 MHz): δ, ppm 
169.0, 167.0, 156.7, 145.2, 143.7, 142.9, 134.4, 133.8, 128.3, 127.1, 125.8, 124.5, 120.4, 
120.3, 118.9, 118.7, 114.5, 102.3, 80.8, 42.2, 27.4. MS (MALDI-TOF): m/z 867.913, 
calcd. for C51H41N5O9 867.290. UV-vis (Acetone): λmax , nm (ε ) 423 (364000), 519 
(18300), 555 (7400), 598 (6000), 654 (3500). 
Compound 2.27   
Porphyrin 4  (14.7 mg, 0.017 mmol) and K2CO3  (28.0 mg, 0.20 mmol) were 
refluxed in 10 mL acetone in a 50 mL round bottom flask under argon for 15 min. The 
reaction mixture was cooled to room temperature and [3,3 ′-Co(8-C4H8O2– 1,2-C2B9H10 ) 
(1′,2′-C2B9H11)] (42.0 mg, 0.10 mmol) was added. The resulting mixture was stirred at 
room temperature for 2 h under argon, and then refluxed overnight. The second portion of 
[3,3′-Co(8-C4H8O2-1,2-C2B9H10) (1′ ,2′-C2B9H11)] (21.0 mg, 0.05 mmol) was added and 
reflux continued for 24 h. The last portion of [3,3′-Co(8-C4H8O2–1,2-C2B9H10) (1′,2′-
C2B9H11)] (21.0 mg, 0.05 mmol) was added and reflux continued for an additional 24 h. 
The reaction was stopped, acetone was evaporated and the resulting solid was washed 
with diethyl ether several times to remove excess cobaltabisdicarbollide. The resulting 
orange-red color solid of the corresponding tert-butyl-protected porphyrin was kept under 
vacuum to remove traces of diethyl ether; this porphyrin was obtained (49 mg) in 85% 
yield. 1H NMR (Acetone-d6, 400 MHz): δ, ppm 9.01 (s, 6H, β-H), 8.86 (s, 2H, β-H), 8.37 
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(s, 4H, o,m-PhH), 7.48 (s, 6H, o-PhH), 7.08 (s, 3H, p-PhH), 4.40 (s, 12H, OCH2), 4.17 (s, 
24H, OCH2), 3.93 (s, 12H, OCH2), 3.67 (s, 24H, Carb-H), 1.6–3.0 (br, 104, BH, CH2), 
1.54 (s, 9H, COOC(CH3)3), -2.79 (s, 2H, NH). 13C NMR (Acetone-d6, 100 MHz): δ, ppm 
170.1, 162.0, 158.3, 158.0, 149.9, 145.1, 143.7, 114.5, 101.1, 100.7, 72.2, 69.4, 68.4, 
68.0, 59.7, 54.5, 46.6, 28.8. HRMS-ESI: m/z 670.4627 [M-6K+Na]5- , calcd. for 
[C99H209B108Co6NaN5O21]5-  670.0437. UV-vis (acetone): λmax, nm (ε ) 424 (367702), 
519 (7041). 
To this porphyrin (49 mg, 15 mmol) dissolved in 5 mL of CH2Cl2/acetone 1:1, 
TFA (5 mL) was added and the final mixture was stirred at room temperature for 4 h. The 
solvents were removed under vacuum and the resulting residue was washed several times 
with diethyl ether and dried under vacuum. The carboxylated porphyrin was obtained (45 
mg) as a green powder in 95% yield. 1H NMR (Acetone-d6, 400 MHz): δ, ppm 9.01 (s, 
6H, β -H), 8.86 (s, 2H, β -H), 8.37 (s, 4H, o,m-PhH), 7.47 (s, 6H, o-PhH), 7.08 (s, 3H, p-
PhH), 4.39 (s, 12H, OCH2), 4.19 (s, 24H, OCH2), 3.93 (s, 12H, OCH2), 3.67 (s, 24H, 
Carb-H), 1.50–2.51 (br, 104, BH, CH2), -2.79 (s, 2H, NH). HRMS-ESI m/z 818.3561 [M- 
6K+2H]4-, calcd. For [C95H203B108Co6N5O21]4-  818.2954. UV-vis (acetone): λmax , nm (ε 
) 424 (584300), 520 (28500), 556 (8000), 599 (7700), 655 (2900).  
Compound 2.28 
This porphyrin (45 mg, 0.013 mmol) was dissolved in DMF (200 µL) and DIEA 
(13 mg, 0.1 mmol) and the solution stirred at room temperature for 30 min. HOBt (1.84 
mg, 0.014 mmol) and HATU (5.18 mg, 0.014 mmol) were added and the mixture was 
stirred for 1 h. Tert-butyl-12-amino-4,7,10-trioxadodecanoate (4.7 mg, 0.014 mmol) was 
added to the reaction solution at once and the final mixture was stirred for 72 h at room 
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temperature, under nitrogen. The solvents were evaporated under vacuum and the 
resulting residue dissolved in ethyl acetate. The organic solution was washed with 
saturated aqueous NaCl and water. The solvent was evaporated to give a dry residue, 
which was purified by silica gel column chromatography using acetonitrile/CH2Cl2 7:3 as 
the eluent. The resulting tert –butyl-protected porphyrin-PEG was obtained in 20% yield 
(9.7 mg). 1 H NMR (d-acetone, 400 MHz): δ, ppm 9.03 (s, 6H, β -H), 8.88 (s, 2H, β -H), 
8.39 (s, 4H, o,m-PhH), 7.47 (s, 6H, o-PhH), 7.07 (s, 3H, p-PhH), 4.38 (s, 12H, OCH2), 
4.24 (s, 24H, OCH2), 3.93 (s, 12H, OCH2), 3.66–3.57 (m, 36H, Carb-H, OCH2), 1.50–
2.51 (bs, 108, BH, CH2), -2.79 (s, 2H, NH). HRMS-ESI: m/z 714.5167 [M-5K]5-, calcd. 
for [C108H226B108Co6 KN6O25]5-  714.0612. UV-vis (acetone): λmax, nm (ε ) 424 
(455900), 519 (5740), 555 (2500), 598 (2050), 654 (1400). To a solution of the tert butyl-
protected porphyrin-PEG (9.7 mg, 0.0025 mmol) in acetone (1 mL), TFA (1 mL) was 
added and the reaction mixture was stirred at room temperature for 4 h. The solvents 
were evaporated under vacuum and the resulting solid was washed several times with 
diethyl ether. After drying, porphyrin 5 was obtained in 95% (9 mg) yield. 1 H NMR (d-
acetone, 400 MHz): δ, ppm 9.15 (s, 6H, β -H), 9.01 (s, 2H, β -H), 8.61 (s, 4H, o,m-PhH), 
7.91 (s, 3H, p-PhH), 7.31 (s, 6H, o-PhH), 4.51 (s, 12H, OCH2), 4.30 (s, 24H, OCH2), 4.02 
(s, 12H, OCH2), 3.69 (s, 24H, Carb-H), 3.60 (s, 12H, OCH2), 1.55–2.85 (bs, 108, BH, 
CH2). HRMS-ESI: m/z 707.1274 [M-5K-H+Na]5-, calcd. for 
[C104H217B108Co6KNaN6O25]5- 707.0457. UV-vis (acetone): λmax , nm (ε ) 424 (493600), 
519 (25400), 555 (10250), 598 (8350), 654 (5300). HPLC tR  = 8.76.           
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Synthesis 5,10,15-tri(3,5-dibenzyloxyphenyl)-20-(4-methylesterphenyl) porphyrin 
(2.30) 
 
3,5-dibenzyloxybenzaldehyde (0.954 g, 3.0 mmol), methyl-4-formyl benzoate 
(0.246 g, 1.5 mmol), and freshly distilled pyrrole (0.278 mL, 4.0 mmol) were mixed in a 
1 L flask. Dry CH2Cl2 (500 mL) was added and the mixture stirred under argon for 20 
min. BF3.OEt2 (0.16 mL of a 2.5 M solution in CH2Cl2) was added at once. The reaction 
mixture was stirred for 2 h under argon in the dark. DDQ (0.492 g, 2.16 mmol) was 
added and the stirring continued for 45 min. Then the resulting mixture was neutralized 
using aqueous NaHCO3 and filtered through a silica gel pad using CH2Cl2 as the solvent. 
The resulting residue was further purified by silica gel column chromatography using 
CH2Cl2/hexanes (9.5:0.5) for elution. The second and main fraction was collected and 
dried under vacuum (0.14 g, 11%), mp > 3000C. 1H NMR (CDCl3, 400 MHz): δ, ppm 
8.95 (d, J = 8.08 Hz, 6H, β-H), 8.76 (d, J = 6.64 Hz, 2H, β-H), 8.45 (d, J = 8.04 Hz, 2H, 
o-PhH), 8.31 (d, J = 8.00 Hz, 2H, m-PhH), 7.40 (m, 18H, o-PhH), 7.23 (m, 12H, m-PhH), 
6.9 (m, 9H, p-PhH), 4.74 (s, 18H, OCH2Ph), 4.14 (s, 3H, COOCH3), -2.83 (s, 2H, NH). 
13C NMR (CDCl3, 100 MHz): δ, ppm 168.4, 152.9, 141.0, 140.9, 134.6, 131.8, 129.6, 
128.3, 127.6, 121.6, 120.4, 120.0, 118.6, 113.9, 100.2, 55.6, 52.5. MS (MALDI-TOF): 
m/z 1308.5035, calcd. for C88H68N4O8 1308.5037. UV-vis (acetone): λmax, nm (ε) 422 
(485100), 519 (19600), 553 (5480), 596 (1230).  
5,10,15-tri(3,5-dibenzyloxyphenyl)-20-[4-carboxyGly(Boc)]phenyl)porphyrin (2.31)  
To 5,10,15-tri(3,5-dibenzyloxyphenyl)-20-(4-methylesterphenyl) (0.14 g, 0.11 
mmol) in 30 ml Chloroform, 10 ml saturated NaOH/MeOH is added and stirred overnight 
at room temperature. Then the resulting mixture is neutralized with 1N HCl and the 
organic layer is extracted and evaporated to give the desired product in 85% yield (122 g, 
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0.09 mmol).  1H NMR (CDCl3, 400 MHz): δ, ppm 8.91 (s, 6H, β-H), 8.71 (s, 2H, β-H), 
8.15 (d, J = 7.96 Hz, 2H, o-PhH), 8.01 (d, J = 8.8 Hz, 2H, m-PhH), 7.32 (m, 18H, o-
PhH), 7.14 (m, 12H, m-PhH), 6.21 (m, 9H, p-PhH), 4.72 (s, 18H, OCH2Ph), -2.81 (s, 2H, 
NH). MS (MALDI-TOF): m/z [M+Na]+ 1317.4739, calcd. for C88H67N4O8Na 1317.4765. 
To 5,10,15-tri(3,5-dibenzyloxyphenyl)-20-(4-carboxyphenyl)porphyrin (0.09 g, 0.066 
mmol) was added N ,N–diisopropylethylamine (0.0854 g, 0.66 mmol) and 1.5 mL DMF 
and the resulting mixture was stirred for 5 min. HOBt (0.009 g, 0.066 mmol) and TBTU 
(0.021 g, 0.066 mmol) were added and the stirring continued at room temperature for 15 
min. Glycine tert-butyl ester hydrochloride (0.101 g, 0.1 mmol) was added and the final 
reaction mixture was stirred at room temperature under nitrogen for 48 h. Ethyl acetate 
was added and the organic solution was washed with brine. The resulting residue was 
purified by silica gel column chromatography using ethyl acetate for elution. The title 
porphyrin was obtained in 80% yield (0.07 g, 0.05 mm0l). mp> 3000C. 1H NMR (d-
acetone, 400 MHz): δ, ppm 9.08 (s, 6H, β -H), 8.79 (s, 2H, β -H), 7.90 (d, J  = 8.44 Hz, 
2H, o-PhH), 7.69 (d, J  = 8.32 Hz, 2H, m-PhH), 7.36 (m, 18H, o-PhH), 7.24 (m, 12H, m-
PhH), 6.35 (m, 9H, p-PhH), 2.41 (s, 2H, CH2), 1.54 (s, 9H, C(CH3)3 ), -2.81 (s, 2H, NH). 
13C NMR (d-acetone, 100 MHz): δ, ppm 169.2, 166.8, 156.9, 144.1, 143.2, 142.5, 141.4, 
133.1, 127.3, 126.1, 125.8, 125.7, 125.1, 124.1, 120.2, 120.3, 119.1, 118.6, 115.4, 106.1, 
80.4, 42.3, 27.9. MS (MALDI-TOF): m/z 1408.6318, calcd. for C93H77N5O9 1408.6321. 








(0.07 g, 0.05 mmol) was added 5 ml 1:1 TFA/DCM and stirred for 4 h under room 
temperature and after evaporation of solvent resulted in 95% (0.065 g, 0.05 mmol) of 
desired product. 1H NMR (d-acetone, 400 MHz): δ; 9.01 (s, 6H, β -H), 8.65 (s, 2H, β -H), 
7.89 (s, 2H, o-PhH), 7.71 (s, 2H, m-PhH), 7.41 (m, 18H, o-PhH), 7.21 (m, 12H, m-PhH), 
6.36 (m, 9H, p-PhH), 2.46 (s, 2H, CH2). MS (MALDI-TOF): m/z 1373.4398, calcd. for 
C89H68N5NaO9 1373.4345. 
To the above compound (0.09 g, 0.066 mmol) was added N ,N–
diisopropylethylamine (0.0854 g, 0.66 mmol) and 1.5 mL DMF and the resulting mixture 
was stirred for 5 min. HOBt (0.009 g, 0.066 mmol) and TBTU (0.021 g, 0.066 mmol) 
were added and the stirring continued at room temperature for 15 min. Tert-butyl-12-
amino-4,7,10- trioxadodecanoate (0.276 g, 0.1 mmol) was added and the final reaction 
mixture was stirred at room temperature under nitrogen for 48 h. Ethyl acetate was added 
and the organic solution was washed with brine. The resulting residue was purified by 
silica gel column chromatography using ethyl acetate for elution. The title porphyrin was 
obtained in 20% yield (0.02 g, 0.013 mmol). mp= 2950C, 1H NMR (d-acetone, 400 
MHz): δ; 9.01 (s, 6H, β -H), 8.77 (s, 2H, β -H), 7.80 (s, 2H, o-PhH), 7.56 (s, 2H, m-PhH), 
7.16 (m, 18H, o-PhH), 7.32 (m, 12H, m-PhH), 6.31 (m, 9H, p-PhH), 3.81 (s, 4H, CH2), 
3.62-3.78 (m, 12H, CH2), 2.41 (s, 2H, CH2), 1.44 (s, 9H, C(CH3)3 ), -2.81 (s, 2H, NH). 
13C NMR (d-acetone, 100 MHz): δ, ppm 172.7, 169.4, 166.9, 157.2, 144.9, 143.4, 142.4, 
141.6, 133.9, 127.3, 126.1, 125.8, 125.7, 125.1, 124.1, 120.2, 120.3, 119.1, 118.6, 117.8, 
115.4, 106.1, 80.4, 79.9, 53.4, 42.3, 27.9. MS (MALDI-TOF): m/z 1611.6814, calcd. for 
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C102H94N6O13 1611.6704. UV-vis (acetone): λmax , nm (ε ) 423 (463900), 519 (21400), 
555 (10400), 598 (7100), 654 (2950). 
Compound 2.33 
  To compound 2.32 (0.037 g, 0.023 mmol) in 10 ml THF was added Pd/C and 
mixed for 5 min before H2 gas was used and stirred for 24 h. Then the mixture is passed 
through celite to remove Pd/C and after evaporation of solvent resulted in the desired 
product in 82% yield (0.02 g, 0.018 mmol). 1H NMR (d-acetone, 400 MHz): δ; 9.04 (s, 
6H, β -H), 8.67-8.87 (m, 8H, β –H, OH), 8.33 (s, 4H, o,m-PhH), 7.25 (s, 2H, o-PhH), 
6.84 (s, 3H, p-PhH), 4.05-4.18 (m, 4H, CH2), 3.48-3.55 (m, 12H, CH2), 1.37 (s, 9H, 
C(CH3)3), -2.79 (s, 2H, NH). 13C NMR (d-acetone, 100 MHz): δ , ppm 172.6, 169.1, 
165.1, 158.8, 144.7, 143.4, 142.4, 141.6, 133.9, 127.3, 126.1, 125.8, 125.7, 125.1, 124.1, 
118.9, 117.3, 115.7, 106.1, 80.6, 79.1, 53.8, 42.7, 27.3. MS (MALDI-TOF): m/z [M+1]+ 
1071.1378, calcd. for C60H58N6O13 1071.1348. UV-vis (acetone): λmax , nm (ε ) 423 
(493100), 519 (22300), 555 (9900), 598 (6900), 654 (3150). 
X-ray crystallographic data 
  Crystals of porphyrins 2.21, 2.23 and 2.25  for X-ray crystallographic analysis 
were grown by slow evaporation of their hexane/dichloromethane solutions. Diffraction 
data were collected at low temperature on a Bruker Kappa Apex-II CCD diffractometer 
equipped with CuKα radiation (λ  = 1.54178 .) and an Oxford Cryosystems Cryostream 
chiller. Refinement was by full-matrix least squares using SHELXL, with H atoms in 
idealized positions, guided by difference maps. For porphyrins 2.23 and 2.25, the NH 
hydrogen atoms are disordered, and were placed into four half-populated sites. In 
porphyrin 2.23, dichloromethane and hexane solvent molecules shared a disordered site 
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on an inversion center. For porphyrin 2.25, electron density amounting to 0.85 molecules 
of disordered dichloromethane per porphyrin molecule was removed using the 
SQUEEZE procedure. 
Crystal data of porphyrin 2.21 
 
C57H48N4O7 Z = 1, Mr = 900.99 F000 = 474, Triclinic, P1 Dx = 1.269 Mg m−3, Hall 
symbol: P 1 Cu Kα radiation, λ = 1.54178 Å, a = 9.420 (2) Å Cell parameters from 2726 
reflections, b = 9.786 (2) Å θ = 3.4–66.8º, c = 13.609 (3) Å µ = 0.68 mm−1, α = 102.099 
(14)º T = 90 K, β = 102.101 (15)º Lath, orange, γ = 97.645 (15)º 0.28 × 0.18 × 0.04 mm, 
V = 1178.7 (4) Å3, Data collection, Bruker Kappa Apex-II CCD area detector 
diffractometer 6619 independent reflections, Radiation source: fine-focus sealed tube 
4739 reflections with I > 2σ(I), Monochromator: graphite Rint = 0.043, T = 90 K θmax = 
68.4º, phi and ω scans θmin = 3.4º, Absorption correction: multi-scan SADABS 
(Sheldrick, 2002) h = −11→10, Tmin = 0.833, Tmax = 0.973 k = −11→11, 
14545measured reflections l = −16→16. 
Crystal data of porphyrin 2.23 
 
C52H44N4O8·0.307(C6H14)·0.386(CH2Cl2) Z = 2, Mr = 912.11 F000 = 959, Triclinic, P1 
Dx = 1.300 Mg m−3, Hall symbol: -P 1 Cu Kα radiation, λ = 1.54178 Å, a = 9.7437 (5) Å 
Cell parameters from 9947 reflections, b = 13.4281 (10) Å θ = 4.2–68.4º, c = 18.2079 
(15) Å µ = 1.10 mm−1, α = 87.136 (6)º T = 90 K, β = 78.429 (6)º Prism, orange, γ = 
89.623 (5)º 0.32 × 0.28 × 0.22 mm, V = 2331.0 (3) Å3; Data collection Bruker Kappa 
Apex-II CCD area detector diffractometer 8270 independent reflections, Radiation 
source: fine-focus sealed tube 7789 reflections with I > 2σ(I), Monochromator: graphite 
Rint = 0.022, T = 90 K θmax = 69.0º, phi and ω scans θmin = 2.4º, Absorption 
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correction: multi-scan SADABS (Sheldrick, 2002) h = −10→11, Tmin = 0.719, Tmax = 
0.794 k = −15→16, 23985 measured reflections l = −21→21. 
 
Crystal data 2.25 
 
C52H44N4O8·0.85(CH2Cl2) Z = 2, Mr = 925.13 F000 = 967, Triclinic, P1 Dx = 1.333 Mg 
m−3, Hall symbol: -P 1 Cu Kα radiation, λ = 1.54178 Å, a = 9.7004 (5) Å Cell 
parameters from 9980 reflections, b = 13.3343 (9) Å θ = 3.3–68.0º, c = 18.2186 (10) Å µ 
= 1.61 mm−1, α = 86.830 (5)º T = 90 K, β = 78.328 (5)º Needle, orange-purple, γ = 
89.435 (5)º 0.26 × 0.22 × 0.13 mm, V = 2304.3 (2) Å3. Data collection Bruker Kappa 
Apex-II CCD area detector diffractometer 8188 independent reflections. Radiation 
source: fine-focus sealed tube 7440 reflections with I > 2σ(I). Monochromator: graphite 
Rint = 0.023, T = 90 K θmax = 68.9º, phi and ω scans θmin = 2.4º, Absorption 
correction: multi-scan SADABS (Sheldrick, 2002) h = −11→11, Tmin = 0.746, Tmax = 
0.811 k = −15→15, 22993 measured reflections l = −19→21. 
 
2.4.3: Cell studies 
 
  All tissue culture media and reagents were obtained from Invitrogen. Human 
HEp2 cells were obtained from ATCC and maintained in a 50:50 mixture of 
DMEM:Advanced MEM containing 5% FBS. The cells were sub-cultured biweekly to 
maintain sub-confluent stocks. 
2.4.3.1.Cytotoxicity.  The HEp2 cells were plated at 10 000 per well in a Costar 
96 well plate and allowed to grow 36 h. Conjugate stocks 1–5 were prepared in DMSO at 
a concentration of 10 mM and then diluted into medium to final working concentrations. 
The cells were exposed to increasing concentrations of HCP–PEG up to 400 µ M and 
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incubated overnight. The loading medium was then removed and the cells fed with 
medium containing Cell Titer Blue (Promega) as per manufacturer’s instructions. Cell 
viability was then measured by reading the fluorescence at 520/584 nm using a BMG 
FLUOstar plate reader. 
The signal was normalized to 100% viable (untreated) cells and 0% viable 
(treated with 0.2% saponin from Sigma) cells. For the phototoxicity experiment the cells 
were prepared as described above and exposed to HCP–PEG concentrations up to 100 µ 
M. The cells were exposed to a 100 W halogen lamp for 20 min, filtered through a 610 
nm long pass filter to provide approximately 1 J/cm2 light dose. The cells were kept cool 
by filtering the IR radiation through 10 mm of water and placing the culture in an ice-
water bath. After exposure to light, the plate was incubated overnight and the cell 
viability was measured as described above. 
2.4.3.2.Microscopy.  The HEp2 cells were incubated in a glass bottom 6-well 
plate (MatTek) and allowed to grow for 48 h, before being exposed to 10 µ M of HCP–
PEG for 6 h. For the co-localization experiments the cells were incubated for 24 h 
concurrently with porphyrin and one of the following organelle tracers (Invitrogen), for 
30 min: ER Tracker Blue/White 100 nM (endoplasmic reticulum), MitoTracker Green at 
250 nM (mitochondria), LysoSensor Green at 50 nM (lysosomes), BODIPY FL C5 -
ceramide at 50 nM (Golgi network). The slides were washed three times with growth 
medium and new medium containing 50 mM HEPES pH 7.4 was added. The images 
were acquired using a Leica DMRXA microscope with 40Å~ NA 0.8 dip objective lens 







  The mice which we used in this project were obtained from the breeding colony 
operated by the Division of Laboratory Animal Medicine, School of Veterinary 
Medicine, Louisiana State University. The experiments were conducted according to the 
guidelines in the protocol approved by Louisiana State University Institutional Animal 
Care and Use Committee, fully accredited by the Association of Laboratory Animal Care, 
International. 
Six groups of two BALB/c mice, 4–11 weeks of age and weighing 12–24 g, were 
used; among these 11 were females and 1 male. Mice in groups 2,3,4,5, and 6 were 
administrated compound 2.28 in 3% DMSO diluted in PBS once via ip injection, at 
increasing dosages; group 2 (20 mg/kg of a 2 mg/mL solution), group 3 (40 mg/kg of a 2 
mg/mL solution), group 4 (80 mg/kg of a 4 mg/mL solution), group 5 (120 mg/kg of a 4 
mg/mL solution), group 6 (160 mg/kg of a 4 mg/mL solution).  
Mice in group 1 served as vehicle control and administered 1.0 mL/25 gms body weight 
of 3% DMSO, which corresponded to the volume of DMSO injected into mice in group 
3. This represented the maximum volume of 3% DMSO injected into any group of mice. 
Groups of mice were dosed sequentially and each group evaluated daily for signs 
of toxicity, including hunched posture, rough hair coat, and decreased responsiveness. 
Mice were anesthetized with CO2 48 h after compound administration, and blood 
collected by cardiocentesis for plasma clinical chemistry evaluation. Plasma chemistries 
performed included glucose, aspartic acid aminotransaminase (AST), alanine 
aminotransaminase (ALT), alkaline phosphatase (AP), bilirubin, total protein (TP), 
albumin, and globulin. Mice were exsanguinated and a necropsy performed. Tissues, 
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including lung, kidney, thymus, heart, Harderian gland, spleen, stomach, small intestine 
and colon were fixed in 10% neutral buffered formalin. Fixed tissues were processed 
routinely and examined by a board-certified pathologist. For the statistical analysis the 
clinical chemistry values were compared using the Number Cruncher Statistical System 
software (NCSS, Kaysville, UT). Variables of interest were statistically evaluated for 
group effect, using One-Way ANOVA. When the overall F statistic was significant (p  < 
0.05), the Fisher’s Least Significant Differences test was performed to compare the 
groups. Significant differences existed when p  > 0.05. 
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CHAPTER 3: SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL 




 Putrescine, spermine and spermidine are the natural polymines found in both 
prokaryotic and eukaryotic cell types.1-3 These polyamines are essential for every cell to 
support their function. Similar kind of polyamine metabolism pathways are involved in 
both eukaryotic and prokaryotic cells (human and mammalian); with some difference in 
their interspecies produced during the process. The mammalian pathway for biosynthesis 
of polyamines is shown in the Figure 3.1.4  
This pathway can be both forward and reverse.4 In the forward path ornithine is 
converted to putrescine by an amino acid decarboxylase (ODC). Putrescine is next 
converted to spermidine by Spermidine synthase followed by biosynthesis of spermine 
using Spermine synthase. In the reverse metabolic pathway spermine undergoes 
acetylation on the three-carbon containing nitrogen end followed by oxidation by 
Acetylpolyamine oxidase (PAO). Similarly, spermidine undergoes acetylation on the 
three-carbon containing nitrogen followed by oxidation by PAO to give putrescine. 
During this reverse pathway a deacetylase enzyme can reverse the enzymatic acetylation. 
In the cell all the above enzymatic processes take place so as to control the level 
of polyamines. The daily supply of polyamines can be obtained exogenously from dietary 
intake, resulting in the total polyamine in the body.5-7 This will exert effect on the 
immature intestine resulting in gut maturation.7 Disrupting a variety of cellular functions 
by using polyamine derivatives during the metabolic pathway of polyamine has been
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investigated as a potential chemotherapeutic pathway of treating tumors.9-11 One such 
example is using α-difluoromethylornithine (DFMO),12 which inhibits the ODC protein 
that converts ornithine to putrescine in the forward metabolic pathway (Figure 3.1). 
Symmetrical polyamines have also been used to downregulate the polyamine biosynthetic 
enzymes ODC and AdoMet-DC, after cellular uptake through the polyamine transport 
system.13,14  
 
Figure 3.1: Mammalian metabolic pathway of polyamines.4 
 
Since cancerous cells have upregulated polyamine transport system, they can be 
effectively destroyed using this strategy.15-17 Under physiological conditions the
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nitrogen atoms present on the polyamines can be protonated resulting in high degree of 
positive charge. Therefore a possible interactions of the cationic polyamines with 
negatively charged molecules such as DNA, RNA, ATP and proteins can occur.2 
Polyamine interactions with these biomolecules results in the activation and regulation of 
cell proliferation and differentiation.11,18 Consequently Polyamines conjugated to several 
drugs19-24 is an attractive strategy to increase the tumor selectivity. In this Chapter we 
reported the synthesis and biological studies of closo-p-carboranyl-fluorinated porphyrin 
polyamine conjugates for application in BNCT. Boronated polyamines have been studied 
previously,25-29 where they have shown DNA binding affinity and significant toxicity. 
Examples are shown in Figure 3.2. 
 
Figure 3.2: Carborane polyamine conjugates.25-29 
 
Porphyrin polyamine conjugates for the treatment of cancers using PDT have also 
been studied. These studies have shown that the porphyrin macromolecule once 


































the polyamine transport mechanism.30-32 The two porphyrin polyamine conjugates shown 
in Figure 3.3 have shown good PDT activity and DNA photocleavage. Although, PDT is 
successfully used to treat lung and melanoma;33,34 tumors that are difficult to treat, such 
as glioblastoma multiforme, due to limited light penetration can be treated using boron 
neutron capture therapy (BNCT).  
As discussed in Chapter 1, high tumor to boron concentration (20-35 µg/g of 
tumor) is required for an effective BNCT, which can be attained by conjugating 
carboranes to porphyrin.35,36 The selectivity of carboranyl-porphyrins for tumors could be 
achieved by conjugating polyamines, although this strategy has not yet been studied. To 
date, anionic carborane derivatives of closo-CB11H12-, niodo-C2B9H11- and [3,3’-Co(1,2-
C2B9H11)2]- have been used for conjugation of porphyrins, which resulted in anionic 
carboranyl-porphyrins.37 In this work we used para-carborane as the source of boron 
because it is stable under acidic and basic conditions, unlike ortho-carborane and meta- 
 





















carborane which are easily degraded to nido-carborane. The presence of icosahedral 
carborane cluster would also result in high hydrophobic character of porphyrin-carborane 
conjugates. A fluorinated porphyrin was chosen as the starting materialso that the 
reactive para-fluorine can be substituted by the nucleophilic thiol-carborane or 
polyamine. On the other hand, fluorinated porphyrins have shown increased PDT activity 
compared with non-fluorinated porphyrin analogs, and can facilitate imaging using 18F-
PET in addition to fluorescence for monitoring of treatment outcome. Both linear and 
branched polyamines were studied to investigate their biological properties and to 
compare their activities with those of polyethylene glycol conjugates.    
 We have also conducted in vitro BBB permeability experiments on these 
polyamine conjugates, as polyamines can disrupt the blood-brain barrier in different 
pathological states and under physiological conditions the cationic polyamines can 
undergo adsorptive-mediated endocytosis which would allow the drug to cross the 
BBB.38  
3.2: Results and Discussion 
 
3.2.1: Synthesis and characterization 
 
The precursors 1-mercaptomethyl-p-carborane 3.11,39 5,10,15,20-tetra (4-
pentafluorophenyl) porphyrin 3.19,40 and the Boc-protected polyamines 3.12-3.1841 were 
synthesized according to published procedures. 1-Mercaptomethyl-p-carborane was 
obtained from commercially available p-carborane 3.9 by reacting with n-BuLi to form a 
nucleophilic carborane, followed by reaction with carbon disulfide to give 
dithiolcarboxylate p-carborane 3.10. As shown in Scheme 3.1, reaction with iodomethane 
gave a dithiocarboxylate ester p-carborane, which was then reduced to ether using BH3-
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Me2S, followed by deprotection of the methyl ether using conc. HCl to give the desired 
1-mercaptomethyl-p-carborane 3.11. The p-carborane thioester and thiol p-carborane 
were characterized by NMR (1H, 13C). For compound 3.10 a singlet peak with three 
protons at 2.48 ppm due to the methyl hydrogens was observed and a broad 11 proton 
peak due to the BH and CH on carborane was also observed.  Compound 3.11 having a 
methylene thiol showed a doublet two-proton peak at 3.60 ppm and a broad 11 proton 
peak due to the BH and CH on carborane.   Porphyrin 3.19 was obtained using the 
Lindsey method in good yield.40 A catalytic amount of BF3.OEt2 was used to form the 
macrocycle followed by oxidation to produce the stable π- conjugated and aromatic 
porphyrin using DDQ as the oxidizing agent.  
 
Scheme 3.1: Synthesis of p-thiol carborane.39 
 
Some of the BOC-protected polyamines used in this work were synthesized from 
commercially available polyamines with different length of the carbon chains: 2–2–2, 2-
2-2-2, 2-2-2-2-2, 2–3–2, 3–3–3, 3–4–3, 3–2–3, in one pot procedures. First the ethyl 
trifluoroacetate (1 eq) was reacted with polyamine to give a mono amino protected 
polyamine then the remaining amine groups were BOC-protected after reaction of the 
above polyamines with (BOC)2O in methanol at 00C for 60 minutes followed by stirring 
at room temperature for 18 hours as shown in Scheme 3.2. Then concentrated aq. NH3 
H
H
i) 1.05 eq. n-BuLi, THF/Hexanes, -100C, 90 min
ii) 0.2 eq. CuBr + 0.4 eq. LiBr, THF, -150C, 15 min
iii) 1.4 eq. CS2, -100C, 90 min




i) 1.05 eq. BH3-Me2S, reflux, 90 min




was added to the mixture until the pH reaches 11, where the deprotection of 
trifluoroacetate occurs. The BOC-protected polyamines were characterized by NMR and 
mass spectrometry. The 1H-NMR spectra showed a singlet peak due to the tert-butyl 
protons at ∼1.42 ppm and the N-CH2 peak around 3.30 ppm. MS-ESI analysis gave a 
molecular ion peak at m/z 3.12: 447.3183; 3.13: 590.4123; 3.14: 733.5074; 3.15: 
461.3375; 3.16: 489.3673; 3.17: 503.4198; 3.18: 475.3509.  
The 1-mercapitomethyl-p-carborane was reacted with 3.19 in DMF at room 
temperature using K2CO3 as the base to give a mixture of p-thiol carborane porphyrins, 
where nucleophilic substitution took place at the reactive p-fluorine position of porphyrin 
3.19 (See Scheme 3.3). The resulting mixture of porphyrins was difficult to purify by 
 
Scheme 3.2: Synthesis of BOC protected polyamines.41 
 
normal silica gel column due to the non-polarity nature of all the porphyrins. Prep-TLC 
was also used with no success for the separation. Therefore the mixture was metallated 
with Zn(OAc)2 to obtain a zinc(II) porphyrin mixture. Separation of the mixture of zinc 












1. MeOH, CH3CH2OCOCF3, -780C to 00C overnight
2. (BOC)2O, 30 to 60 min at 00C then 18 hrs at r.t






1. MeOH, CH3CH2OCOCF3, -780C to 00C overnight
2. (BOC)2O, 30 to 60 min at 00C then 18 hrs at r.t
3. Conc. aq. NH3, PH 11, 15 hrs at r.t



















Scheme 3.3: Synthesis of carboranyl-porphyrin polyamine conjugates. 
 
ether 1:1. The desired tri p-carborane substituted porphyrin was optimized using 6 eq. of  
1-mercaptomethyl-p-carborane with an overall yield of 30%, after demetallation using 
TFA (Table 3.1). The free p-flourine of porphyrin 3.20 was then used to conjugate 
several biomolecules as shown in Scheme 3.3. Commercially available linear 
polyamines, branched polyamines, tert-butyl-12-amino- 4,7,10-trioxadodecanoate, and 
synthesized BOC protected polyamines were used for conjugation.  
Using NMP as a solvent, the free terminal amino group of the polyamine 
molecules underwent nucleophilic substitution at the remaining p-fluorine of porphyrin 
3.20. Then the BOC group was deprotected using TFA and after purification using HPLC 















































2. Zn(OAc)2, CHCl3, rt, 24 h
3. TFA, CHCl3, rt, 4h
       (30% overall)
1. H2N Polyamine or PEG
    NMP, 1000C, 4h
2. TFA, CH2Cl2, rt, 4h































































obtained in quantitative yields. All these porphyrin conjugates were structurally 
characterized by NMR, MS, fluorescence and UV–Vis spectroscopy.  19F-NMR of all 
these conjugates showed peaks in the range of -135.2 ppm, -139.7 ppm, -140.1 ppm, -
164.5 ppm respectively. MS-ESI analysis gave a molecular ion peak at m/z 3.21: 
1611.7042; 3.22: 1567.7826; 3.23: 1612.7414; 3.24: 1656.8000; 3.25: 1698.8939; 3.26: 
1626.7602; 3.27: 1654.7848; 3.28: 1668.8031; 3.29: 1640.7763. Porphyrin 3.30 was 
characterized using MS-MALDI which showed a peak at 1691.758. UV-Visible studies 
on these compounds dissolved in acetone showed a soret band at 415 nm and Q bands at 
510, 555, 585, and 650 nm respectively. All conjugates showed an emission maximum 
around 650 nm when the studies were carried using DMSO as the solvent (see Figure 
3.4).   




K2CO3 (eq.) % yield of 3.20 
3 6 19 
3.5 6 25 
4 6 30 
 
 
3.2.2: Partition Coefficient (log P) 
 
The partition coefficient (log P) values between 1-octanol and HEPES buffer (pH 
7.4) were obtained using the shaking-flak method42 and are shown in Table 3.2. The 
hydrophobic character for the conjugates follows the order 
3.28<3.25∼3.24<3.27<3.26<3.29<<3.23∼3.30∼3.22∼3.21, depending on the number of 
amine groups and the carbon skeleton of the polyamine. The most hydrophobic 
polyamine conjugates were found to be 3.23, 3.21, 3.22 and 3.30 with a log P value 1.86, 
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1.85, 1.84 and 1.84, where the conjugate 3.23 showed similar log P to that of the PEG 
conjugate 3.30. Conjugate 3.28 bearing a spermine group was the least hydrophobic of 
this series with a log P value of 1.06. The PEG group has been used previously as a linker 
between the porphyrin macrocycle and biomolecules (peptides and antibodies), as well to 
increase the water solubility of the conjugates.43,44 For this reason the PEG conjugate was 
synthesized to compare with the polyamine conjugates and their use as a linker. 
Table 3.2. Partition Coefficient (log P) values for polyamine- and PEG-porphyrin 
conjugates 3.21-3.30. 
 
Conjugate 3.21 3.22 3.23 3.24 3.25 3.26 3.27 3.28 3.29 3.30 




3.2.3: Cell Culture 
 
3.2.3.1: Cytotoxicity. The cytotoxicity of all the conjugates synthesized were 
investgated in T98G (human glioblastoma multiforme) cells with different 
concentrations. Since we chose to develop drugs for grade IV brain tumors (human 
gliobalstoma multiforme), T98G cell line was used in this study. Previous studies on the 
o-carborane polyamine (spermine and spermidine) conjugates showed significant dark 
toxicities in F98 rat glioma cells with IC50 (50% inhibition of cell proliferation based on 
dose-response curves) < 25.45 This would result in predicament when treating tumors, as 
the strategic treatment using BNCT would not be possible. On the other hand the 
polyamine and PEG carboranyl-porphyrin conjugates synthesized didn’t show any 
significant toxicity under dark; the PEG conjugate showed only slight dark toxicity with 
IC50 = 296 µM but for all the other conjugates IC50 > 400 µM as shown in Figure 3.5. 
Upon exposure to 1.5 J/cm2, the spermine derivatives 3.28, 3.22, 3.29, 3.27 and 3.26 were 
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found to be the most toxic with IC50 = 40, 41, 41, 64 and 87 µM, respectively as shown in 
the Figure 3.6. This low toxicity of the conjugates may be attributed to the attachment of 
the polyamines to the porphyrin macrocycle rather than to the carborane clusters directly. 
The use of closo-1,12-(para) rather than closo-1,2-(ortho) carboranes might be the other 
reason, as in the o-carborane clusters the boron atoms bound to both carbons are highly 
susceptible to nucleophilic attack by amine groups, producing the corresponding 
negatively charged nido-carboranes, therefore changing the overall charge and 
lipophilicity of the conjugates.46  
 
Fig. 3.4.  Fluorescence emission spectra at 10 µM in DMSO for conjugates 3.21 (brown), 
3.22 (pink), 3.23 (red), 3.24 (dark blue), 3.25 (purple), 3.26 (dark green), 3.27 (orange), 





Figure 3.5: Dark cytotoxicity of conjugates 3.21 (brown), 3.22 (pink), 3.23 (red), 3.24 
(dark blue), 3.25 (purple), 3.26 (dark green), 3.27 (orange), 3.28 (light blue), 3.29 (light 




Figure 3.6: Phototoxicity (1.5 J/cm2) of conjugates 3.21 (brown), 3.22 (pink), 3.23 (red), 
3.24 (dark blue), 3.25 (purple), 3.26 (dark green), 3.27 (orange), 3.28 (light blue), 3.29 






3.2.3.2: Time-Dependent Cellular Uptake. Cellular uptake studies of polyamine 
and PEG conjugates were conducted on T98G cells. The tests were conducted using 
conjugates at 10 µM concentrations at different time intervals (0, 1, 2, 4, 8, 24 h). The 
observed uptake of the conjugates was in the order 3.28 > 3.27 > 3.24 > 3.25 > 3.26 > 
3.29 > 3.30 ∼ 3.23 ∼ 3.21 ∼ 3.22 which follows the order of hydrophilicity, as observed 
from the log P values (see Figure 3.7). Cojugates 3.21, 3.22, and 3.23 showed a similar 
uptake to that of the PEG conjugate. The other polyamine conjugates have higher uptake 
than the PEG conjugate, which is the standard in this case. Conjugate 3.28 showed uptake 
of about 12 times higher than the PEG conjugate (see Figure 3.7). This high uptake of 
polyamine conjugates might be due to the polyamine transport across the cell membrane 
through the polyamine transport system. The protonation of the amine groups under 
physiological conditions results in the formation of cationic polyamines.47 Then the 
positively charged polyamine porphyrin compounds can undergo adsorptive mediated 
endocytosis, where the positively charged drug interacts electrostatically with negatively 
charged cell membrane, facilitating penetration across the cell membrane. The 
hydrophobic nature of the fluorinated porphyrin and carborane moieties might 
additionally favor penetration of the conjugate through the lipid membrane. Negatively 
charged polysialic acid residues are over-expressed on tumor cell membranes compared 
to the normal cells.48 So the polyamine drugs can be taken by the tumor cells selectively 
and used as effective BNCT agents. Some polyamines (3.13-3.18) used in this chapter 
can be used as an alternative to the PEG as a linker to conjugate different peptides. 
3.2.2.3: Subcellular localization: Localization studies on all the polyamine and PEG 
conjugates (3.21-3.30) were carried using fluorescence microscopy. HEp2 cells were 
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used instead of T98G cells due to the adhering issues on the six-well plastic plate. Once 
the cells were plated the specific compound (400 µM ) to be tested was added to the four 
of the six-well plates containing 4 ml cell culture medium and incubated for 6h. Then 
ERTracker Blue/White (ER) to one of the wells containing the compound; followed by 
MitoTracker Green (mitochondria), BODIPY-FL Ceramide (Golgi), and LysoSensor 
Green (lysosomes) imaging agents to the remaining three wells containing the compound 
were added. Then using fluorescence microscope, the images were obtained. Thus 
obtained results are shown in Figures 3.8-3.17. ERTracker Blue/White fluoresce blue 
color, and the reamaing trackers fluoresce green and the compounds fluoresce red. The 
fluorescent images with tracker alone are shown on the left side (c,e,g,i) and the overlay 
of compound with tracker are shown on the right side (d,f,h,j). Purple color can be seen 
when blue colored flourescent tracker overlays with red color florescent compound and 
yellow or orange color can be seen when green colored fluorescent tracker overlays with            
red color fluorescent compound.  
 
Figure 3.7: Time-dependent uptake of conjugates 3.21 (brown), 3.22 (pink), 3.23 (red), 
3.24 (dark blue), 3.25 (purple), 3.26 (dark green), 3.27 (orange), 3.28 (light blue), 3.29 




Figure 3.8: Subcellular fluorescence of conjugate 3.21 in HEp2 cells at 10 µM for 6h. (a) 
Phase contrast, (b) overlay of the 3.21 fluorescence and phase contrast, (c) ER Tracker 
Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY Ceramide, 
(i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers with 3.21 




Figure 3.9: Subcellular fluorescence of conjugate 3.22 in HEp2 cells at 10 µM for 6h. (a) 
Phase contrast, (b) overlay of the 3.22 fluorescence and phase contrast, (c) ER Tracker 
Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY Ceramide, 
(i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers with 3.22 





Figure 3.10: Subcellular fluorescence of conjugate 3.23 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 3.23 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 





Figure 3.11: Subcellular fluorescence of conjugate 3.24 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 3.24 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 





Figure 3.12: Subcellular fluorescence of conjugate 3.25 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 3.25 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 





Figure 3.13: Subcellular fluorescence of conjugate 3.26 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 3.26 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 





Figure 3.14: Subcellular fluorescence of conjugate 3.27 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 3.27 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 





Figure 3.15: Subcellular fluorescence of conjugate 3.28 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 3.28 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 




Figure 3.16: Subcellular fluorescence of conjugate 3.29 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 3.29 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 




Figure 3.17: Subcellular localization of Conjugate 3.30 in HEp2 cells at 10 µM for 6h. a) 
Phase contrast, b) overlay of the 3.30 fluorescence and phase contrast, c) ER tracker 
Blue/White fluorescence, e) MitoTracker Green fluorescence, g) BODIPY Ceramide, i) 
LysoSensor Green fluorescence, and d), f), h), and j) overlays of organelle tracers with 
the 3.30 fluorescence. Scale bar: 10 µm. 
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From the overlay images we can observe that most of the conjugates 
preferentially localize in endoplasmic reticulum (see Figures 3.8d-3.17d and Table 3.3), 
and the PEG conjugate 3.30 was found to localize in mitochondria. Compounds 3.21 and 
3.22 were also found to localize in mitochondria. Golgi and the cell lysosomes were the 
minor localization sites.   
Table 3.3. Major (++), minor (+) sites of localization in HEp2 cells. 
 
Porphyrin ER Mitochondria Golgi Lysosomes 
3.21 - ++ + + 
3.22 ++ + + + 
3.23 - ++ - + 
3.24 - + - + 
3.25 ++ - + + 
3.26 ++ + + + 
3.27 ++ - + - 
3.28 ++ - + + 
3.29 ++ - + + 
3.30 - ++ - - 
 
 
3.2.2.4: In vitro BBB permeability studies: hCMEC/D3 (human brain endothelial) 
cell line was found to be the ideal human BBB model and in vitro BBB studies were 
previously conducted to study the drug transportation across the BBB.49-52 Therefore, the 
polyamine and PEG conjugates were studied for their BBB permeability on hCMEC/D3 
cells and compared with standard lucifer yellow FTIC40K, which is a known fluorescent 
molecule that cross the BBB.51 First the in vitro BBB model (see Figure 3.18) was 
prepared using the known protocol which contains a basolateral chamber and apical 
chamber.52 Compounds were added to the apical chamber containing monolayered cell 
membrane. Then at different time intervels (0, 30, and 60 min) the concentration of 
compounds in basolateral layer was measured using fluorosence plate reader. Then using 
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the equation 3.152 the permeability coefficient (P) results were obtained at 30 minutes and 
60 minutes. These results are shown in table 3.4. 
𝑃 =   
(𝐶𝑓 − 𝐶0)




𝑠 ……………… (𝒆𝒒𝒖𝒂𝒕𝒊𝒐𝒏  𝟑.𝟏) 
 
where 𝐶𝑓  is the final concentration of the compound (ng/ml), 𝐶0   is the initial 
concentration of compound (ng/ml). 𝑡𝑓 is the final time (min), 𝑡0 is the initial time (min) 
and  𝐴 is the surface area of the filter (cm2). 
None of the conjugates showed high permeability comparable with the standard, 
yet interesting results were obtained. The permeability results are different from that 
observed for uptake. The most permeability is seen with polyamine conjugate 3.26 and 
least by 3.22 (Table 3.4). This could be because of the most hydrophilic character of 3.22 
and lipophilic character of 3.26 in the series. 
 





Table 3.4. In vitro permeabilty coefficient values for polyamine- and PEG-porphyrin 
conjugates 3.21-3.30. 
 
COMPOUND Permeability Coefficient (cm/s) 
at 30 min 
Permeability Coefficient (cm/s) 
at 60 min 
3.21 1.29 e-6 2.3 e-6 
3.22 4.88 e-7 8.29 e-7 
3.23 1.18 e-6 1.35 e-6 
3.24 7.4 e-7 8.4 e-7 
3.25 1.06 e-6 1.21 e-6 
3.26 2.03 e-6 3.32 e-6 
3.27 1.05 e-6 1.02 e-6 
3.28 9.11 e-7 8.7 e-7 
3.29 1.37 e-6 1.42 e-6 
3.30 7.98 e-7 1.19 e-6 
Lucifier yellow 1.1 e-5 2.29 e-5 
 
3.3: Conclusions 
 The synthesis of polyamine and PEG p-carboranyl-porphyrin conjugates were 
carried out in good yields. All the synthesized compounds were characterized using 
analytical techniques such as NMR, ESI, MALDI-TOF, UV-Vis and fluorescence 
spectroscopy. The compounds were purified (>95% purity) using reverse-phase HPLC. 
Cytotoxic in vitro studies revealed that none of the conjugates was toxic in the dark. 
Phototoxicity results revealed that, the sperminederivatives 3.28, 3.22, 3.29, 3.27 and 
3.26 were found to be the most toxic with IC50 = 40, 41, 41, 64 and 87 µM, respectively. 
The hydrophobic character of the conjugates was investigated by determining the 
logarithm of their partition coefficient (log P) between 1-octanol and buffered water (pH 
= 7.4). We observed the spermine conjugate has the most cellular uptake which was also 
the most hydrophilic character (log P = 1.06) and had 12-fold increase in uptake 
compared to the pegylated-porphyrin, 3.21, 3.22 and 3.23 derivatives. The polyamine 
transport system and adsorptive mediated endocytosis might have caused the high uptake 
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across the tumor cell membrane of these polyamine conjugates. In contrast there is some 
variation in the BBB permeability results with the highest shown by conjugate 3.26. This 
is generally expected as the most lipophilic molecule show the good cell permeability. 
The main intracellular sites of localization for all conjugates were the ER; in addition, the 
polyamine conjugates were also observed in the Golgi and lysosomes. With these 
polyamine conjugates showing low dark toxicity, moderate phototoxicity, good cell 
uptake and BBB permeability, they can be promising BNCT agents.      
3.4: Experimental Section 
 
3.4.1: General Information 
 
  Reactions that are sensitive were conducted under argon atmosphere in oven-dried 
glassware. Commercially available reagents and solvents (HPLC grade) were purchased 
from Sigma-Aldrich, Acros Organics and used without further purification. p-carborane 
was purchased from Katchem, Inc. Anhydrous methanol was prepared by distillation 
from magnesium turnings and was stored under nitrogen over 3 A0 molecular sieves. 
Anhydrous THF was prepared by distillation from sodium and benzophenone. Analytical 
thin-layer-chromatography (TLC) was performed on polyester backed TLC plates 254 
(pre-coated, 200 µm, Sorbent Technologies). Silica gel 60 (70–230 mesh, Merk) used for 
column chromatography and silica gel TLC plates (0.2 mm thickness) were purchased 
from Sorbent Technologies. 1H NMR and 13C NMR spectra were obtained using a Bruker 
AV-4 400 MHz spectrometer; chemical shifts are expressed in ppm. 19F NMR spectra 
were obtained using a Bruker DPX-250 250 MHz spectrometer; chemical shifts are 
expressed in ppm. Electronic absorption spectra were measured on a Perkin Elmer 
Lambda 35 UV-vis spectrophotometer. Mass analysis was conducted at the LSU Mass 
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Spectrometry Facility on a Bruker Omniflex MALDI-TOF mass spectrometer and exact 
masses were obtained from HRMS-ESI on an Applied Biosystems QSTAR XL. Melting 
points were measured on a Thomas hoover melting point apparatus. Reversed-phase 
HPLC was performed on a Waters system including a 2545 quaternary gradient module 
pump with a 2489 UV-vis detector and a fraction collector III. An analytical column 
(4.6X250 mm-XBridgeTM BED300 C18 5 µm) was used for the purification of all 
polyamine conjugates (3.21-3.29) and a stepwise gradient from 0 to 100% Buffer B in the 
first 10 min to 50% B and 50% C in next 10 min to 100% B in next 10 min. A stepwise 
gradient 10-90% Buffer B with Buffer A was used for the PEG conjugate 3.30. Buffer A 
(0.1% TFA, H2O), Buffer B (0.1% TFA, acetonitrile), Buffer C (0.1% TFA, acetone). All 
Boc-protected polyamines were synthesized as previously described.41 1-
Mercaptomethyl-p-carborane was prepared from p-carborane, as described in literature.39  
3.4.2: Synthesis 
Synthesis of dithiocarboxylate ester (3.10)  
A solution of 1.0 g (6.93 mmol) p-carborane in 45 ml dry THF was cooled to –
400C and 4.6 ml (7.28 mmol) n-BuLi in hexane was slowly added. The reaction mixture 
was then stirred at –30oC for 40 min. Then a mixture of 0.20 g (1.39 mmol) CuBr and 
0.24 g (2.77 mmol) LiBr in 10 ml dry THF was added at –400C. The reaction mixtue was 
then stirred at –400C for 10 min followed by the addition of 0.60 ml (10 mmol) CS2. 
Stirring was continued at –30oC for 40 min. Then 0.5 ml (8 mmol) methyl iodide was 
added at –40oC. The stirred reaction mixture was then allowed to reach 15oC over 1 hr. 
The dark solution was partitioned between 50 ml ethyl ether and 50 ml cold water. The 
phases were separated, the aqueous extracted with ether (50 ml), the organic phases were 
combined, washed with water (50 ml), and dried (MgSO4). Evaporation of the solvent 
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afforded 1.3 g crude product (TLC in hexane indicated the presence of some unreacted 
carborane and possibly some bis-dithiocarboxylated derivative).  Purified by 
chromatography (silica gel, hexane) gave 0.7 g (43%) final product. 1H-NMR (CDCl3, 
400 MHz): δ 2.48 (s, 3H), 1.1-3.6 (br, 11H). 13C-NMR (CDCl3, 100 MHz): δ 22.7, 61.3, 
93.7, 221.4. 
Synthesis of methylthiol p-carborane (3.11) 
 
A solution of 0.5 ml (1.0 mmol) 2M BH3-SMe2 in toluene was injected slowly under the 
surface of a refluxing solution of 0.23 g (1.0 mmol) of the above dithiocarboxylate ester 
in 3 ml dry toluene. The reaction mixture was then slowly stirred at reflux temperature 
for 1.5 hr; during which time the yellow colour disappeared. The reaction flask was 
raised above the surface of the oil bath and 1 ml cc. HCl was carefully added dropwise 
during 3 min. The reaction mixture was refluxed while stirring overnight, then cooled and 
diluted with 20 ml hexane. The organic layer was separated, washed with brine, dried 
(MgSO4), and concentrated under vacuum. The crude product (0.17 g) was purified by 
column chromatography (silica gel, hexane) to give 99 mg (52%) product. 1H-NMR 
(CDCl3, 400 MHz): δ 3.60 (d, 2H), 1.1-3.6 (br, 12H, BH, CH, SH). 13C-NMR (CDCl3, 
100 MHz): δ 22.6, 29.3, 60.3, 61.2. 
General Procedure for synthesis of BOC protected polyamines41 
To a 140 ml methanol containing 10 mmol polyamine at -780C under argon was added 
dropwise 10 mmol of ethyl trifluoroacetate over 30 min while stirring.  Then the stirring 
was continued for another 30 min and Temperature was increased to 00C to get mostly 
mono protection.  The remaining amino functional groups were protected by adding 
excess amount of di-tert-butyl dicarbonate (2 equivalent for each amino group) in 
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methanol over 30 to 60 minutes. Then the reaction mixture was continued stirring at 
room temperature for 18 h.  Then concentrated aqueous ammonia was added to the above 
solution till the pH reaches 11. This solution is continued mixing for another 15 h at room 
temperature. Then methanol is evaporated and the remaining residue was passed through 
silica column to get the desired product. 
 (N1, N3, N6 – Tri-tert-butoxycarbonyl)-1,8-di-amino-3,6-diazaoctane (3.12) 
Synthesized from 1,8-Diamino-3,6-diazaoctane (10 mmol) according to the general 
procedure. Purified over silica gel (CH2Cl2-MeOH-conc NH3 200:10:1 to 100:10:1). 1H-
NMR (CDCl3, 400 MHz): δ 3.486 (s, 2H, NCH2), 3.26-3.32 (m, 10H, NCH2), 1.65 (s, 
2H, NH2), 1.42-1.45 (m, 27H, t-Bu). 13C-NMR (CDCl3, 100 MHz): δ 156.08, 155.78, 
80.10, 79.83, 78.99, 53.39, 50.21, 47.59, 46.65, 45.75, 40.68, 39.37, 30.84, 28.34. HRMS 
(ESI-TOF) m/z   found 447.3275 (M++1), C21H42N4O6  requires M++1 = 447.3183. 
 (N1, N3, N6, N9 – Tetra-tert-butoxycarbonyl)-1,11-di-amino-3,6,9-triazaundecane 
(3.13) 
 
Synthesized from 1,11-Diamino-3,6,9-triazaundecane (10 mmol) according to the 
general procedure. Purified over silica gel (CH2Cl2-MeOH-conc NH3 200:10:1 to 
100:10:1). 1H-NMR (CDCl3, 400 MHz): δ 3.26-3.31 (m, 14H, NCH2), 2.83-3.0 (m, 2H, 
NCH2), 1.72 (s, 2H, NH2), 1.42-1.45 (m, 36H, t-Bu). 13C-NMR (CDCl3, 100 MHz): δ 
156.05, 155.68, 155.5, 155.3, 80.15, 79.93, 78.97, 53.39, 50.21, 50.1, 47.59, 46.65, 45.75, 
45.8, 45.3, 45.2, 40.68, 40.3, 39.76, 39.37, 30.84, 28.43, 28.34. HRMS (ESI-TOF) m/z   







(N1, N3, N6, N9, N12 – Penta-tert-butoxycarbonyl)-1,14-di-amino-3,6,9,12-
tetraazatetradecane (3.14) 
 
 Synthesized from 1,14-Diamino-3,6,9,12-tetraazatetradecane (10 mmol) 
according to the general procedure. Purified over silica gel (CH2Cl2-MeOH-conc NH3 
200:10:1 to 100:10:1). 1H-NMR (CDCl3, 400 MHz): δ 3.12-3.40 (m, 18H, NCH2), 2.71-
2.9 (m, 2H, NCH2), 1.84 (s, 2H, NH2), 1.40-1.43 (m, 45H, t-Bu). 13C-NMR (CDCl3, 100 
MHz): δ 156.09, 155.82, 155.56, 155.23, 80.10, 79.95, 79.85, 79.76, 79.08, 51.39, 50.11, 
47.19, 46.05, 45.85, 40.98, 39.67, 39.57, 39.31, 30.84, 28.42, 28.34. HRMS (ESI-TOF) 
m/z   found 733.5074 (M++1), C35H69N6O10 requires M++1 = 733.5075. 
(N1, N3, N7 – Tri-tert-butoxycarbonyl)-1,9-di-amino-3,7-diazanonane (3.15)    
Synthesized from 1,9-Diamino-3,7-diazanonane (10 mmol) according to the 
general procedure. Purified over silica gel (CH2Cl2-MeOH-conc NH3 100:10:1). 1H-
NMR (CDCl3, 400 MHz): δ 3.2-3.29 (m, 10H, NCH2), 2.81-2.85 (t, 2H, J=7, CH2), 1.73-
1.77 (t, 2H, J=7, CH2), 1.65 (s, 2H, NH2), 1.42-1.45 (m, 27H, t-Bu). 13C-NMR (CDCl3, 
100 MHz): δ 155.80, 155.34, 79.28, 79.06, 78.39, 53.30, 50.22, 49.89, 46.34, 45.11, 
40.35, 39.11, 28.12. HRMS (ESI-TOF) m/z   found 461.3375 (M++1), C22H45N4O6  
requires M++1 = 461.3339. 
(N1, N4, N8 – Tri-tert-butoxycarbonyl)-1,11-di-amino-4,8-diazaundecane (3.16)  
Synthesized from 1,11-Diamino-4,8-diazaundecane (10 mmol) according to the 
general procedure. Purified over silica gel (CH2Cl2-MeOH-conc NH3 100:10:1). 1H-
NMR (CDCl3, 400 MHz): δ 3.02-3.18 (m, 10H, NCH2), 2.63 (t, 2H, J=7, NCH2), 1.95-
2.0 (bs, 2H, NH2), 1.59-1.75 (m, 6H, CH2), 1.36-1.38 (m, 27H, t-Bu). 13C-NMR (CDCl3, 
100 MHz): δ 155.97, 155.45, 79.44, 78.76, 53.37, 44.68, 43.74, 39.20, 38.68, 37.35, 
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32.15, 32.03, 30.99, 30.80, 28.34. HRMS (ESI-TOF) m/z   found 489.3673 (M++1), 
C24H49N4O6  requires M++1 = 489.3652. 
(N1, N4, N9 – Tri-tert-butoxycarbonyl)-1,12-di-amino-4,9-diazadodecane (3.17)  
Synthesized from 1,12-Diamino-4,9-diazadodecane (10 mmol) according to the 
general procedure. Purified over silica gel (CH2Cl2-MeOH-conc NH3 70:10:1 to 50:10:1). 
1H-NMR (CDCl3, 400 MHz): δ 3.07-3.21 (m, 10H, NCH2), 2.68 (t, 2H, J=7, NCH2), 2.08 
(bs, 2H, NH2), 1.59-1.70 (m, 4H, CH2), 1.41-1.46 (m, 31H, CH2&t-Bu). 13C-NMR 
(CDCl3, 100 MHz): δ 156.04, 155.55, 79.48, 78.88, 46.80, 43.79, 38.76, 37.35, 32.46, 
30.9, 28.42. HRMS (ESI-TOF) m/z   found 503.4198 (M++1), C25H51N4O6 requires M++1 
= 503.3808. 
(N1, N4, N7 – Tri-tert-butoxycarbonyl)-1,10-di-amino-4,7-diazaoctane (3.18)  
Synthesized  from 1,10-Diamino-4,7-diazadecane (10 mmol) according to the 
general procedure. Purified over silica gel (CH2Cl2-MeOH-conc NH3 100:10:1). 1H-
NMR (CDCl3, 400 MHz): δ 3.15-3.4 (m, 8H, NCH2), 2.83 (t, 2H, J=7.6, NCH2), 2.16 (s, 
2H, NH2), 1.59-1.74 (m, 4H, CH2), 1.40-1.43 (m, 27H, t-Bu). 13C-NMR (CDCl3, 100 
MHz): δ 156.09, 155.88, 155.43, 80.04, 79.86, 79.09, 45.98, 45.34, 45.01, 44.45, 43.65, 
37.65, 37.24, 32.78, 29.08, 28.67, 27.79, 26.98. HRMS (ESI-TOF) m/z   found 475.3509 




  To a solution of 3.19 (19.52 mg, 0.02 mmol) in 2 ml of dry DMF was added 
anhydrous K2CO3 (16.6 mg, 0.12 mmol), mercaptomethyl-p-carborane (15.2 mg, 0.08 
mmol). The reaction mixture was stirred at room temperature for 48 h. The resulting 
solution was diluted with ethyl acetate (50 mL) and washed with brine (2 x 50 mL). The 
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organic layer was dried over anhydrous sodium sulfate, the solvents evaporated under 
reduced pressure and the resulting residue was dissolved in dichloromethane (10 mL). A 
saturated solution of Zn(OAc)2 in methanol (10 mL) was added and the resulting mixture 
stirred at room temperature for 24 h. The solvents were evaporated under reduced 
pressure and the resulting residue was purified by prep-TLC using chloroform/petroleum 
ether 1:1 to give 23.3 mg (30%) of desired zinc(II) porphyrin, mp > 3000C . UV-Vis 
(DMSO) λmax (ε/M-1 cm-1) 426 (444 400), 555 (43 800). 1H-NMR (CDCl3, 400 MHz): δ 
8.93 (s, 8H, β-H), 3.45 (s, 6H, -SCH2), 2.19-3.33 (m, 33H, BH, CH). MS (MALDI-TOF) 
m/z 1550.789 [M], calcd for ZnC53H47F17N4B30S3  = 1550.494. The Zn(II) porphyrin 
(23.3 mg, 0.015 mmol) was dissolved in 2 mL of TFA/chloroform 1:1 and stirred at room 
temperature overnight. After removal of the solvents under vacuum, the title porphyrin 
was obtained in quantitative yield. mp > 3000C. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 
(468 900), 511 (45 900), 555 (18 700), 585 (11 200), 650 (8 300). 1H-NMR (CDCl3, 400 
MHz): δ 9.02 (s, 2H, β-H), 8.90 (s, 6H, β-H), 3.46 (s, 6H, -SCH2), 1.78-2.96 (m, 33H, 
BH & CH), -2.87 (s, 2H, NH). 13C-NMR (CDCl3, 100 MHz): δ 147.82, 145.34, 143.62, 
141.07, 138.89, 136.35, 120.85, 115.54, 104.64, 81.88, 59.23, 14.13. 19F-NMR (Acetone-
d6, 233.33 MHz): δ -135.7 (m, 6F), -139.8 (m, 6F), -140.4 (d, J = 15.7 Hz, 2F), -156.2 (t, 
J = 19.0 Hz, 1F), -165.0 (d, J = 16.1 Hz, 2F). MS (MALDI-TOF) m/z 1485.672 [M], 
calcd for C53H49F17N4B30S3  = 1485.565. 
Conjugate 3.21 
  To (14.9 mg, 0.01 mmol) of above compound in 10 ml round bottom flask, N-(2-
aminoethyl)-N-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester 
(5.2 mg, 0.015 mmol), 2 ml NMP are added and the mixture is heated for 4 hours at 
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1000C.53,54 After cooling to room temperature, the solution is dissolved in ethyl acetate 
and washed five times with brine solution in a separatory funnel. Then after drying the 
mixture in sodium sulfate, solvent is evaporated to give a reddish brown residue. This 
residue is passed through silica gel using dichloromethane followed by 
dichloromethane:ethylacetate (9:1) to obtain pure product in 96% (17.5 mg). mp > 3000C. 
UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (469 200), 511 (45 200), 555 (18 400), 585 (11 
400), 650 (8 100). 1H-NMR (CDCl3, 400 MHz): δ 9.04 (s, 2H, β-H), 8.92 (s, 6H, β-H), 
3.74 (s, 2H, NCH2), 3.47 (s, 6H, -SCH2), 3.32 (bs, 4H, NCH2), 2.90 (s, 2H, NCH2), 2.79 
(s, 2H, NCH2), 1.62-2.68 (m, 33H, BH & CH), 1.49 (s, 18H, OtBu), -2.85 (s, 2H, NH). 
13C-NMR (CDCl3, 100 MHz): δ 156.72, 147.86, 145.16, 138.51, 135.81, 121.04, 115.14, 
106.28, 104.07, 81.92, 79.71, 60.77, 59.29, 54.37, 43.05, 40.59, 38.62, 28.78, 21.15, 
14.13. 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.9 (m, 6F), -139.6 (m, 6F), -141.4 (d, 
J = 15.9 Hz, 2F), -164.9 (d, J = 16.3 Hz, 2F). MS (MALDI-TOF) m/z 1811.878 [M], 
calcd for C69H82F16N8B30O4S3  = 1811.839. 
This Boc protected conjugate is then mixed with 1ml TFA in 1 ml 
dichloromethane in 10 ml round bottom flask and mixed at room temperature for 6 hrs. 
Then the solvent is evaporated to give the residue which is the purified using HPLC 
95%(15.5 mg). mp > 3000C. HPLC tR =26.332. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 
(467 900), 511 (45 300), 555 (18 900), 585 (11 500), 650 (8 100). 1H-NMR (Acetone-d6, 
400 MHz): δ 9.26 (s, 8H, β-H), 3.58 (s, 6H, -SCH2), 2.23-3.53 (m, 45H, BH, NCH2 & 
CH). 13C-NMR (Acetone-d6, 100 MHz): δ 147.76, 145.86, 139.01, 136.11, 122.34, 
114.18, 107.18, 102.07, 82.82, 79.91, 61.07, 58.89, 55.07, 43.45, 40.39, 39.12, 29.98, 
14.13.19F-NMR (Acetone-d6, 233.33 MHz): δ -135.9 (m, 6F), -139.1 (m, 6F), -140.5 (d, J 
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= 14.7 Hz, 2F), -164.5 (d, J = 13.4 Hz, 2F). HRMS (ESI-TOF) m/z 1611.7042 [M], calcd 
for C59H66F16N8B30S3  = 1611.7335. 
Conjugate 3.22 
  To (14.9 mg, 0.01 mmol) of above compound in 10 ml round bottom flask, 4-(2-
Aminoethyl)-1,7-bis(tert-butoxycarbonyl)-1,4,7-triazaheptane (4.5 mg, 0.015 mmol), 2 
ml NMP are added and the mixture is heated for 4 hours at 1000C. 53,54 After cooling to 
room temperature, the solution is dissolved in ethyl acetate and washed five times with 
brine solution in a separatory funnel. Then after drying the mixture in sodium sulfate, 
solvent is evaporated to give a reddish brown residue. This residue is passed through 
silica gel using dichloromethane followed by dichloromethane:ethylacetate (9:1) to 
obtain pure product in 96% (17.0 mg). mp > 3000C. UV-vis (DMSO) λmax (ε/M-1 cm-1) 
416 (465 800), 511 (44 800), 555 (19 600), 585 (12 900), 650 (8 200). 1H-NMR (CDCl3, 
400 MHz): δ 9.09 (s, 2H, β-H), 8.95 (s, 6H, β-H), 3.90 (s, 2H, NCH2), 3.85 (s, 2H, 
NCH2), 3.42-3.53 (m, 10H, SCH2, NCH2), 1.81-2.96 (m, 33H, BH & CH), -2.83 (s, 2H, 
NH). 13C-NMR (CDCl3, 100 MHz): δ 157.0, 156.28, 147.81, 147.68, 145.33, 145.19, 
145.05, 121.69, 121.28, 121.09, 120.90, 120.51, 115.53, 115.34, 115.15, 106.41, 103.99, 
103.80, 84.46, 81.91, 81.04, 79.67, 60.42, 59.23, 40.63, 28.43. 19F-NMR (Acetone-d6, 
233.33 MHz): δ -135.9 (m, 6F), -139.6 (m, 6F), -140.9 (d, J = 16.0 Hz, 2F), -164.8 (d, J = 
14.8 Hz, 2F). MS (MALDI-TOF) m/z 1768.783 [M], calcd for C53H49F17N4B30S3  = 
1768.796. 
This Boc protected conjugate is then mixed with 1ml TFA in 1 ml 
dichloromethane in 10 ml round bottom flask and mixed at room temperature for 6 hrs. 
Then the solvent is evaporated to give the residue which is the purified using HPLC 
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95.6% (15.0 mg). mp > 3000C. HPLC tR =23.866. UV-vis (DMSO) λmax (ε/M-1 cm-1) 415 
(468 000), 511 (45 300), 555 (18 200), 585 (11 800), 650 (8 100). 1H-NMR (Acetone-d6, 
400 MHz): δ 9.14-9.25 (bs, 8H, β-H), 3.59 (s, 6H, -SCH2), 2.27-3.34 (m, 41H, BH, 
NCH2 & CH). 13C-NMR (Acetone-d6, 100 MHz): δ 147.51, 145.23, 145.15, 121.48, 
121.29, 120.60, 120.01, 115.14, 115.05, 104.21, 103.90, 84.26, 81.41, 81.02, 79.81, 
59.13, 40.63, 14.43. 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.2 (m, 6F), -139.7 (m, 
6F), -140.1 (d, J = 16.0 Hz, 2F), -164.7 (d, J = 14.1 Hz, 2F). HRMS (ESI-TOF) m/z 
1567.7826 [M], calcd for C53H49F17N4B30S3  = 1568.6941. 
Conjugate 3.23 
  To porphyrin 2.20 (14.9 mg, 0.01 mmol) were added (N1,N3,N6–tri-tert-
butoxycarbonyl)-1,8-di-amino-3,6-diazaoctane41 (6.7 mg, 0.015 mmol) and NMP (2 mL) 
and the mixture was heated at 100 oC for 4 h. 53,54 After cooling to room temperature, the 
solution was diluted with ethyl acetate (50 mL) and washed with brine (5 x 50 mL). The 
organic layer was dried over anhydrous sodium sulfate, the solvents removed under 
vacuum and the resulting reddish brown residue purified by silica gel column 
chromatography using dichloromethane for elution, followed by dichloromethane/ethyl 
acetate 9:1. The Boc-protected conjugate was obtained (18.6 mg) in 96% yield, mp = 
292-294 oC. UV-Vis (DMSO) λmax (ε/M-1 cm-1) 416 (401 700), 510 (28 400) , 555 (22 
000) , 585 (11 000), 650 (10 500). 1H-NMR (CDCl3, 400 MHz): δ 9.06 (s, 2H, β-H), 8.91 
(s, 6H, β-H), 3.33-3.53 (m, 16H, SCH2, NCH2), 2.72-2.79 (m, 2H, CH2), 1.89-2.71 (m, 
33H, BH and CH), 1.58 (s, 9H, tBu), 1.52 (s, 9H, tBu), 1.46 (s, 9H, tBu),  -2.86 (s, 2H, 
NH). 13C-NMR (CDCl3, 100 MHz): δ 155.92, 155.61, 147.54, 146.84, 143.23, 142.87, 
137.89, 136.15, 119.85, 115.44, 103.84, 81.58, 79.78, 79.67, 78.54, 59.43 52.67, 49.96, 
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47.19, 46.35, 45.43, 40.34, 38.98, 30.78, 28.14, 14.23. 19F-NMR (Acetone-d6, 233.33 
MHz): δ -135.8 (m, 6F), -139.9 (m, 6F), -144.2 (d, J = 14.8 Hz, 2F), -162.3 (d, J = 15.6 
Hz, 2F).  
The Boc-protected conjugate was dissolved in TFA/dichloromethane 1:1 (2 mL) 
and stirred at room temperature for 6 h. After removal of the solvent under vacuum, the 
resulting residue was purified by HPLC to give conjugate 2.23 (14.7 mg) in 95% yield; 
mp > 3000C. HPLC tR = 27.01 min. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (591 400) , 
510 (52 600) , 555 (21 900), 585 (11 400) , 650 (10 000). 1H-NMR (CDCl3, 400 MHz): δ 
8.75-9.75 (br s, 8H, β-H), 3.33-3.69 (m, 16H, SCH2 & CH2), 2.35-3.11 (m, 35H, CH2, 
BH, CH). 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.6 (m, 6F), -139.8 (m, 6F), -144.2 
(d, J = 15.4 Hz, 2F), -162.4 (d, J = 15.9 Hz, 2F). HRMS (ESI-TOF) m/z found 1612.7414 
[M+H+], 806.3720 [M+2H+]2+, calcd for C59H64F16N8B30S3 = 1612.7008,  
[C59H64F16N8B30S3]2+ = 806.3504. 
Conjugate 3.24 
  A similar procedure was used to that described above for conjugate 3.21, using 
porphyrin 3.20 (14.9 mg, 0.01 mmol), (N1,N3,N6,N9-tetra-tert-butoxycarbonyl)-1,11-di-
amino-3,6,9-triazaundecane (8.85 mg, 0.015 mmol)41 and NMP (2 mL). 53,54 The Boc-
protected conjugate was obtained (20 mg) in 96% yield, mp = 292-295 oC. UV-vis 
(DMSO) λmax (ε/M-1 cm-1) 416 (592 500), 510 (21 200), 555 (18 000), 585 (9 400), 650 
(8 600); 1H-NMR (CDCl3, 400 MHz): δ 9.05 (s, 2H, β-H), 8.90 (s, 6H, β-H), 3.25-3.45 
(m, 22H, SCH2, NCH2), 1.75-2.98 (m, 33H, CH2, BH, CH), 1.57 (s, 9H, tBu), 1.50 (s, 
18H, tBu), 1.43 (s, 9H, tBu),  -2.86 (s, 2H, NH). 13C-NMR (CDCl3, 100 MHz): δ 156.92, 
156.16, 155.39, 147.64, 145.60, 143.30, 141.16, 138.06, 135.68, 120.86, 115.30, 103.94, 
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81.89, 80.69, 79.14, 77.24, 60.41, 59.22, 50.21, 47.45, 47.36, 45.42, 40.62, 39.47, 29.71, 
28.43, 28.21, 24.83, 21.06, 14.21. 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.9 (m, 
6F), -139.8 (m, 6F), -144.3 (d, J = 15.3 Hz, 2F), -162.5 (d, J = 16.0 Hz, 2F).  
The Boc protected conjugate was deprotected using TFA in dichloromethane, as 
described above, and conjugate 3.24 was obtained (15.1 mg) in 95% yield after HPLC 
purification; mp > 300 oC; HPLC tR = 26.68 min. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 
(596 900), 510 (54 500), 555 (24 400), 585 (12 500), 650 (10 900). 1H-NMR (CDCl3, 400 
MHz): δ 8.88-9.60 (br s, 8H, β-H), 3.33-4.02 (m, 20H, SCH2, CH2), 1.22-3.25 (m, 35H, 
CH2, BH, CH). 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.9 (m, 6F), -139.9 (m, 6F), -
144.4 (d, J = 15.1 Hz, 2F), -162.3 (d, J = 16.4 Hz, 2F). HRMS (ESI-TOF) m/z found 
1656.8000 [M+H+], 828.4016 [M+2H]2+, calcd for [C61H68F16N9B30S3] = 1656.7418,  
[C61H68F16N9B30S3]2+ = 828.3709. 
Conjugate 3.25 
  A similar procedure was used to that described above for conjugate 3.21, using 
porphyrin 3.20 (14.9 mg, 0.01 mmol), (N1,N3,N6,N9,N12-penta-tert-butoxycarbonyl)-
1,14-di-amino-3,6,9,12-tetraazatetradecane (11.0 mg, 0.015 mmol)41 and NMP (2 
mL).53,54 The Boc-protected conjugate was obtained (21.4 mg) in 96% yield, mp = 293-
2960C; UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (456 000), 510 (24 000), 555 (21 000), 585 
(12 500), 650 (10 300). 1H-NMR (CDCl3, 400 MHz): δ 9.06 (s, 2H, β-H), 8.91 (s, 6H, β-
H), 3.22-3.56 (m, 24H, SCH2, NCH2), 2.72-2.79 (m, 2H, CH2), 1.8-3.15 (m, 35H, CH2, 
BH, CH), 1.58 (s, 9H, tBu), 1.48-1.51 (m, 27H, tBu), 1.43 (s, 9H, tBu),  -2.86 (s, 2H, 
NH). 13C-NMR (CDCl3, 100 MHz): δ 156.99, 156.14, 155.33, 147.64, 145.49, 145.16, 
143.53, 138.09, 137.90, 121.06, 120.88, 115.31, 103.94, 81.90, 80.95, 80.63, 80.23, 
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80.04, 79.12, 60.41, 59.23, 47.39, 45.43, 39.45, 38.76, 37.65, 28.91, 21.06, 14.21. 19F-
NMR (Acetone-d6, 233.33 MHz): δ -135.8 (m, 6F), -139.6 (m, 6F), -144.0 (d, J = 15.4 
Hz, 2F), -162.2 (d, J = 16.1 Hz, 2F).  
The Boc protected conjugate was deprotected using TFA in dichloromethane, as 
described above, and conjugate 3.25 was obtained (15.5 mg) in 95% yield after HPLC 
purification, mp > 3000C; HPLC tR = 26.14 min. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 
(552 300), 510 (45 900), 555 (18 400), 585 (14 100), 650 (5 700). 1H-NMR (CDCl3, 400 
MHz): δ 8.78-9.61 (br s, 8H, β-H), 3.25-3.87 (m, 24H, SCH2, CH2), 1.65-3.11 (m, 35H, 
CH2, BH, CH). 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.4 (m, 6F), -139.7 (m, 6F), -
144.3 (d, J = 15.8 Hz, 2F), -162.5 (d, J = 16.3 Hz, 2F). HRMS (ESI-TOF) m/z found 
1698.8939 [M+H+], 849.9461 [M+2H+]2+, 566.9658 [M+3H+]3+; calcd for 
C63H72F16N10B30S3 = 1698.7639, [C63H72F16N10B30S3]2+ = 849.3819, 
[C63H72F16N10B30S3]3+ = 566.2546. 
Conjugate 3.26 
  A similar procedure was used to that described above for conjugate 3.21, using 
porphyrin 3.20 (14.9 mg, 0.01 mmol), (N1,N3,N7-tri-tert-butoxycarbonyl)-1,9-di-amino-
3,7-diazanonane (6.7 mg, 0.015 mmol)41 and NMP (2 mL).53,54 The Boc-protected 
conjugate was obtained (18.7 mg) in 96% yield, mp = 280-283 oC. UV-vis (DMSO) λmax 
(ε/M-1 cm-1) 416 (512 300), 510 (35 900), 555 (16 700), 585 (12 100), 650 (9 000). 1H-
NMR (CDCl3, 400 MHz): δ 9.06 (s, 2H, β-H), 8.91 (s, 6H, β-H), 3.85 (s, 2H, CH2), 3.74 
(s, 2H, CH2), 3.47 (s, 6H, SCH2), 3.3-3.45 (m, 6H, NCH2), 1.73-3.09 (m, 37H, CH2, BH, 
CH), 1.58 (s, 9H, tBu), 1.51 (s, 9H, tBu), 1.45 (s, 9H, tBu),  -2.86 (s, 2H, NH). 13C-NMR 
(CDCl3, 100 MHz): δ 156.07, 147.63, 145.30, 143.01, 135.67, 130.73, 120.86, 115.29, 
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103.94, 81.88, 80.63, 80.12, 79.28, 60.41, 59.22, 47.08, 45.59, 40.62, 39.62, 28.06, 14.21. 
19F-NMR (Acetone-d6, 233.33 MHz): δ -135.9 (m, 6F), -139.4 (m, 6F), -144.6 (d, J = 
15.2 Hz, 2F), -162.6 (d, J = 15.8 Hz, 2F).  
The Boc protected conjugate was deprotected using TFA in dichloromethane, as 
described above, and conjugate 3.26 was obtained (14.8 mg) in 95% yield after HPLC 
purification; mp = 292-294 oC. HPLC tR = 26.80 min; UV-vis (DMSO) λmax (ε/M-1 cm-1) 
416 (482 600), 510 (41 800), 555 (17 696), 585 (10 863), 650 (6 763). 1H-NMR (CDCl3, 
400 MHz): δ 8.90-9.70 (br s, 8H, β-H), 3.60 (s, 6H, SCH2), 3.33-3.53 (m, 10H, CH2), 
2.24-3.11 (m, 37H, CH2, BH, CH). 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.4 (m, 
6F), -139.6 (m, 6F), -144.8 (d, J = 15.4 Hz, 2F), -162.1 (d, J = 15.9 Hz, 2F). HRMS (ESI-
TOF) m/z found 1626.7602 [M+H+], 813.8820 [M+2H+]2+, calcd for C60H66F16N8B30S3 = 
1626.7262,  [C60H66F16N8B30S3]2+ = 813.3631. 
Conjugate 3.27 
 A similar procedure was used to that described above for conjugate 3.21, using 
porphyrin 3.20 (14.9 mg, 0.01 mmol), (N1,N4,N8-tri-tert-butoxycarbonyl)-1,11-di-
amino-4,8-diazaundecane (7.34 mg, 0.015 mmol)41 and NMP (2 mL).53,54 The Boc-
protected conjugate was obtained (19.0 mg) in 96% yield, mp = 270-2740C; UV-vis 
(DMSO) λmax (ε/M-1 cm-1) 416 (496 100), 510 (39 600), 555 (18 600), 585 (10 800), 650 
(9 300). 1H-NMR (CDCl3, 400 MHz): δ 9.04 (s, 2H, β-H), 8.91 (s, 6H, β-H), 3.47 (s, 6H, 
SCH2), 3.14-3.33 (m, 10H, NCH2), 1.71-3.05 (m, 41H, CH2, BH, CH), 1.56 (s, 9H, tBu), 
1.51 (s, 9H, tBu), 1.45 (s, 9H, tBu),  -2.85 (s, 2H, NH). 13C-NMR (CDCl3, 100 MHz): δ 
156.05, 147.63, 145.15, 142.43, 141.09, 135.65, 130.95, 121.05, 115.30, 103.94, 81.89, 
80.05, 79.88, 60.41, 59.22, 44.99, 40.62, 38.78, 36.54, 31.89, 31.76, 30.78, 21.06, 14.21. 
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19F-NMR (Acetone-d6, 233.33 MHz): δ -135.3 (m, 6F), -139.7 (m, 6F), -144.5 (d, J = 
15.4 Hz, 2F), -162.3 (d, J = 15.9 Hz, 2F).  
The Boc protected conjugate was deprotected using TFA in dichloromethane, as 
described above, and conjugate 3.27 was obtained (15.0 mg) in 95% yield after HPLC 
purification, mp = 284-287 oC. HPLC tR = 26.35 min. UV-vis (DMSO) λmax (ε/M-1 cm-1) 
417 (453 300), 510 (37 500), 555 (14 600), 585 (11 000), 650 (9 700). 1H-NMR (CDCl3, 
400 MHz): δ 8.81-9.82 (br s, 8H, β-H), 3.33-3.83 (m, 16H, SCH2, NCH2), 2.06-3.29 (m, 
41H, CH2, BH, CH). 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.6 (m, 6F), -139.4 (m, 
6F), -144.4 (d, J = 15.6 Hz, 2F), -162.3 (d, J = 16.0 Hz, 2F). HRMS (ESI-TOF) m/z found 
1654.7848 [M+H+], 827.8940 [M+2H+]2+, calcd for [C62H70F16N8B30S3] = 1654.7577, 
[C62H70F16N8B30S3]2+ = 827.3788. 
Conjugate 3.28 
  A similar procedure was used to that described above for conjugate 3.21, using 
porphyrin 3.20 (14.9 mg, 0.01 mmol), (N1,N4,N9-tri-tert-butoxycarbonyl)-1,12-di-
amino-4,9-diazadodecane (7.5 mg, 0.015 mmol)41 and NMP (2 mL).53,54 The Boc-
protected conjugate was obtained (19.1 mg) in 96% yield, mp = 276-278 oC. UV-vis 
(DMSO) λmax (ε/M-1 cm-1) 416 (490 800), 510 (39 600), 555 (18 600), 585 (11 900), 650 
(9 900). 1H-NMR (CDCl3, 400 MHz): δ 9.04 (s, 2H, β-H), 8.91 (s, 6H, β-H), 3.47 (s, 6H, 
SCH2), 3.33-3.43 (m, 10H, CH2), 1.57-3.13 (m, 43H, CH2, BH, CH), 1.55 (s, 9H, tBu), 
1.50 (s, 9H, tBu), 1.45 (s, 9H, tBu), -2.86 (s, 2H, NH). 13C-NMR (CDCl3, 100 MHz): δ 
156.10, 147.77, 145.64, 143.30, 139.15, 137.01, 121.05, 115.30, 103.94, 81.89, 79.90, 
77.28, 59.22, 49.42, 46.82, 40.62, 30.68, 29.72, 29.58, 17.66. 19F-NMR (Acetone-d6, 
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233.33 MHz): δ -135.4 (m, 6F), -139.4 (m, 6F), -144.5 (d, J = 15.3 Hz, 2F), -162.1 (d, J = 
16.2 Hz, 2F).  
The Boc protected conjugate was deprotected using TFA in dichloromethane, as 
described above, and conjugate 3.28 was obtained (15.2 mg) in 95% yield after HPLC 
purification; mp = 284-287 oC. HPLC tR = 26.17 min. UV-vis (DMSO) λmax (ε/M-1 cm-1) 
416 (491 875), 510 (40 656), 555 (15 991), 585 (10 700), 650 (6 500). 1H-NMR (CDCl3, 
400 MHz): δ 8.90-9.24 (br s, 8H, β-H), 3.61 (s, 6H, SCH2), 1.89-3.47 (m, 53H, NCH2, 
CH2, BH, CH). 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.5 (m, 6F), -139.8 (m, 6F), -
144.4 (d, J = 15.4 Hz, 2F), -162.2 (d, J = 15.9 Hz, 2F). HRMS (ESI-TOF) m/z found 
1668.8031 [M+H+], 834.9022 [M+2H+]2+, calcd for [C63H72F16N8B30S3] = 1668.7734, 
[C63H72F16N8B30S3]2+ = 834.3867. 
Conjugate 3.29 
 A similar procedure was used to that described above for conjugate 3.21, using 
porphyrin 3.20 (14.9 mg, 0.01 mmol), (N1,N4,N7-tri-tert-butoxycarbonyl)-1,10-di-
amino-4,7-diazaoctane (7.1 mg, 0.015 mmol)41 and NMP (2 mL).53,54 The Boc-protected 
conjugate was obtained (18.8 mg) in 96% yield, mp = 289-292 oC. UV-vis (DMSO) λmax 
(ε/M-1 cm-1) 416 (480 800), 510 (41 500), 555 (18 900), 585 (11 600), 650 (8 900). 1H-
NMR (CDCl3, 400 MHz): δ 9.03 (s, 2H, β-H), 8.90 (s, 6H, β-H), 3.33-3.68 (m, 14H, 
SCH2, NCH2), 1.6-3.1 (m, 41H, CH2, BH, CH), 1.56 (s, 9H, tBu), 1.52 (s, 9H, tBu), 1.45 
(s, 9H, tBu), -2.86 (s, 2H, NH). 13C-NMR (CDCl3, 100 MHz): δ 156.10, 155.89, 147.63, 
145.15, 143.65, 140.89, 137.78, 121.04, 115.29, 103.94, 81.87, 80.19, 79.87, 77.89, 
60.40, 59.22, 45.76, 45.34, 44.95, 40.62, 36.78, 36.54, 31.56, 28.96, 28.65, 28.50, 21.05, 
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14.20. 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.4 (m, 6F), -139.8 (m, 6F), -144.2 (d, 
J = 15.5 Hz, 2F), -162.3 (d, J = 16.1 Hz, 2F).  
The Boc protected conjugate was deprotected using TFA in dichloromethane, as 
described above, and conjugate 3.29 was obtained (15.0 mg) in 95% yield after HPLC 
purification; mp = 295-298 oC. HPLC tR = 26.77 min. UV-vis (DMSO) λmax (ε/M-1 cm-1) 
417 (438 225), 510 (40 593), 555 (19 538), 585 (12 560), 650 (9 800). 1H-NMR (CDCl3, 
400 MHz): δ 8.78-9.24 (br s, 8H, β-H), 3.33-3.53 (m, 20H, SCH2, NCH2), 1.63-3.29 (m, 
37H, CH2, BH, CH). 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.6 (m, 6F), -139.6 (m, 
6F), -144.4 (d, J = 15.6 Hz, 2F), -162.4 (d, J = 16.1 Hz, 2F). HRMS (ESI-TOF) m/z found 
1640.7763 [M+H+], 820.8882 [M+2H+]2+, calcd for [C61H67F16N8B30S3] = 1640.7323, 
[C61H67F16N8B30S3] = 820.3661. 
Conjugate 3.30 
  A similar procedure was used to that described above for conjugate 3.21, using 
porphyrin 3.20 (14.9 mg, 0.01 mmol), tert-butyl-12-amino-4,7,10-trioxadodecanoate (4.1 
mg, 0.015 mmol) and NMP (2 mL).53,54 The Boc-protected conjugate was obtained (16.8 
mg) in 95% yield, mp = 289-292 oC; UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (460 800), 
510 (38 450), 555 (16 700), 585 (10 200), 650 (8 100). 1H-NMR (CDCl3, 400 MHz): δ 
9.02 (s, 2H, β-H), 8.90 (s, 6H, β-H), 3.89 (s, 4H, CH2), 3.68-3.82 (m, 18H, CH2, SCH2), 
1.67-3.10 (m, 33H, BH, CH), 1.43 (s, 9H, tBu), -2.88 (s, 2H, NH). 13C-NMR (CDCl3, 100 
MHz): δ 171.23, 149.78, 149.51, 145.42, 145.28, 143.77, 131.17, 125.50, 120.45, 120.07, 
119.23, 118.86, 114.49, 101.13, 100.60, 80.16, 79.93, 53.45, 46.56, 35.85, 27.41. 19F-
NMR (Acetone-d6, 233.33 MHz): δ -135.4 (m, 6F), -139.6 (m, 6F), -144.8 (d, J = 15.5 
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Hz, 2F), -162.3 (d, J = 16.1 Hz, 2F). HRMS (MALDI-TOF) m/z found 1747.822 [M]+, 
calcd for C66H75F16N5B30S3 O5 [M]+ = 1747.746.  
The Boc protected conjugate was deprotected using TFA in dichloromethane, as 
described above, and conjugate 3.30 was obtained (15.4 mg) in 95% yield after HPLC 
purification; mp = 295-298 oC; HPLC tR = 51.21 min. UV-vis (DMSO) λmax (ε/M-1 cm-1) 
417 (430 200), 510 (36 700), 555 (18 500), 585 (10 500), 650 (8 800). 1H-NMR (CDCl3, 
400 MHz): δ 8.88-9.32 (br s, 8H, β-H), 3.68-3.82 (m, 14H, CH2), 3.45 (s, 6H, SCH2), 
1.73-2.99 (m, 35H, BH, CH2, CH), -2.83 (s, 2H, NH). 19F-NMR (Acetone-d6, 233.33 
MHz): δ -135.5 (m, 6F), -139.8 (m, 6F), -144.6 (d, J = 15.6 Hz, 2F), -162.4 (d, J = 16.2 
Hz, 2F). HRMS (MALDI-TOF) m/z found 1691.758 [M]+, calcd for C62H67F16N5B30S3O5 
[M]+ = 1691.684. 
3.4.3: Octanol-water partition coefficients 
  The partition coefficients (log P) were measured at room temperature by adding 
0.3 mL of a porphyrin stock solution in DMSO (0.333 mM) to a 4 mL volumetric tube 
containing 2.0 mL of HEPES buffer (50 mM, pH 7.4), followed by addition of 2.0 mL of 
1-octanol.41 After vortexing for 5 min, the phases were separated by centrifugation. An 
aliquot of 0.3 mL from each layer was diluted with 2 mL of methanol and the absorbance 
was read on a Perkin Elmer Lambda 35 UV-Vis spectrophotometer with 10 mm path 
length quartz cuvettes. 
3.4.4: Cell Studies 
All tissue culture medium and reagents were purchased from Invitrogen 
(Carlsbad, CA). Human glioma T98G cells were purchased from ATCC and cultured in 
ATCC-formulated Eagle's Minimum Essential Medium containing 10% FBS and 1% 
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antibiotic (Penicillin Streptomycin). The cells were split twice weekly to maintain a sub-
confluent stock. All compound solutions were filter-sterilized using a 0.22 µm syringe 
filter.  
 3.4.4.1: Dark Cytotoxicity. 10,000 T98G cells were plated per well in a Costar 96 
well plate and allowed to grow 36 h.  Porphyrin stock solutions (32 mM) were prepared 
in DMSO and then diluted into final working concentrations (25, 50, 100, 200, 400 µM). 
The cells were exposed to increasing concentrations of porphyrin up to 400 µM and 
incubated overnight. The loading medium was removed and the cells washed with 100 
µL PBS. Then medium containing Cell Titer Blue (Promega) 120 µL was added as per 
manufacturer’s instructions. After incubating for 4 h the cytotoxicity was then measured 
by reading the fluorescence at 520/584 nm using a BMG FLUOstar plate reader. The 
signal was normalized to 100% viable (untreated) cells and 0% viable (treated with 0.2% 
saponin from Sigma) cells. 
 3.4.4.2: Phototoxicity. The T98G cells were prepared as described above for the 
dark cytotoxicity assay and treated with porphyrin concentrations of 0, 6.25, 12.5, 25, 50, 
and 100 µM. After compound loading, the medium was removed and replaced with 
medium containing 50 mM HEPES pH 7.4.  The cells were exposed to a NewPort light 
system with 175 W halogen lamp for 20 min, filtered through a water filter to provide 
approximated 1.5 J/cm2 light dose. The cells were kept cool by placing the culture on a 
50C Echotherm chilling/heating plate (Torrey Pines Scientific, Inc.). The cells were 
returned to the incubator overnight and assayed for viability as described above for the 
dark cytotoxicity experiment and adding medium containing Cell Titer Blue to determine 
the toxicity of the compounds. 
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 3.4.4.3. Time-Dependent Cellular Uptake. The T98G cells were prepared as 
described above for the dark cytotoxicity assay. The cells were exposed to 10 µM of each 
conjugate for 0, 1, 2, 4, 8, and 24 h. At the end of the incubation time the loading medium 
was removed and the cells were washed with 200 µL PBS. The cells were solubilized 
upon addition of 100 µL of 0.25% Triton X-100 (Calbiochem) in PBS. To determine the 
porphyrin concentration, fluorescence emission was read at 415/650 nm 
(excitation/emission) using a BMG FLUOstar plate reader. The cell numbers were 
quantified using the CyQuant cell proliferation assay (Invitrogen) as per the 
manufacturer’s instructions, and the uptake was expressed in terms of nM compound per 
cell. 
 3.4.4.4. In vitro Blood Brain Barrier Studies. The hCMEC/D3 cells were 
incubated in a 6-well, 0.4 µm porosity PET transwell plate (Corninig) and allowed to 
grow for 48 h. 0.5 ml of 1mg/ml porphyrin conjugates were added to the upper chamber 
and 1.5 ml HBSS buffer is added to the bottom chamber. The cells were incubated for 0, 
30 and 60 min. At the end of the incubation time 5X100 µL of solution form the bottom 
chamber is pipetted and added to a 96 well plate. To determine the porphyrin 
concentration, fluorescence emission was read at 415/650 nm (excitation/emission) using 
a BMG FLUOstar plate reader.       
 3.4.4.5. Microscopy. The HEp2 cells were incubated in a glass bottom 6-well 
plate (MatTek) and allowed to grow for 48 h. The cells were then exposed to 10 µM of 
each porphyrin conjugate for 6 h. Organelle tracers were obtained from In- vitrogen and 
used at the following concentrations: LysoSensor Green 50 nm, MitoTracker Green 250 
nm, ER Tracker Blue/white 100 nm, and BODIPY FL C5 Ceramide 1 mm. The organelle 
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tracers were diluted in medium and the cells were incubated concurrently with porphyrin 
conjugate and tracers for 30 min before washing 3 times with PBS and microscopy. 
Images were acquired using a Leica DM RXA2 upright microscope with 40 X NA 0.8dip 
objective lens and DAPI, GFP and Texas Red filter cubes (Chroma Technologies). 
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CHAPTER 4: SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL 
EVALUATION OF CARBORANYLPORPHYRIN GLUCOSE AND 
POLYETHYLENE GLYCOL PEPTIDE CONJUGATES 
4.1: Introduction 
  
 A single cell is the basic component from where life began and the human body is 
made of millions of different types of cells. Therefore, in developing a therapeutically 
important drug, one needs to understand the biology and components involved in a cell. 
A plethora of drugs have been developed since centuries after extracting components 
from cell and investigating the mechanism by which the drugs can interact with certain 
cell components. For example protein-protein interaction and peptide-protein interactions 
on the surface of the cell, facilitating drug transport into the cell and ultimately the 
treatment of disease in particular of brain tumors which are the focus of this study. 
Opioid peptides and cell penetrating peptides that can either cross the BBB or selectively 
accumulate in brain tumor cells by the processes of adsorptive mediated endocytosis and 
receptor mediated endocytosis were used in this Chapter.     
4.1.1: Opioid receptors and Opioids 
 
 Opioid peptides are a class of peptides, which specifically bind to opioid receptors 
that are present in large quantity all around spinal cord and brain.1-7 Among these, the 
endogenous opioid peptides are naturally produced with in the body, specifically in the 
central nervous system (CNS) (see examples in Figures 4.1, 4.2 and 4.3).8 Opioid 
peptides show the same narcotic properties as the non-peptidic opioiate drugs such as 
morphine, codeine, heroine, and thebaine that are derived from opium.9,10 All the 
naturally occurring and synthetic opioid peptides, and non-peptidic molecules which 
specifically have affinity for opioid receptors are called opioids.  
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4.1.1.1: Opioid receptors. Opioid receptors are one of the classes of receptors that 
are coupled to pertussin-toxin-sensitive inhibitory G-proteins.2,11-13 The opioid receptors 
were initially classified in the 1970’s by Martin after the clinical studies on nalorphine 
and morphine.14,15 Then, after several bioassay and binding studies, the  current 
classification includes three different types of opioid receptors, namely µ-opioid 
receptors (MOR), κ-opioid receptors (KOR), and δ-opioid receptors (DOR).14-16 MOR 
are sub-classified into µ1-opioid receptor (MOR-1) and µ2 opioid receptor (MOR-2),17-33 
KOR are sub-classified into κ1 (KOR-1), κ2 (KOR-2) and κ3 (KOR-3) opioid receptors,34-
40 and the sub-classification of DOR has also been suggested but not yet confirmed.41-44 
MOR has high selectivity for morphine and their derivatives, KOR has high selectivity 
for ketocyclazocine, and DOR has high selectivity for enkephalins.15,45-47 These opioid 
receptors are present in spinal cord with about 70% consisting of MOR, 24% DOR and 















    
 




































Figure 4.2: Structure of α-neoendorphin (4.3) 8 and β-neoendorphin (4.4) 8 
 
 
The study on genetics of opioid receptors revealed that all the opioid receptors 
contain seven transmembrane domains which share about 60% of similar amino acids,48 
which are divided into three exons called exon 1, containing N-terminus and first 
transmembrane domain, exon 2, contains the next three transmembrane domains, and 
exon 3, containing the last three transmembrane domains and the C-terminus.5,49-52 The 
MOR-1 has an extra fourth exon along with the three exons present in other opioid 
receptors.50,53-56 Activation of opioid receptors occurs after the ligand binds to the 
receptor. The information signal is transduced through the gene during the activation, 

































































4.1.1.2: Opioid peptides. These are a family of peptides that show affinity for 
different types of opioid receptors (MOR, DOR and KOR). These endogeneous peptides 





The endorphins are derived from the precursor protein pre-opiomelano cortin 
(POMC) and are found in pituitary glands, brain and nervous system.58-60 α-
neoendorphin, β-neoendorphin, and βh-endorphin are examples of endogenous peptides 
that come under this category (Figure 4.2). These peptides show high affininty for MOR 
and low affinity for both DOR and KOR. 
Table 4.1. Endogenous opioid peptides. 
 
Endogenous opioid Sequence 
Met-Enkepalin (4.1) YGGFM 
Leu-Enkepalin (4.2) YGGFL 
α-neoendorphin (4.3) YGGFLRKYPK 
β-neoendorphin (4.4) YGGFLRKYP 
Dynorphin A YGGFLRRIRPKLKWDNQ 
Dynorphin B YGGFLRRQFKWT 
Endomorphin-1 (4.5) YPWF 
Endomorphin-2 (4.6) YPFF 
 
 
Enkephalins are derived from the precursor protein preproenkephalin.61 Met-
enkephalins (4.1) and leu-enkephalins (4.2) (Figure 4.1) are two opioid peptides that 
come under this category, that were discovered in 1975. Met-enkephaline unlike 
endorphins are neurotransmitters found mostly in the brain. Leu-enkephalins have high 
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affinity for DOR, compared to MOR and KOR, which is not the case for met-enkephalins 
and endorphins which have higher affinity for MOR.   
 
 
Figure 4.3: Structure of endomorphin-1 (4.5)8 and endomorphin-2 (4.6) 8 
 
 
Dynorphins are derived from the precursor protein prodynorphin.62 These are 
produced in different parts of the brain (hypothalamus, hippocampus, mid brain, medulla, 
pons) and spinal cord. Dynorphin A and Dynorphin B (Table 4.1) are long chain peptides 
with arginine and lysine amino acids in their sequence. These peptides show high affinity 
for KOR.  
Recently, two endomorphins called endomorphin-1 (4.5) and endomorphin-2 
(4.6) were discovered that show high affinity for MOR, higher than any other known 
opioids (see Figure 4.3). Endomorphin-1 was found to be distributed throughout the 
























endomorphins, all other endogeneous peptides have a common peptapeptide YGGF(M/L) 
sequence as shown in Table 4.1.    
 
 
Figure 4.4: Structure of HIV-1 TAT (48-60) (4.7)63 and Arg 9 (4.8)68 
 
  
4.1.2: Cell penetrating peptides (CPPs) 
 
Cell penetrating peptides (CPPs) are a class of peptides with a high positive 
charge containing arginine or lysine in the peptide sequence that can get easy access into 
the cell after translocation of cell membrane. Transactivator of transcription (TAT) 
peptide, derived from HIV-1 (Human Immunodeficiency Virus) was the first CPP 
discovered in 1988 after the peptide got internalized into the cell.63,64 This discovery 






































































































Figure 4.4), HIV-1 TAT (43-60), HIV-1 TAT (37-60), HIV-1 TAT (37-53) and several 
hundrend CPPs such as Penetratin,65 Transportan,66 MAP,67 and Arg9 (4.8)68 as shown in 
the Table 4.2. These CPPs have been used successfully to deliver several biomolecules 
into different cell lines.69-72 Although the exact mechanism of the penetration of peptide 
into the cell is unknown, it is proposed that either endocytosis73 or energy-dependent 
pathway74 or combination of both endocytosis and energy-dependent pathway occurs as 
shown in Figure 4.5 (highly positive charge HIV-1 TAT (48-60) (4.7) and Arg9 
(4.8)).75,76 
Table 4.2. Examples of Cell penetrating peptides (CPPs) 
 
Cell Penetrating Peptide Sequence 








Carbohydrates also play an important role in cell biology as they act as storage 
units, help in protein folding, signal transduction, inflammation, and viral entry.77 As 
explained in Chapter 1 the carbohydrates are essential units for a cell and high amount of 
carbohydrates are required to maintain the metabolic activity for cancerous cell compared 
to normal ones.78 These carbohydrates when conjugated to a hydrophobic drug can 
improve the solubility. This would allow drugs conjugated to sugars, selectively target 
tumors and have good uptake in to tumor cells. Carbohydrate porphyrin conjugates were 
investigated as a PDT agent in vitro.79-81 Drain et al used 5,10,15,20-tetrakis-(2,3,4,5,6-
pentafluorophenyl)-porphyrin to conjugate several carbohydrates.79,80 These porphyrin 
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carbohydrate conjugates have showed to be effective PDT agents and can be used to 
target different tumor cells by inducing apoptosis and necrosis.      
 
 
Figure 4.5: Mechanisms of transporting CPPs into cells.76 
 
 
In this Chapter we performed the synthesis of porphyrin-peptide conjugates and a 
carbohydrate-porphyrin conjugate for the specific targeting of brain tumors. We chose the 
two short chain endogenous peptides met-enkephalins and endomorphin-1 that are found 
mostly in brain and have high affinity for µ-opioid receptors. Two synthetic opioid 
peptides, TAPA82,83 an analogue of dermorphin a naturally occurring hepta-peptide and 
YGGFLRRA an analogue of leu-enkephaline, and CPP octa-arginine was also used. 
Thiol glucose was also used so as to check the biological efficacy and compare with the 
above peptide conjugates.    
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 The strategy of conjugating peptides to fluorescent biomolecules has been widely 
employed for imaging and potentially treatment of tumors using PDT,84-87 BNCT,88 
positron emission topology (PET),89-91 and single-photon emission computed tomography 
(SPECT).92-94 In this Chapter we are interested in conjugating opioid peptides or CPPs to 
hydrophobic closo-carboraned porphyrins as a potential BNCT agent for treating brain 
tumors. All the peptides used were prepared on solid support (PAL-PEG resin) on bench 
top or on a peptide synthesizer using Fmoc strategy of solid-phase peptide synthesis.  
 The synthesis of symmetrical tetra(closo-o-carboronyltetrafluoro)phenyl 
porphyrin  4.9 was attempted after nucleophilic substitution of commercially available 1-
mercapto-o-carborane on the para-fluorine of 3.19, but we observed a degraded product 
4.10 which was found to have lost the boron atom on the carborane cages resulting in the 
nido-carborane containing porphyrin (see Scheme 4.1). This could be due to the presence 
of base K2CO3 in the reaction mixture, as the basic reagents can convert the closo-ortho 
and meta-carboranes to their nido-forms.95 Another attempt using an aprotic solvent, 
dioxane, and triethyl-amine as the base also resulted in the degraded product (4.10). As 
the p-closo-carborane is stable under basic conditions96 we opt to synthesize the thiol-p-
carborane and use it in the substitution reaction. The synthesis of 1-mercapitomethyl-p-




Scheme 4.1: Synthesis of  tetra(nido-carborane)porphyrin 4.10 
 
 
The synthesis of symmetric tetra(p-thiolcarboranyltetrafluoro) phenylporphyrin 
4.11 was achieved in high yield after nucleophilic substitution of 1-mercapitomethyl-p-
carborane on the four para-fluorines using K2CO3 as the base and DMF as solvent at 
room temperature for 48 h. The yield was optimized using 6 eq. of 1- mercapitomethyl-p-
carborane and 8 eq. K2CO3 with 1 eq. of porphyrin 3.19 (see Table 4.3). The product was 
characterized using 1H-NMR, 19F-NMR, UV-Vis, 13C-NMR, and MALDI-MS. The 1H 
















































































singlet peak at 3.47 due to the methylene protons, a 44 proton broad multiplet peak 
between 2.16-3.02 due to the BH and CH protons on the carborane, and a singlet two 
proton peak due to the NH of the porphyrin at -2.87. The structure of 4.11 was further 
supported by the MALDI-MS spectrum where a peak at m/z 1655 was observed, 
corresponding to compound 4.11. This compound due to its symmetric structure was easy 
to recrystallize using a DCM/Hexane mixture as shown in Figure 4.6. In the X-ray 
structure the phenyl rings are perpendicular to the planar porphyrin moiety and the C-S-C 
has a 800 angle.  
 
 




Scheme 4.3: Synthesis of t-butyl protected azido polyethylene glycol 4.14 
 
 






























































    1100C, 2.5 h, 85%
2. NaH/THF, BrCH2COOtBu













K2CO3 (eq.) % yield of 4.11 
8 8 65 
7 8 79 
6 8 90 
 
 
Previous studies showed that the mono-substituted porphyrin peptide 
conjugates86,87 or the tri substituted carborane porphyrin with one free phenyl group97 for 
conjugating biomolecules had good biological efficacy. Therefore a successful synthesis 
of tri-p-carborane porphyrin 4.15 with an alkyne moiety was achieved and optimized 
using 4 eq. of 1-mercaptomethyl p-carborane as shown in Scheme 4.4. First porphyrin 
3.19 was reacted with propargyl alcohol in the presence of K2CO3 to obtain the mono-
alkylated product, The remaining three free para-fluoro groups were substituted by the 
mercapto p-carborane to obtain the desired product in 80% yield. The tert-butyl protected 
hexaethylene glycol containing an azido group 4.14 was synthesized as shown in Scheme 
4.3 and conjugated to the zinc porphyrin 4.15 using azido-alkyne click chemistry.81  
Polyethylene glycol (PEG) was used previously as a linker between the peptide 
and porphyrin. PEG linker increases the water solubility of the compound and facilitates 
the binding of peptides to the surface of the targeted cell.86,87 The PEG linker also 
facilitates the coupling of peptides to the porphyrin, increases the yields of the desired 
porphyrin-PEG-peptide conjugate. The hexaethylene glycol 4.14 used is not 
commercially available so its synthesis was carried out in three steps form commercially 
available hexaethylene glycol. Zn-porphyrin was used to prevent side reactions, which 
can occur in the click chemistry reaction conditions, such as insertion of Cu metal in the 
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free porphyrin ring. The click chemistry of azido polyethylene glycol and alkyne 
porphyrin 4.15 using CuSO4/CuI and ascorbic acid resulted in the targeted product 4.16, 
but the purification was difficult from the unreacted tert-butyl azido PEG. Therefore the 
tert-butyl group and the zinc metal were removed using TFA/DCM in an attempt to 
obtain the free porphyrin-PEG 4.17, but with no success. For this reason, the conjugation 
of peptides to the porphyrin-PEG 3.30 was chosen. As discussed in Chapter 3 the 
synthesis procedure for compound 3.30 was successfully carried, yet utilizes lot of 
expensive 1-mercaptomethyl-p-carborane. Therefore, an alternative synthesis was 
carried, which is discussed below. 
 






































































































K2CO3, Acetone, 600C, 4h, 75%
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THF:H2O 3:1, reflux,12 h
(4.15)
(4.16)(4.17)
3. Zn(OAc)2, CHCl3, rt, 24 h, (98%)
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  In the alternative method for synthesis of 3.30 the mono-substituted tert-butyl 
protected porphyrin-PEG 4.18 was synthesized by replacing one fluorine on the para-
position of phenyl group with amine-containing tert-butyl protected PEG. NMP was used 
as the solvent and tetra(pentafluorophenyl)porphyrin 3.19 as well as tert-butyl-12-amino-
4,7,10-trioxadodecanoate were heated at 1000C for 4 h as shown in Scheme 4.5. After 
work-up the compound was passed through silica gel with DCM/EtOAc (9.8:0.2) as 
elutant to obtain pure compound 4.18 as the second fraction in 32% yield. A nine proton 
singlet peak around 1.4 ppm due to tert-butyl ester and a multiplet 12 proton peak 
between 3.7-3.8 ppm due to PEG were by 1H-NMR.  The nucleophilic substitution of 
thiol-carborane on the p-fluro position of the remaining phenyl group of 4.18 followed by 
deprotection of tert-butyl group using TFA was carried out to obtain compound 3.30 in 
85% yield. The nucleophilic substitution reaction was optimized using 4 eq. of thiol-
carborane and 6 eq. K2CO3 for 1 eq. of compound 4.18 in DMF for 48 h (see table 4.4). 
The 1H-NMR spectrum of 3.30 showed a singlet six proton peak around 3.5 ppm and a 33 
proton peak due to the carboranes (BH and CH).   
The free acid group on the PEG was conjugated to arginine or peptides. We chose 
the CPPs octa-arginine and the opioid peptides YRFA, YGGFM, YPWF, and 
YGGFLRRA. Compound 4.19 containing arginine was obtained after activating the 
carboxylic acid with base and HATU in DMF for 10 min followed by addition of L-
arginine amide at room temperature for 48 h. The obtained product was purified by 
HPLC to obtain pure product 4.19 (>95% purity) in 85% yield.  Unlike the coupling of 
the amino acid arginine in solution phase, all peptide coupling reactions were carried on 
solid support. The-octa arginine containing glycine as N-terminus amino acid on solid 
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support was coupled to activated porphyrin 3.30 using HATU and DIEA. The octa-
arginine peptide on solid support was prepared in a peptide synthesizer and then added in 
a 2-fold excess of activated porphyrin 3.30 and the mixture was left shaking for 4 days. 
 







The excess unreacted porphyrin was washed with DMF followed by DCM and methanol. 
The red color solid support was dried and then the cleavage cocktail 
TFA/phenol/TIS/H2O (88:5:2:5) or TFA/H2O (95:5) was added to cleave the product off 
the resin. To the resulting mixture, cold diethyl ether was added and a red color 
precipitate was obtained. The same solid phase synthesis procedure was followed to 
conjugate the opioid peptides YPWF, YGGFM, YGGFLRRA, and YRFA but the 
coupling reagents used in these reactions were HOBt/DEPBT. All the conjugates 4.20-
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HATU or HOBT/DEPBT
DIEA, DMF, 48 h, rt
33-85%
R = R (4.19)
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The synthesis of carborane-porphyrin containing a thiol-beta-D-glucose 4.25 was 
achieved after nucleophilic substitution of porphyrin 3.20 commercially available 1-thio-
beta-D-glucose tetraacetate using DMF as solvent and K2CO3 as the base at room 
temperature as shown in Scheme 4.6. The resulting product was reacted with 
NaOMe/MeOH at room temperature for 3 hours to obtain compound 4.25 in 88% yield.  
1H NMR, 13C NMR, HR-ESI studies has confirmed the formation of products. 




K2CO3 (eq.) % yield of 3.30 
6 6 76 
4.5 6 82 








4.2.2: In Vitro Studies  
 
 Compounds 4.11, 3.30, 4.19, 4.21 and 4.25 were tested for their biological 
efficacy on T98G cells, while the remaining 4.20, 4.22, 4.23 and 4.24 are under 

























































DMF, K2CO3, RT, 48 h
1. 1-Thio-beta-D-glucose tetraacetate





formulated Eagle's Minimum Essential Medium containing 10% FBS and 1% antibiotic 
(Penicillin Streptomycin). 32 mM Solutions were prepared initially and diluted according 
to the requirement for the assay. The cytotoxicity, cellular uptake and localization studies 
on these compounds are discussed below.   
4.2.2.1: Cytotoxicity. When tested for the toxicity of compounds under dark with 
a maximum concentration being 400 µM, none of the compounds showed high toxicity 
(IC50 > 200 µM). To the plated cells were added different concentrations (25 µM, 100 
µM, 200 µM, 400 µM) of compounds in five repetitions. After adding the compounds the 
96 well plate was incubated overnight and the solution in the 96-well plate was replaced 
with Cell Titer Blue which determines the number of survived cells by fluorescence. The 
resulting plot in Figure 4.7 shows the percent viability giving us an idea about the toxicity 
of the compounds. The most toxic compound observed form the graph is found to be 3.30 
with an IC50 about 296 µM.  
 
Figure 4.7: Dark cytotoxicity of conjugates 3.30 (black), 4.11 (red), 4.19 (orange), 4.21 






 Phototoxicity using a light dose of 1.5 J/cm2 of the compounds when tested with 
different concentrations (6.25 µM, 12.5 µM, 25 µM, 50 µM and 100 µM) were obtained. 
None of the compounds showed any phototoxicity (Figure 4.8). Similar to the dark 
toxicity assays, the compounds were added to the 96-well plate in different 
concentrations (6.25 to 100 µM) and then left under 1.5J/cm2 light dose for 20 min. Then 
the 96-well plate was incubated overnight followed by removal of the medium-containing 
compound. Cell Titer Blue was added and incubated for 4 h before reading the cell 
viability value. The low toxicity of the compounds may be attributed due to the non-toxic 
neutral form of the carboranyl porphyrins. Due to the non-toxicity of these porphyrins the 
uptake and localization studies were conducted.     
 
Figure 4.8: Phototoxicity (1.5 J/cm2) of conjugates 3.30 (black), 4.11 (red), 4.19 (blue), 
4.21 (purple) and 4.25 (Pink) toward human glioma T98G. 
 
 
4.2.2.2: Cellular Uptake. The uptake of compounds were studied on T98G cells at 
various time intervals (0, 1, 2, 4, 8 and 24). Compounds of 10 µM concentration were 
added to 96-well plated cells at different intervals and since there is no toxicity observed 
at 10 µM concentration, cells are considered to be healthy without interfering with the 
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uptake study. The excitation/emission (415/650) filter was used to obtain the 
concentration of the compound taken up by the cells using a fluorescence plate reader. 
The uptake results are shown in Figure 4.9.  The uptake into the T98G cells for this set of 
compounds follows the order 4.19>4.11>4.25∼2.30>4.21. All the compounds except 
4.25 showed high uptake within 2 h before reaching a plateau, where as compound 4.25 
showed a slow increment in uptake for the first 10 h, before reaching a plateau. The high 
uptake of compound 4.19 may be due to its high hydrophilicity. Interestingly the 
compound 4.21 having the TAPA peptide (µ-opioid peptide) showed the least uptake, 
which may be due to its high hydrophobicity or due to high expression (95%) of EGFR98-
102 on glioblastoma cells. Although, it was found that T98G cells consist of opioid 
receptors,103 the expression of these receptors on glioblastoma multiforme cancer might 
be minimal, that could have resulted in low uptake of TAPA peptide conjugate. 
Compounds 4.20, 4.22, 4.23 and 4.24 currently under study can give us better 
understanding of the biological behavior of the opioid peptides and cell penetrating 
peptides when conjugated to an hydrophobic carborane porphyrin.        
 
Figure 4.9: Time-dependent uptake of conjugates 3.30 (black), 4.11 (red), 4.19 (blue), 
4.21 (purple) and 4.25 (pink) toward human glioma T98G. 
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  4.2.2.3: Localization Studies. Localization studies were carried using HEp2 cells 
instead of T98G cells as it was a challenge adhering and spread the cells on the six well 
plastic well plate. This would facilitate in carrying the live cell imaging studies without 
the cells floating in the medium while taking the images. The organelle specific 
fluorescent probes ERTracker Blue/White (ER), MitoTracker Green (mitochondria), 
BODIPY-FL Ceramide (Golgi), and LysoSensor Green (lysosomes) were used in the 
imaging studies. After the cells were attached and spread in a six well plate with 4 ml 
medium, 400 µM concentration of compound was added into four of the six well plate 
containing cells and incubated for 4 hours before adding one of the each trackers in to the 
plates containing compound. Then the fluorescent images were obtained with tracker 
alone (c,e,g,i) and the overlay of compound with the tracker (d,f,h,j). Compounds 
fluoresce red and when overlapped with blue should show purple, which confirms the 
compound localizing in ER. When overlapped with green color should show yellow 
color, which confirms the compound localizing in mitochondria, Golgi and lysosomes. 
The results are shown in Table 4.5 and Figures 4.10-4.13. All the compounds localized 
mainly in mitochondria with minor localization sites being Golgi and lysosomes. The 
minor localization site for compound 4.25 was found to be the ER.  
Table 4.5. Major (++), minor (+) sites of localization in HEp2 cells 
 
Porphyrin ER Mitochondria Golgi Lysosomes 
3.30 - + + + 
4.11 - + + - 
4.19 - + - + 
4.21 - ++ - + 







Figure 4.10: Subcellular fluorescence of conjugate 4.11 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 4.11 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 






Figure 4.11: Subcellular fluorescence of conjugate 4.19 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 4.19 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 






Figure 4.12: Subcellular fluorescence of conjugate 4.21 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 4.21 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 






Figure 4.13: Subcellular fluorescence of conjugate 4.25 in HEp2 cells at 10 µM for 6h. 
(a) Phase contrast, (b) overlay of the 4.25 fluorescence and phase contrast, (c) ER 
Tracker Blue/White fluorescence, (e) MitoTracker Green fluorescence, (g) BODIPY 
Ceramide, (i) LysoSensor Green fluorescence, and (d, f, h, j) overlays of organelle tracers 




4.2.2.4: Blood brain barrier studies. In vitro blood brain permeability of porphyrin 
conjugates was evaluated at a concentration of 1mg/ml over a time period of up to1 h and 
the results obtained are shown in Table 4.6. Permeability coefficients at 30 min and 60 
min were obtained using equation 3.1 as discussed in Chapter 3. The permeability of 
compounds at 60 min has the following order 4.21> 4.19> 4.11> 3.30> 4.25. Unlike the 
least uptake of compound 4.21, it showed the highest permeability. None of the 
conjugates that were studied showed permeability greater than lucifier yellow FTIC40K 
which had a permeability coefficient of 1.1 e-5 at 30 min and 2.29 e-5 at 60 min.104 Since 
the µ-opiate morphin showed better permeability than lucifer yellow104 we expected a 
comparable results of TAPA conjugate with lucifer yellow, but it wasn’t the result due to 
the hydrophobic character of the conjugate. 
Table 4.6. In vitro BBB studies. 
COMPOUND Permeability Coefficient (cm/s) 
at 30 min 
Permeability Coefficient (cm/s) 
at 60 min 
3.30 7.98 e-7 1.19 e-6 
4.11 8.64 e-7 1.37 e-6 
4.19 7.79 e-7 1.44 e-6 
4.21 8.53 e-7 1.71 e-6 
4.25 3.45 e-7 6.23 e-7 
Lucifer yellow 1.10 e-5 2.29 e-5 
 
4.3: Conclusions 
 The synthesis of symmetrical tetra-(p-thiolcarboranyltetrafluorophenyl) porphyrin 
4.11, carboranyl-porphyrin glucose 4.25 and PEG peptide conjugates 4.19-4.24 were 
successfully carried out and the targeted products were characterized using NMR, ESI, 
MALDI-TOF and UV-Vis. The synthesis of pegylated porphyrins 4.16 and 4.17 using 
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click chemistry was achieved but the product could not be purified due to free azido 
hexaethylene glycol 4.14 as is evident by 1H-NMR. All other compounds 3.30, 4.11, 
4.19-4.25 were purified (>95%) using reversed phase HPLC. Studies on 3.30, 4.11, 4.19, 
4.21, 4.25 using human glioma T98G cells showed that none of the conjugates tested had 
any toxicity (photo and dark) except for compound 3.30 with IC50 296 µM and 4.19 with 
IC50 325 µM. the order of cellular uptake was found to be 4.19>4.11>4.25>3.30>4.21 in 
T98G cells. Most of the conjugates preferentially localized in mitochondria and 
lysosomes with compound 3.30 and 4.11 also localizing in the Golgi apparatus and 
compound 4.25 localizing in the ER. There isn’t much BBB permeability of conjugates 
observed when compared to the standard lucifier yellow, but among the set of compounds 
tested the peptide conjugate 4.21 showed the highest permeability. We are currently 
performing biological evaluation of the remaining synthesized compounds 4.20, 4.22-
4.24. 
4.4. Experimental section 
 
4.4.1: General Information 
 Reactions that are sensitive were conducted under argon atmosphere in oven-
dried glassware. Commercially available reagents and solvents (HPLC grade) were 
purchased from Sigma-Aldrich, Acros Organics and used without further purification. p-
carborane was purchased from Katchem, Inc. Anhydrous methanol was prepared by 
distillation from magnesium turnings and was stored under nitrogen over 3 A0 molecular 
sieves. Anhydrous THF was prepared by distillation from sodium and benzophenone. 
Analytical thin-layer-chromatography (TLC) was performed on polyester backed TLC 
plates 254 (pre-coated, 200 µm, Sorbent Technologies). Silica gel 60 (70–230 mesh, 
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Merk) used for column chromatography and silica gel TLC plates (0.2 mm thickness) 
were purchased from Sorbent Technologies. 1H NMR and 13C NMR spectra were 
obtained using a Bruker AV-4 400 MHz spectrometer; chemical shifts are expressed in 
ppm. 19F NMR spectra were obtained using a Bruker DPX-250 250 MHz spectrometer; 
chemical shifts are expressed in ppm. Electronic absorption spectra were measured on a 
Perkin Elmer Lambda 35 UV-vis spectrophotometer. Mass analysis was conducted at the 
LSU Mass Spectrometry Facility on a Bruker Omniflex MALDI-TOF mass spectrometer 
and exact masses were obtained from HRMS-ESI on an Applied Biosystems QSTAR 
XL. Melting points were measured on a Thomas hoover melting point apparatus. 
Reversed-phase HPLC was performed on a Waters system including a 2545 quaternary 
gradient module pump with a 2489 UV-vis detector and a fraction collector III. An 
analytical column (4.6X250 mm-XBridgeTM BED300 C18 5 µm) was used for the 
purification of all conjugates and a stepwise gradient from 0 to 100% Buffer B in the first 
10 min to 50% B and 50% C in next 10 min to 100% B in next 10 min. A stepwise 
gradient 10-90% Buffer B with Buffer A was used for the PEG conjugate. Buffer A 
(0.1% TFA, H2O), Buffer B (0.1% TFA, acetonitrile), Buffer C (0.1% TFA, acetone). 1-
Mercaptomethyl-p-carborane was prepared from p-carborane, as described in literature.63 
4.4.2: Peptide Synthesis and Conjugations  
 Applied Biosystems Pioneer, Peptide Synthesis System was used to synthesize 
peptide YGGFLRRA and YRFA. Peptides GRRRRRRRR, YGGFM and YPWF were 
synthesized using bench top solid phase synthesis. All the peptides were synthesized 
using Fmoc-PAL-PEG-PS on 0.2 mmol scale using Fmoc strategy of solid-phase peptide 
synthesis. The first Fmoc protected amino acid was conjugated or loaded on the resin 
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twice with 4 fold excess before loading on the next amino acid in the sequence so as to 
have 100% loading of the first amino acid and obtain maximium yield of the desired 
eptide. To synthesize the peptide GRRRRRRRR, coupling reagents HATU was used and 
for the remaining peptides HOBt/TBTU coupling reagents were used. The sequence was 
monitered using MALDI after cleaving from resin using cleavage cocktail 
TFA/phenol/TIS/H2O (88:5:2:5). 
Conjugation of porphyrin to peptides was achieved first by soaking the resin 
containing peptides with DMF for about 2h. The Porphyrin 2.30 was dissolved in DMF, 
the base and coupling reagents (HATU for GRRRRRRRR and HOBt/DEPBT for the 
remaining peptdes) added to the porphyrin mixture. The activated mixture was 
transferred into the reaction vessel containing the resin and left to shake for 4 days. The 
resin was washed under vacuum several times using DMF, then methanol and finally 
DCM. A cleavage cocktail – TFA/phenol/TIS/H2O (88:5:2:5) – was added with constant 
shaking for 4 h. The solution was washed with TFA into a flask and concentrated under 
vacuum. Cold diethyl ether was added to the residue and the mixture centrifuged. The 
porphyrin peptide conjugates were purified using reverse-phase HPLC using a Waters 
system including a 2545 quaternary gradient module pump, 2489 UV/Visible detector, 
and a fraction collector III. Analytical HPLC was carried out using a XBridge C18 300Å, 
5µm, 4.6 x 250 mm (Waters, USA) column using a stepwise gradient. Semi-preparative 
HPLC was carried out a XBridge C18 300Å, 5 µm, 10 x 250 mm (Waters, USA) column 










 Porphyrin 3.19 (19.5 mg, 20 µmol), thiol-o-carborane (35 mg, 200 µmol) and K2CO3 (28 
mg, 200 µmol) were mixed into 5 mL DMF in a reaction tube. The mixture was stirred at 
room temperature for two days under ambient condition. Then KF (12 mg, 200 µmol) 
was added and the reaction mixture was refluxing for 2 hours. The mixture was poured 
into 50 mL KCl concentrated water solution and extracted with EtOAc (50 m L). The 
organic layer was washed three times by KCl solution. The solution was dried under 
vacuum and was purified by silica gel column using 50 % HPLC acetone in EtOAc. The 
major fraction was collected and recrystallized in EtOAc and Hexane. The target purple 
powder was dried under vacuum, giving 20.4 mg in 61% yield. 1H-NMR (400 MHz, 
Acetone-d6) δ 9.36 (8H, s), 2.40 (4H, s), 1.5-3.5 (36H, br), -2.35 (4H, br), -2.81 (2H, s).  
5,10,15,20-(p-thiolcarboronyl tetrafluoro) phenyl porphyrin (4.11) 
 To 19.52 mg of compound 3.19 in 10 ml round bottom flask 31.5 mg of K2CO3, 22.8 
mg of p-thiol carborane is added followed by 2 ml DMF. The reaction mixture is stirred 
at room temperature for 48 hours. The resulting solution taken in seperatory funnel is 
dissolved in ethyl acetate and washed with brine solution thrice. The resulting organic 
layer is passed through sodium sulfate. The residue obtained after evaporation of solvent 
is passed through silica gel (3:7 pet.ether:chloroform) giving 30 mg  (89%) product. mp > 
3000C. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (467 600), 511 (46 800), 555 (19 500), 585 
(12 100), 650 (9 200). 1H-NMR (CDCl3, 400 MHz): δ 8.93 (s, 8H, β-H), 3.47 (s, 8H, -
SCH2), 2.16-3.02 (m, 44H, BH & CH), -2.87 (s, 2H, NH). 13C-NMR (CDCl3, 100 MHz): 
δ 147.78, 147.63, 147.48, 145.30, 145.15, 144.99, 131.93, 131.28, 120.99, 120.80, 
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120.61, 115.69, 115.50, 115.31, 104.33, 81.87, 59.22, 53.57, 51.82, 40.60, 31.64, 30.93, 
29.72, 29.04, 19.15, 14.13. 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.9 (m, 8F), -
140.1 (m, 8F). MS (MALDI-TOF) m/z 1655.789. [M], calcd for C56H63F16N4B40S4  = 
1655.773. 
Compound 4.13 
 Methane sulfonyl chloride ( 0.974 g, 8.5 mmol) was dissolved in 3 ml of CH2Cl2 and 
added to a mixture of hexaethylene glycol (2.0 g, 7.04 mmol) and Ag2O (1.804 g, 7.78 
mmol) in 15 ml of CH2Cl2. The reaction mixture was stirred at room temperature for 48 
hrs and then filtered through celite. The compound is passed through flash 
chromatography using 10:3:1 DCM:EtOH:MeOH as elutant giving the resultant product 
in 65% yield. 1H-NMR (d-CDCl3, 400 MHz):  δ 4.2-4.17 (m, 2H, -SOCH2), 3.59-3.38 
(m, 22H, OCH2), 2.91 (s, 3H, SO2CH3). 13C-NMR (d-CDCl3, 400 MHz): 72.44, 70.35, 
70.31, 70.22, 70.06, 69.46, 68.79, 61.31, 61.28, 57.61, 37.45. MS (ESI-TOF) [M+Na]+ 
383.1331. Calc for C13H28NaO9S 383.1346. 
Compound 4.14 
Sodium azide (0.30 g, 4.644 mmol) was added to a solution of compound 1 (1.12 g, 3.1 
mmol) in 6 ml of dry DMF. The reaction mixture was heated at 1100C/2.5 hrs and then 
cooled to room temperature. Then the DMF is co-evaporated using toluene and purified 
by flash chromatography using 10:1 DCM:MeOH as elutant. Product was isolated as 
colorless oil in 85% yield. 1H-NMR (d-CDCl3, 400 MHz): δ 3.63-3.5 (m, 22H, OCH2), 
3.3 (t, J=4.92, 3H, N3CH2). 13C-NMR (d-CDCl3, 400 MHz): 128.94, 128.14, 125.21, 
77.54, 77.22, 76.90, 72.52, 70.57, 70.19, 69.93, 61.50, 61.33, 50.58. MS (ESI-TOF) 
[M+Na]+ 330.1643. Calc for C12H25NaN3 330.1643. 
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  To the above compound (0.52 g, 1.755 mmol) was dissolved in 30 ml of 
anhydrous THF under argon. Then the solution was cooled to 00Cand then NaH (0.091 g, 
2.73 mmol) was added and continued stirring for 20 min. Then the mixture is continued 
stirring for 1 hrs before adding BrCH2CO2t-Bu and refluxed for 15 hrs. After colling to 
room temperature the titled compound is obtained by passing through silica flash 
chromatography using EtOAc:MeOH 9:1 for elution in 90% yield. 1H-NMR (d-CDCl3, 
400 MHz): δ 3.97 (s, 2H, -OCH2CO), 3.66-3.60 (m, 22H, OCH2), 3.34 (t, J= 5.06, 2H, 
N3CH2), 1.42 (s, 9H, -OC(CH3)3). 13C-NMR (d-CDCl3, 400 MHz): 169.63, 81.45, 77.44, 
77.12, 76.80, 70.65, 70.59, 70.54, 69.99, 68.99, 68.43, 68.30, 50.64, 28.07. MS (ESI-
TOF) [M+Na]+ 444.2286. Calc for C18H35NaO8N3 444.2316. 
Compound 4.15 
Porphyrin 3.19 (292.5 mg, 0.3 mmol), propagyl alcohol (5.6 mg, 0.1 mmol) and 
K2CO3 (138 mg, 1 mmol) are added to a 50 ml RBF. To this 15 ml of DMSO is added and 
the reaction mixture is heated to 600C and stirred for 4 hrs. After 4 hrs DMSO is removed 
then the resulting compound is passed through silica column (4:1 pet.ether:chloroform) to 
get pure mono propagyl porphyrin (227 mg) in 75% yield. UV-vis (DMSO) λmax (ε/M-1 cm-
1) 416 (464 500), 511 (46 100), 555 (18 900), 585 (11 200), 650 (8 100). 1H-NMR (400 MHz, 
Chloroform-d6) δ 9.02 (d, J=4.4, 2H, βH), 8.97 (s, 6H, βH), 5.25 (d, J=2.4, 2H, OCH2), 
2.84 (t, J=2.4, 1H), -2.81 (2H, s). MS (MALDI-TOF) m/z 1010.2 Calculated for 
C47H13N4F19O  1010.0786. 
 To the above compound (100 mg, 0.1 mmol), K2CO3 (70 mg, 0.6 mmol), thiol 
carboane 3.11 (76 mg, 0.4 mmol) and 2 ml DMF are added in a round bottom flask and 
stirred at room temperature under argon for 48 h. Then the mixture is dissolved in ethyl 
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acetate and washed with brine. The organic layer is collected and passed through sodium 
sulfate. After evaporation of solvent the compound is purified using silica gel column 
chromatography with DCM:EtOAc (9:1) as eluent to obtain the product in 80% (yield. 
UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (468 500), 511 (47 400), 555 (17 400), 585 (13 600), 650 
(7 900).  1H-NMR (400 MHz, Chloroform-d6) δ 9.01 (s, 2H, βH), 8.91 (s, 6H, βH), 5.24 
(d, J=4.2, 2H, OCH2), 3.46 (s, 6H, SCH2), 2.78 (t, J=5.6, 1H), -2.79 (2H, s). 13C-NMR 
(CDCl3, 100 MHz): δ 147.78, 147.63, 145.31, 145.15, 144.99, 121.04, 120.85, 120.66, 115.65, 
115.46, 115.27, 104.64, 104.21, 81.87, 62.01, 59.23, 40.61, 30.92, 29.72, 22.71, 14.13. MS 
(MALDI-TOF) m/z 1523.856 Calculated for C56H50N4F16S3OB30  1523.453.  
The above compound is dissolved in DCM then Zn(OAC)2 in methanol is added 
and the mixture  is stirred overnight. Then the solvent are evaporated. The resulting 
compound is passed through celite followed by solvent evaporation resulting in the 
desired Zn complexed porphyrin in 100% yield. 1H-NMR (400 MHz, Chloroform-d6) δ 
9.02 (s, 2H, βH), 8.93 (s, 6H, βH), 5.21 (d, J=6.4, 2H, OCH2), 3.47 (s, 6H, SCH2). MS 
(MALDI-TOF) m/z 1584.098 Calculated for C56H48N4F16S3OB30Zn  1584.992. 
Compound 4.18 
  To (19.52 mg, 0.02) of compound 2.19, tert-butyl-12-amino-4,7,10-
trioxadodecanoate (8.2 mg, 0.03 mmol) and NMP (2 mL) were mixed in a 5 ml round 
bottom flask and heated to 1000C for 4 h. 64,65 Then the reaction mixture is added to a 
separatory funnel containing 10 ml brine solution and extracted with ethyl acetate. The 
organic layer is separated and evaporated. The obtained residue is passed through silica 
gel with DCM:EtOAc (9.8:0.2) as elutant. The second band was separated during the 
column, which contains the desired product 4.10 in 32% (8 mg, 0.006 mmol). Mp > 
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3000C; UV-vis (DMSO) λmax (ε/M-1 cm-1) 415 (461 700), 510 (40 150), 555 (21 100), 585 
(12 900), 650 (9 200). 1H-NMR (CDCl3, 400 MHz): δ 9.01 (s, 2H, β-H), 8.89 (s, 6H, β-
H), 3.86 (s, 4H, CH2), 3.65-3.81 (m, 12H, CH2), 1.43 (s, 9H, tBu), -2.88 (s, 2H, NH). 13C-
NMR (CDCl3, 100 MHz): δ 170.13, 148.98, 148.71, 145.41, 145.29, 143.97, 132.97, 
124.50, 121.05, 120.15, 119.98, 118.65, 114.76, 101.43, 100.54, 36.95, 27.91. HRMS 
(MALDI-TOF) m/z found 1231.786 [M]+, calcd for C57H36F19N5O5 [M]+ = 1231.896.  
Compound 3.30 
  To 24.6 mg (0.02 mmol) of compound 4.10 in 2 ml DMF was added anhydrous 
K2CO3 (16.6 mg, 0.12 mmol), mercaptomethyl-p-carborane (15.2 mg, 0.08 mmol). The 
reaction mixture was stirred at room temperature for 48 h. The resulting solution was 
diluted with ethyl acetate (50 mL) and washed with brine (2 x 50 mL). The organic layer 
was dried over anhydrous sodium sulfate, the solvents evaporated under reduced pressure 
and the resulting residue was dissolved in dichloromethane and passed through silica 
column and 9.8:0.2 DCM/EtOAc was used as the elutant to obtain the Boc-protected 
conjugate was obtained (33.6 mg) in 90% yield, mp = 289-292 0C; UV-vis (DMSO) λmax 
(ε/M-1 cm-1) 416 (460 800), 510 (38 450), 555 (16 700), 585 (10 200), 650 (8 100). 1H-
NMR (CDCl3, 400 MHz): δ 9.02 (s, 2H, β-H), 8.90 (s, 6H, β-H), 3.89 (s, 4H, CH2), 3.68-
3.82 (m, 12H, CH2), 3.45 (s, 6H, -SCH2), 1.67-3.10 (m, 33H, BH, CH), 1.43 (s, 9H, tBu), 
-2.88 (s, 2H, NH). 13C-NMR (CDCl3, 100 MHz): δ 171.23, 149.78, 149.51, 145.42, 
145.28, 143.77, 131.17, 125.50, 120.45, 120.07, 119.23, 118.86, 114.49, 101.13, 100.60, 
80.16, 79.93, 53.45, 46.56, 35.85, 27.41. 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.4 
(m, 6F), -139.6 (m, 6F), -144.8 (d, J = 15.5 Hz, 2F), -162.3 (d, J = 16.1 Hz, 2F). HRMS 
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(MALDI-TOF) m/z found 1747.822 [M]+, calcd for C66H75F16N5B30S3 O5 [M]+ = 
1747.746.  
The Boc protected conjugate was deprotected using TFA in dichloromethane, as 
described above, and conjugate 3.30 was obtained (15.4 mg) in 95% yield after HPLC 
purification; mp = 295-298 oC; HPLC tR = 51.21 min. UV-vis (DMSO) λmax (ε/M-1 cm-1) 
417 (430 200), 510 (36 700), 555 (18 500), 585 (10 500), 650 (8 800). 1H-NMR (CDCl3, 
400 MHz): δ 8.88-9.32 (br s, 8H, β-H), 3.92 (s, 4H, CH2), 3.68-3.82 (m, 18H, CH2, 
SCH2), 2.01-3.31 (m, 33H, BH, CH). 19F-NMR (Acetone-d6, 233.33 MHz): δ -135.5 (m, 
6F), -139.8 (m, 6F), -144.6 (d, J = 15.6 Hz, 2F), -162.4 (d, J = 16.2 Hz, 2F). HRMS 
(MALDI-TOF) m/z found 1691.758 [M]+, calcd for C62H67F16N5B30S3O5 [M]+ = 
1691.684. 
Compound 4.19 
  To (16.91 mg, 0.01 mmol) of conjugate 3.30 in 0.5 ml DMF, (7.8 mg, 0.06 mmol) 
DIEA is added and stirred for 10 min. Then (3.82 mg, 0.01 mmol) of HATU is added and 
continued stirring for 15 minutes. Then (1.8 mg, 0.01 mmol) of arginine is added and 
mixed for another 48 hours. The resulting residue after the removal of DMF is purified 
using HPLC resulting in compound 4.11 in 85% yield. mp > 3000C. HPLC tR =25.856. 
UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (458 100), 511 (44 100), 555 (17 100), 585 (11 
100), 650 (7 500). 1H-NMR (Acetone-d6, 400 MHz): δ 8.9-9.5 (bs, 8H, β-H), 3.52-4.51 
(m, 25H, -SCH2, -NCH2, OCH2), 1.08-3.46 (m, 37H, CH2, BH & CH). 13C-NMR 
(Acetone-d6, 100 MHz): δ 173.20, 171.48, 157.95, 148.60, 145.65, 121.04, 115.14, 
106.53, 104.31, 70.32, 70.24, 70.15, 70.06, 67.0, 59.89, 51.31, 40.47, 36.23, 24.80, 22.42, 
13.46. 19F-NMR (Acetone-d6, 233.33 MHz): δ -134.9 (m, 6F), -139.2 (m, 6F), -140.8 (d, 
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J = 15.4 Hz, 2F), -156.1 (t, J = 16.0 Hz, 1F), -164.1 (d, J = 12.1 Hz, 2F). MS (MALDI-
TOF) m/z 1841.744 [M], calcd for C68H80F16N10B30S3O5  = 1841.824. 
Compound 4.20 
General procedure of peptide conjugation on solid support is used with (16.91 mg, 
0.01 mmol) of conjugate 2.30 in 0.5 ml DMF, (7.8 mg, 0.06 mmol) DIEA, 0.005 mmol 
resin, and (3.82 mg, 0.01 mmol) HATU is used. Product obtained in 33% (4.5 mg) yield 
.mp > 3000C. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (448 900), 511 (45 900), 555 (15 
900), 585 (12 500), 650 (8 100). 1H-NMR (DMSO-d6, 400 MHz): δ 9.03-9.34 (bs, 8H, β-
H), 3.54-4.51 (m, 54H, -SCH2, -NCH2, OCH2), 1.32-3.36 (m, 65H, BH and peptide-H). 
MS (MALDI-TOF) m/z 2993.621 [M+K+Na]+, calcd for C110H162F16N38B30S3O12KNa  = 
2993.542. 
Compound 4.21 
General procedure of peptide conjugation on solid support is used with (16.91 mg, 
0.01 mmol) of conjugate 3.30 in 0.5 ml DMF, (7.8 mg, 0.06 mmol) DIEA, 0.005 mmol 
resin, (3.82 mg, 0.015 mmol) DEPBT, and (3.82 mg, 0.015 mmol) HOBt was used. The 
resulting residue is purified using HPLC. Product obtained in 65% (7 mg) yield. mp > 
3000C. HPLC tR =25.698. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (462 100), 511 (44 
300), 555 (17 900), 585 (12 100), 650 (8 100). 1H-NMR (Acetone-d6, 400 MHz): δ 9.02 
(s, 2H, β-H), 8.90 (m, 6H, Ph-H), 7.16-7.28 (m, 4H, o-Ph-H), 7.13 (bs, 1H, p-Ph-H), 
7.03-7.1 (d, J=3.44, 2H, m-Ph-H), 6.72-6.79 (d, J=4.56, 2H, m-Ph-H), 3.85-4.01 (m, 4H, 
OCH2), 3.63-3.78 (m, 12H, OCH2), 3.6 (s, 6H, SCH2), 3.4-3.51 (m, 6H, NCH2), 1.24-
2.95 (m, 48H, BH & CH, Peptide-CH), -2.89 (s, 2H, NH). 13C-NMR (Acetone-d6, 100 
MHz): δ 172.47, 162.62, 159.01, 158.62, 156.72, 148.11, 145.65, 138.27, 130.33, 129.25, 
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128.19, 126.32, 123.95, 117.22, 115.24, 114.36, 81.68, 70.12, 66.92, 60.03, 56.58, 55.60, 
52.65, 45.27, 40.34, 36.65, 35.67, 26.57, 24.60, 19.43. 19F-NMR (Acetone-d6, 233.33 
MHz): δ -135.2 (m, 6F), -139.2 (m, 6F), -140.9 (d, J = 15.9 Hz, 2F), -156.1 (t, J = 18.0 
Hz, 1F), -164.7 (d, J = 16.5 Hz, 2F). MS (MALDI-TOF) m/z 2224.998 [M+H]+, calcd for 
C89H103F16N13B30S3O9  = 2224.990. MS-MS (MALDI- TOF-TOF) m/z 2224.998 
[PorPEG-TAPA-CONH2 + H]+, 2205.800 [(PorPEG-TAPACO) – 2H]+, 2108.591 
[PorPEG-TAP], 1888.405 [(PorPEG-TCONH2 + K + H]+, 1805.420 [PorpPEG-T], calc 
for C89H103F16N13B30S3O9  = 2224.990, C89H98F16N12B30S3O9 = 2205.957, 
C85H96F16N11B30S3O7 = 2108.591, C71H77F16N7B30S3O6 = 1888.758, C70H76F16N6B30S3O5 
= 1805.781. 
Compound 4.22 
General procedure of peptide conjugation on solid support is used with (16.91 mg, 
0.01 mmol) of conjugate 2.30 in 0.5 ml DMF, (7.8 mg, 0.06 mmol) DIEA, 0.005 mmol 
resin, (3.82 mg, 0.015 mmol) DEPBT, and (3.82 mg, 0.015 mmol) HOBt was used. The 
resulting residue is purified using HPLC. Product obtained in 61% (7 mg). mp > 2500C. 
HPLC tR =34.147. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (468 600), 511 (44 900), 555 
(17 400), 585 (11 600), 650 (6 500). 1H-NMR (Acetone-d6, 400 MHz): δ 8.91-9.18 (bs, 
8H, β-H), 7.0-7.42 (m, 12H, Ph-H), 6.79-6.91 (s, 2H, Ph-H), 3.67-3.92 (m, 16H, CH2), 
3.57 (s, 6H, SCH2), 2.06-3.425 (m, 51H, BH, peptide-H), -2.85 (s, 2H, NH). 13C-NMR 
(Acetone-d6, 100 MHz): δ 172.61, 172.18, 162.51, 159.41, 156.78, 156.18, 147.11, 
146.73, 138.47, 130.14, 129.21, 120.94, 115.14, 106.53, 104.31, 70.32, 70.24, 70.15, 
70.06, 67.0, 59.89, 51.31, 47.07, 37.83, 24.68, 22.32, 14.16. MS (MALDI-TOF) m/z 




General procedure of peptide conjugation on solid support is used with (16.91 mg, 
0.01 mmol) of conjugate 2.30 in 0.5 ml DMF, (7.8 mg, 0.06 mmol) DIEA, 0.005 mmol 
resin, (3.82 mg, 0.015 mmol) DEPBT, and (3.82 mg, 0.015 mmol) HOBt was used. The 
resulting residue is purified using HPLC. Product obtained in 59% (6.8 mg). mp > 2500C. 
HPLC tR =33.899. 1H-NMR (Acetone-d6, 400 MHz): δ 9.01-9.34 (bs, 8H, β-H), 7.19-
7.30 (m, 4H, o-Ph-H), 7.09 (bs, 1H, p-Ph-H), 6.98-7.01 (d, J=4.14, 2H, m-Ph-H), 6.71-
6.78 (d, J=3.46, 2H, m-Ph-H), 3.42-4.46 (m, 37H, SCH2, SCH3, NCH2, OCH2), 1.28-3.48 
(m, 39H, BH & peptide-H), -2.82 (s, 2H, NH). 13C-NMR (Acetone-d6, 100 MHz): δ 
172.10, 170.98, 169.97, 158.25, 147.90, 145.95, 121.94, 114.94, 107.63, 104.41, 73.92, 
70.66, 59.89, 51.31, 40.89, 39.33, 24.86, 22.62, 14.76. MS (MALDI-TOF) m/z 2305.998 
[M+K+Na]+, calcd for C89H99F16N11B30S4O10KNa  = 2305.567.  
Compound 4.24 
General procedure of peptide conjugation on solid support is used with (16.91 mg, 
0.01 mmol) of conjugate 2.30 in 0.5 ml DMF, (7.8 mg, 0.06 mmol) DIEA, 0.005 mmol 
resin, (3.82 mg, 0.015 mmol) DEPBT, and (3.82 mg, 0.015 mmol) HOBt was used. The 
resulting residue is purified using HPLC with 40% (5.5 mg) yield. mp > 2500C. HPLC tR 
=5.163. UV-vis (DMSO) λmax (ε/M-1 cm-1) 416 (458 100), 511 (44 100), 555 (17 100), 
585 (11 100), 650 (7 500). 1H-NMR (DMSO-d6, 400 MHz): δ 8.89-9.41 (bs, 8H, β-H), 
7.29-7.40 (m, 4H, o-Ph-H), 7.12 (bs, 1H, p-Ph-H), 6.87-7.98 (bs, 2H, m-Ph-H), 6.69-6.75 
(bs, J=3.46, 2H, m-Ph-H), 3.49-4.46 (m, 36H, -SCH2, -NCH2, OCH2), 1.16-3.41 (m, 
65H, BH & Peptide-H). MS (MALDI-TOF) m/z 2623.358 [M]+, calcd for 




Porphyrin 3.20 (14.9 mg, 0.01 mmol) in 2 ml DMF was mixed with K2CO3 (1.1 
mg, 0.02 mmol) and 1-Thiol-β-D-glucose tetraacetate (5.5 mg, 0.015 mmol) for 48 hours 
at room temperature. Then the mixture is added to 10 ml water and extracted with ethyl 
acetate using separatory funnel. The organic layer (ethyl acetate) is evaporated and the 
compound is purified by silica gel; first using CH2Cl2 followed by CH2Cl2:EtOAc (7:3) 
which gave us 95 %  yield (17.4 mg). mp = 289-292 oC; UV-vis (DMSO) λmax (ε/M-1 cm-
1) 417 (420 100), 510 (35 700), 555 (17 500), 585 (11 100), 650 (6 800). 1H-NMR 
(CDCl3, 250 MHz): δ 9.09 (s, 2H, β-H), 9.01 (s, 6H, β-H), 5.25-5.44 (m, 4H), 4.39 (m, 
2H), 3.98 (m, 1H), 1.83-3.49 (m, 51H, BH, SCH2, OAc, CH), -2.79 (s, 2H, NH). 13C-
NMR (CDCl3, 62.5 MHz): δ 170.58, 170.12, 169.41, 169.33, 148.33, 144.36, 131.31, 
128.75, 122.03, 121.02, 120.71, 120.41, 115.74, 115.44, 115.13, 112.11, 111.78, 104.29, 
103.52, 84.43, 81.77, 73.87, 70.53, 68.01, 61.75, 59.13, 40.47, 20.56. 19F-NMR (CDCl3, 
233.33 MHz): δ -135.8 (m, 6F), -139.4 (m, 6F), -144.2 (d, J = 18.6 Hz, 2F), -162.8 (d, J = 
17.2 Hz, 2F). HRMS (ESI-TOF) m/z found 1829.6704 [M]+, calcd for 
C67H68B30F16N4O9S4 [M]+ = 1829.6639. 
To the above compound (17.4 mg, 0.0095 mmol) in 10 ml of 1:1 CHCl3/MeOH is 
added 50 µL of 0.5 M NaOMe in MeOH and mixed for 2 hrs. Then the solvents were 
evaporated to give us a red color residue. The compound is then purified using silica gel 
first by CH2Cl2 followed by 3:7 CH2Cl2/EtOAc, which gave us pure compound in 93% 
yield (14.68 mg). mp = 289-292 oC. HPLC tR =19.433. UV-vis (DMSO) λmax (ε/M-1 cm-1) 
417 (440 010), 510 (37 600), 555 (17 500), 585 (11 100), 650 (9 100). 1H-NMR (CDCl3, 
250 MHz): δ 8.94 (s, 2H, β-H), 8.86 (s, 6H, β-H), 5.32 (b s, 1H), 4.81 (b s, 1H), 4.07-
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4.21 (m, 4H), 3.81 (s, 1H), 1.11-3.50 (m, 39H, BH, SCH2, CH). 13C-NMR (CDCl3, 62.5 
MHz): δ 148.26, 144.26, 130.84, 120.50, 120.41, 115.25, 112.29, 104.19, 86.83, 81.58, 
79.97, 73.74, 69.43, 61.91, 58.90, 40.46, 40.14, 29.58.  19F-NMR (Acetone-d6, 233.33 
MHz): δ -135.3 (m, 6F), -139.6 (m, 6F), -144.9 (d, J = 19.6 Hz, 2F), -162.4 (d, J = 14.2 
Hz, 2F). HRMS (ESI-TOF) m/z found 1661.6211 [M]+, calcd for C59H60B30F16N4O5S4 
[M]+ = 1661.6164. 
X-ray crystallographic data 
  Crystals of porphyrins 2.21 , 2.23 and 2.25  for X-ray crystallographic analysis 
were grown by slow evaporation of their hexane/dichloromethane solutions. Diffraction 
data were collected at low temperature on a Bruker Kappa Apex-II CCD diffractometer 
equipped with CuKα radiation (λ  = 1.54178 .) and an Oxford Cryosystems Cryostream 
chiller. Refinement was by full-matrix least squares using SHELXL, with H atoms in 
idealized positions, guided by difference maps. For porphyrins 2.23 and 2.25 , the NH 
hydrogen atoms are disordered, and were placed into four half-populated sites. In 
porphyrin 2.23 , dichloromethane and hexane solvent molecules shared a disordered site 
on an inversion center. For porphyrin 2.25 , electron density amounting to 0.85 molecules 
of disordered dichloromethane per porphyrin molecule was removed using the 
SQUEEZE procedure. 




C56H62B40F16N4S4·2.28(CHCl3) Z = 1, Mr = 1927.90 F(000) = 966; Triclinic, P1 Dx 
= 1.367 Mg m−3; Hall symbol: -P 1 Cu Kα radiation, λ = 1.54178 Å, a = 12.1535 (15) Å 
Cell parameters from 6090 reflections, b = 14.690 (2) Å θ = 3.1–68.3°, c = 15.015 (2) Å, 
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µ = 3.34 mm−1, α = 71.943 (6)° T = 90 K, β = 76.081 (9)° Fragment, Red, γ = 68.140 
(8)° 0.30 × 0.22 × 0.16 mm, V = 2341.5 (5) Å3, Data collection Bruker APEX-II CCD 
diffractometer 8266 independent reflections, Radiation source: fine-focus sealed tube 
6835 reflections with I > 2σ(I) graphite Rint = 0.024, φ and ω scans θmax = 69.6°, θmin 
= 3.1°, Absorption correction: Multi-scan SADABS (Sheldrick, 2002) h = −14→14, 
Tmin = 0.434, Tmax = 0.617 k = −17→16. 
4.4.4: Cell Studies 
All tissue culture medium and reagents were purchased from Invitrogen 
(Carlsbad, CA). Human glioma T98G cells were purchased from ATCC and cultured in 
ATCC-formulated Eagle's Minimum Essential Medium containing 10% FBS and 1% 
antibiotic (Penicillin Streptomycin). The cells were split twice weekly to maintain a sub-
confluent stock. All compound solutions were filter-sterilized using a 0.22 µm syringe 
filter.  
4.4.4.1: Dark Cytotoxicity. 10,000 T98G cells were plated per well in a Costar 96 
well plate and allowed to grow 36 h.  Porphyrin stock solutions (32 mM) were prepared 
in DMSO and then diluted into final working concentrations (25, 50, 100, 200, 400 µM). 
The cells were exposed to increasing concentrations of porphyrin up to 400 µM and 
incubated overnight. The loading medium was removed and the cells washed with 100 
µL PBS. Then medium containing Cell Titer Blue (Promega) 120 µL was added as per 
manufacturer’s instructions. After incubating for 4 h the cytotoxicity was then measured 
by reading the fluorescence at 520/584 nm using a BMG FLUOstar plate reader. The 
signal was normalized to 100% viable (untreated) cells and 0% viable (treated with 0.2% 
saponin from Sigma) cells. 
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4.4.4.2: Phototoxicity. The T98G cells were prepared as described above for the 
dark cytotoxicity assay and treated with porphyrin concentrations of 6.25, 12.5, 25, 50, 
and 100 µM. After compound loading, the medium was removed and replaced with 
medium containing 50 mM HEPES pH 7.4.  The cells were exposed to a NewPort light 
system with 175 W halogen lamp for 20 min, filtered through a water filter to provide 
approximated 1.5 J/cm2 light dose. The cells were kept cool by placing the culture on a 
50C Echotherm chilling/heating plate (Torrey Pines Scientific, Inc.). The cells were 
returned to the incubator overnight and assayed for viability as described above for the 
dark cytotoxicity experiment and adding medium containing Cell Titer Blue to determine 
the toxicity of the compounds. 
  4.4.4.3: Time-Dependent Cellular Uptake. The T98G cells were prepared as 
described above for the dark cytotoxicity assay. The cells were exposed to 10 µM of each 
conjugate for 0, 1, 2, 4, 8, and 24 h. At the end of the incubation time the loading medium 
was removed and the cells were washed with 200 µL PBS. The cells were solubilized 
upon addition of 100 µL of 0.25% Triton X-100 (Calbiochem) in PBS. To determine the 
porphyrin concentration, fluorescence emission was read at 415/650 nm 
(excitation/emission) using a BMG FLUOstar plate reader. The cell numbers were 
quantified using the CyQuant cell proliferation assay (Invitrogen) as per the 
manufacturer’s instructions, and the uptake was expressed in terms of nM compound per 
cell. 
4.4.4.4: Blood brain permeability. The hCMEC/D3 cells were incubated in a 6-
well, 0.4 µm porosity PET transwell plate (Corninig) and allowed to grow for 48 h. 0.5 
ml of 1mg/ml porphyrin conjugates were added to the upper chamber and 1.5 ml HBSS 
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buffer is added to the bottom chamber. The cells were incubated for 0, 30 and 60 min. At 
the end of the incubation time 5X100 µL of solution form the bottom chamber is pipetted 
and added to a 96 well plate. To determine the porphyrin concentration, fluorescence 
emission was read at 415/650 nm (excitation/emission) using a BMG FLUOstar plate 
reader.       
  4.4.4.5: Microscopy. The HEp2 cells were incubated in a glass bottom 6-well 
plate (MatTek) and allowed to grow for 48 h. The cells were then exposed to 10 µM of 
each porphyrin conjugate for 6 h. Organelle tracers were obtained from In- vitrogen and 
used at the following concentrations: LysoSensor Green 50 nm, MitoTracker Green 250 
nm, ER Tracker Blue/white 100 nm, and BODIPY FL C5 Ceramide 1 mm. The organelle 
tracers were diluted in medium and the cells were incubated concurrently with porphyrin 
conjugate and tracers for 30 min before washing 3 times with PBS and microscopy. 
Images were acquired using a Leica DM RXA2 upright microscope with 40 X NA 0.8dip 
objective lens and DAPI, GFP and Texas Red filter cubes (Chroma Technologies) 
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APPENDIX A: CHAPTER 2 CHARACTERIZATION DATA 
 
 













































































































































































































































































































































































































































































































































































































Figure B -11: 1H-NMR Spectrum of BOC Protected 3.28 in CDCl3 at 400 MHz 
 
 



























































































































































































Analytical HPLC conditions: General: 4.6X250 mm-XBridgeTM BED300 C18 5 µm; 
flow rate 1 mL/min.; injected volume 50 µL.; wavelength detection: 416 nm. 
Solvent system 1: stepwise gradient from 0 to 100% to 50% B and 50% C to 100% B in 
next 10 min. Buffer A (0.1% TFA, H2O), Buffer B (0.1% TFA, acetonitrile), Buffer C 
(0.1% TFA, acetone). 
Solvent system 2: stepwise gradient 10-90% Buffer B with Buffer A was used for the 
PEG conjugate 3.30. Buffer A (0.1% TFA, H2O), Buffer B (0.1% TFA, acetonitrile), 
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Figure C-3: 1H-NMR Spectrum of Compound 4.21 in Acetone-d6 at 400 MHz 
 
 














































































Figure C-5: 1H-NMR Spectrum of Acetyl protected 4.25 in CDCl3 at 250 MHz 
 
 












































































Analytical HPLC conditions: General: 4.6X250 mm-XBridgeTM BED300 C18 5 µm; 
flow rate 1 mL/min.; injected volume 50 µL.; wavelength detection: 416 nm. 
 Solvent system 1: stepwise gradient from 0 to 100% to 50% B and 50% C to 100% B in 
next 10 min. Buffer A (0.1% TFA, H2O), Buffer B (0.1% TFA, acetonitrile), Buffer C 
(0.1% TFA, acetone). 
Solvent system 2: stepwise gradient 0-95% Buffer B (0.1% TFA, acetonitrile) with 
Buffer A (0.1% TFA, H2O) in 30 min. 
Solvent system 3: stepwise gradient 70% Buffer A (0.1% TFA, H2O) and 30% Buffer B 
(0.1% TFA, acetonitrile) at 1 min, 20% Buffer A and 80% Buffer B at 10 min, 10% 
Buffer A and 80% Buffer B and 10% Buffer C (0.1% TFA, acetone) at 12 min, 65% 
Buffer B and 35% Buffer C at 25 min, 70% Buffer A and 30% buffer B at 61 min. 
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